Pediatric Inflammatory Bowel Disease
Pediatric Inflammatory Bowel Disease Edited by
Petar Mamula, M.D. Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine, Attending Physician, Division of GI, Hepatology and Nutrition, Director, Endoscopy Suite, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Jonathan E. Markowitz, M.D., M.S.C.E Associate Professor of Clinical Pediatrics, University of South Carolina School of Medicine, Attending Physician, Children’s Center for Digestive Health, Greenville Hospital System University Medical Center, Greenville, South Carolina
Robert N. Baldassano, M.D. Professor, University of Pennsylvania School of Medicine, Attending Physician and Director, Inflammatory Bowel Disease Center, Division of GI, Hepatology and Nutrition, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Petar Mamula, M.D. Assistant Professor of Pediatrics University of Pennsylvania School of Medicine Attending Physician, Division of GI Hepatology and Nutrition Director, Endoscopy Suite The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania
Jonathan E. Markowitz., M.D., M.S.C.E. Associate Professor of Clinical Pediatrics University of South Carolina School of Medicine Attending Physician, Children’s Center for Digestive Health Greenville Hospital System University Medical Center Greenville, South Carolina
Robert N. Baldassano, M.D. Professor University of Pennsylvania School of Medicine Attending Physician and Director Inflammatory Bowel Disease Center Division of GI, Hepatology and Nutrition The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania
Library of Congress Control Number: 2007929784 ISBN-13: 978-0-387-73480-4
e-ISBN-13: 978-0-387-73481-1
Printed on acid-free paper. © 2008 Springer Science+Business Media, LLC All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. 9 8 7 6 5 4 3 2 1 springer.com
We dedicate this book... To our families. To Gordana-Dana, to Kay, and to Joanne. For their love, understanding and encouragement. To Niko, to Jack, Leo, and Benjamin, and to Chris, Steven, and Julie. For making us believe that the best is yet to come. To our colleagues everywhere, past and present. For working hard each day to make a difference. To our patients. For inspiring us. Petar, Jon, Robert
Foreword Pediatric Inflammatory Bowel Diseases (IBD) are the most common and most significant chronic disorders in Pediatric Gastroenterology. The onset of Crohn disease and ulcerative colitis in the first two decades of life presents a number of diagnostic and therapeutic challenges that are unique to pediatric patients. Although the studies available for pediatric diagnosis have improved dramatically in the past three decades, the improvement in technology alone cannot account for the increased frequency of IBD recognized in early childhood. While therapy for older patients has improved dramatically with the use of immunomodulators and the development of exciting biologic strategies, rarely if ever have comprehensive studies of the pharmacokinetics, safety and efficacy of any of the IBD medications been performed in pediatric patients. A number of excellent medications are not available in liquid preparations that can be swallowed by children, and others, such as timed-release formulations, are developed for delivery to an adult gastrointestinal tract. It is unfortunate that the care we provide to children is often an extrapolation of what is known about and available for adults with IBD. Pediatric patients with IBD face a number of unique challenges. The onset of disease before puberty can be devastating. Growth failure is a particularly difficult problem with potentially permanent consequences. Much of the pediatric specific research has focused on the role of nutritional therapy to treat growth failure and induce remission. Strategies such as nocturnal nasogastric administration of supplements are widespread in most pediatric centers, and are surprisingly well-tolerated even by the youngest patients, particularly when the value of nutritional therapy is presented in advance to both the family and the child. Nutrition must be strongly advocated for pediatric patients, as it has great therapeutic value, and it is the only therapy for which there are no serious potential complications. The long-term consequences of medical and surgical therapy are particularly troubling for pediatric patients. The complications of corticosteroids in childhood and adolescence can seem worse than the disease itself. While most of the cosmetic side effects are reversible, the psychological trauma to an adolescent can be overwhelming. We are only beginning to understand and address the long term consequences of therapy given at an early age. Bone mass accumulation and linear growth are critical processes that are age dependent, with peaks in early adolescence. Failure of therapy at this stage will have permanent, and possibly debilitating consequences. In order to spare cumulative steroid exposure there has been a marked shift in the last two decades to immunodulator therapies, often initiated in the first decade of life. More recently, biologic therapy has resulted in a dramatic shift in therapeutic armamentarium and the style of its administration. In adults, the “therapeutic pyramid” has been turned on all of its sides, with a resulting dramatic improvement in quality of life and a decrease in overall corticosteroid exposure, but with a new set of adverse events from therapy. While pediatric patients undoubtedly benefit from the adult data supporting these “bottom up” and “top down” strategies, the data in adults does not necessarily predict the optimal strategies for children. The effects of more “aggressive” therapy are being recognized for their positives and negatives, and the risks and benefits in pediatrics are undoubtedly different in children and adolescents. Whether it is the state of the immature immune
vii
viii
Foreword
system, the effect of rapid growth, or the background susceptibility to different malignancies at different ages, the incidence of profound problems such as hepatosplenic T cell lymphomas reminds all practitioners that we do not understand the unique aspects of the younger patient that confer such increased susceptibility. There is no better care than that given by a well educated and experienced practitioner who considers all aspects of a patient’s problems. This book is designed for those practitioners who care for children. IBD therapy must be customized for each individual patient. There is no more ultimate “individual” patient that a child or adolescent with IBD. The many challenges of growth, nutrition, psychology and adaptation weigh heavily upon the profound challenges of pediatric Crohn disease and ulcerative colitis. In addition to the need for induction and maintenance of remission, the pediatric gastroenterologist must be obsessed with the long term consequences of therapy, not just a decade away, but hopefully a half century or more hence. Although these patients will move on to adult gastroenterologists, the problems will only accumulate and multiply. “Above all else, do no harm” is a wise admonition for pediatric IBD, where therapies are rapidly improving and there is a great potential for a cure of these devastating illnesses. This therapies and ultimate cures for Crohn disease and ulcerative colitis will come from the extraordinary advances in immunology and immunogenetics that are well detailed in this book. Until that time, we must rely on the conventional approached developed in adults, but with the conviction to verify their efficacy for children with IBD. This book is a landmark step toward better understanding of pediatric IBD and the challenges of IBD therapy in children. The editors are highly respected clinical scientists who have each contributed substantially to the knowledge about pediatric IBD. In addition, their knowledge gained from their extensive clinical experience is reflected in this book. They have assembled a truly extraordinary group of authoritative leaders whose contributions to this volume will guarantee that this will be a reference for all who care for pediatric IBD. The book is a tribute to those authors, but is dedicated to the children and adolescents with Crohn disease and ulcerative colitis. It is a sign of the times that increased focus at every level is directed toward these children, and this book is one significant step along the road toward improving care for the hundreds of thousands of children with inflammatory bowel diseases. It should be required reading for all those who care for these children.
Preface As this first edition of Pediatric Inflammatory Bowel Disease goes to press, we find ourselves reflecting not only upon our hopes and expectations for the textbook, but also upon the discipline of caring for children with inflammatory bowel disease (IBD). We have been saying amongst ourselves for several years that the time has come for a textbook dedicated to the unique aspects of pediatric IBD. This does not imply that the existing textbooks on IBD and pediatric gastroenterology are not useful. Rather, it is a testament that the collective knowledge about children and adolescents with IBD has grown, and continues to grow, to a point that warrants its own volume. Despite its growth, the community of pediatric gastroenterologists remains a fairly intimate one. We were fortunate to have a highly talented and internationally renowned group of physicianscientists who shared our vision for this project and willingly contributed their time and effort to provide the chapters for the book. However, we also recognize that there remain many geographic regions where access to specialists trained to care for children with IBD is limited. To this end, we have tried to design this book as a resource for not just pediatric gastroenterologists, but also for general pediatricians, internists, family practitioners, and internist-gastroenterologists who will likely care for children or adolescents with IBD at some point in their practice. We also aimed to maintain the focus of this book on the pediatric aspects of IBD, rather than simply recapitulating the excellent general IBD textbooks already available. This was easier in some chapters than others, highlighting both the progress that has been made in studying IBD in children and also the need for further pediatric based studies. Also included is a unique section highlighting some topics such as advocacy, and transition of care from pediatric- to internist-gastroenterologists—areas where even experienced physicians may need guiding resources. Pediatric IBD continues to grow as a discipline, and certainly many changes have occurred over the past few years. Our understanding of the immune system and its interplay with the environment and genetic susceptibilities has vastly improved providing us with further insight into the etiology and pathogenesis of the constellation of disorders that are defined by the term IBD. New approaches to treatment have been discovered, and new drugs developed. This textbook discusses these new approaches to treatment and aims at improving one’s knowledge of the pathogenesis, epidemiology, diagnosis, and treatment of Pediatric IBD. We hope that our readers will profit by the collective experience, resulting in improved care for children afflicted by IBD.
ix
Contents
Foreword . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .xxiii Section 1
Etiology and Pathogenesis
Chapter 1. Genetics of Inflammatory Bowel Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Nancy McGreal and Judy H. Cho Introduction........................................................................................................... 3 Crohn Disease and Ulcerative Colitis: Genetic Epidemiology ........................... 4 Identifiable Gene Variants in Crohn Disease ...................................................... 5 Genome-wide Association Studies in Crohn Disease ......................................... 7 Genetic Studies in Ulcerative Colitis................................................................... 8 Genotype-Phenotype Correlations in Pediatric IBD............................................ 9 Summary ............................................................................................................... 11 Chapter 2. Gut Immunity and Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . William A. Faubion and Claudio Fiocchi Introduction........................................................................................................... Innate Intestinal Immunity and IBD .................................................................... Development of the Epithelial Barrier and Innate Immune Cells....................... Adaptive Intestinal Immunity and IBD................................................................ Putting it all Together: Integrating Gut Microbes, Epithelial Cells, and Lymphocytes in the Pathogenesis of IBD .................................... Innate and Adaptive Immune Responses Unique to Pediatrics........................... Summary ...............................................................................................................
15
Chapter 3. Cytokines and Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Edwin F. de Zoeten and Ivan J. Fuss Introduction........................................................................................................... Pro-inflammatory Cytokines ................................................................................ Anti-inflammatory Cytokines............................................................................... Summary ...............................................................................................................
31
Section 2
15 16 19 19 23 24 25
31 32 37 39
Epidemiology and Clinical Features
Chapter 4. Epidemiology of Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . 45 Shehzad Saeed and Subra Kugathasan
xi
xii
Contents
Introduction........................................................................................................... Descriptive Epidemiology .................................................................................... Hygiene Hypothesis and Other Epidemiological Observation in IBD ............................................................................................................. Environmental Risk Factors ................................................................................. Appendectomy ...................................................................................................... Breast Feeding ...................................................................................................... Dietary Factors ..................................................................................................... Drugs..................................................................................................................... Socio-Economical, Educational and Occupational Status ................................... Stress ..................................................................................................................... New Epidemiology ............................................................................................... Genetic Epidemiology & its Impact on the Pathogenesis of IBD ...................... Challenges in the Way Forward; Genes and Environmental Interactions...................................................................................................... IBD Among New Populations ............................................................................. New Approaches................................................................................................... Summary ............................................................................................................... Chapter 5. Early Onset Inflammatory Bowel Disease- Epidemiology and Clinical Features . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Melvin B. Heyman and Neera Gupta Introduction........................................................................................................... Epidemiology of Pediatric Inflammatory Bowel Disease ................................... Clinical Features of Pediatric Inflammatory Bowel Disease ..............................
45 46 49 51 53 53 53 54 54 55 55 55 55 56 56 57 61 61 61 63
Chapter 6. The Natural History of Pediatric Crohn Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . James Markowitz Introduction........................................................................................................... Disease Activity.................................................................................................... Evolution of Disease Phenotype .......................................................................... Growth .................................................................................................................. Corticosteroid Dependence................................................................................... Surgery.................................................................................................................. Postoperative Recurrence ..................................................................................... Cancer Risk........................................................................................................... Quality of Life ......................................................................................................
67
Chapter 7. Natural History of Pediatric Ulcerative Colitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jeffrey S. Hyams Introduction........................................................................................................... Historical Perspective – Children......................................................................... Historical Perspective – Adults............................................................................ Clinical Characteristics Influencing Course......................................................... Drug Modification of Natural History ................................................................. Can We Predict the Course of Disease? .............................................................. Summary ...............................................................................................................
75
67 67 68 69 69 69 70 70 72
75 75 76 77 77 79 79
Chapter 8. Natural History of Pediatric Indeterminate Colitis . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Michael D. Kappelman and Richard J. Grand Introduction........................................................................................................... 83 Factors Leading to a Diagnosis of Indeterminate Colitis.................................... 84
Contents
xiii
Definitions............................................................................................................. Epidemiology........................................................................................................ Natural History ..................................................................................................... Recommendations................................................................................................. Summary ...............................................................................................................
85 85 86 89 89
Chapter 9. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease . . . . . Shervin Rabizadeh and Maria Oliva-Hemker Introduction........................................................................................................... Growth Failure...................................................................................................... Joint Manifestations.............................................................................................. Bone Disease ........................................................................................................ Oral Lesions.......................................................................................................... Skin Lesions ......................................................................................................... Eye Lesions........................................................................................................... Liver Disease ........................................................................................................ Other Extraintestinal Manifestations.................................................................... Summary ...............................................................................................................
91 91 92 93 93 94 94 96 97 98 99
Chapter 10. Growth Impairment in Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . 103 Thomas D. Walters and Anne M. Griffiths Introduction........................................................................................................... 103 Normal Growth and Pubertal Development ........................................................ 103 Growth in Pediatric IBD ...................................................................................... 104 Pathophysiology of Growth Impairment in IBD ................................................. 107 Facilitation of Normal Growth in IBD ................................................................ 110 General Principles of Management ...................................................................... 110 Summary ............................................................................................................... 114 Chapter 11. Skeletal Health in Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . 119 Francisco Sylvester Introduction........................................................................................................... 119 Growth, Bone Modeling and Remodeling ........................................................... 119 Bone Cells and Inflammation............................................................................... 121 Effects of Intestinal Inflammation on Bone......................................................... 123 Conclusions........................................................................................................... 128 Chapter 12. Puberty and Pediatric-Onset Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . 133 Barbara S. Kirschner and Barry H. Rich Introduction........................................................................................................... 133 The Pubertal Process in Healthy Children and Adolescents ............................... 133 The Influence of Inflammatory Bowel Disease on Puberty................................ 135 Pubertal Arrest ...................................................................................................... 136 Potential Causes of Pubertal Delay in Patients with IBD ................................... 136 Psyschosocial Issues and Puberty ........................................................................ 139 Therapeutic Approach to Addressing Pubertal Issues in IBD............................. 139 Chapter 13. Classification of Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . 143 Athos Bousvaros Introduction........................................................................................................... 143 Diagnostic Evaluation of Inflammatory Bowel Disease ..................................... 143
xiv
Contents
Distinguishing Acute Self-limited Colitis from Inflammatory Bowel Disease Involving the Colon ..........................................................................144 Distinguishing Ulcerative Colitis from Crohn Disease ....................................... 145 “Indeterminate Colitis” or “Colonic IBD Type Unclassified” ............................ 150 Subclassification of Ulcerative Colitis and Crohn Disease................................. 152 Summary ............................................................................................................... 153 Section 3
Diagnosis
Chapter 14. The History and Physical Exam in Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 Cheryl Blank and David J. Keljo Introduction........................................................................................................... 159 History................................................................................................................... 159 Physical Exam ...................................................................................................... 161 Conclusion ............................................................................................................ 162 Chapter 15. Differential Diagnosis of Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165 Thierry Lamireau Introduction........................................................................................................... 165 Acute Onset Diarrhea ........................................................................................... 165 Chronic or Recurrent Intestinal Symptoms.......................................................... 167 Abdominal Mass................................................................................................... 172 Isolated Esophagogastroduodenal Involvement ................................................... 173 Isolated Perianal Disease...................................................................................... 173 Chapter 16. Laboratory Evaluation of Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179 Jennifer Strople and Benjamin D. Gold Introduction........................................................................................................... 179 Blood Tests ........................................................................................................... 179 Stool Evaluation ................................................................................................... 186 Summary ............................................................................................................... 187 Chapter 17. Radiologic Evaluation of Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193 Benedict C. Nwomeh and Wallace V. Crandall Introduction........................................................................................................... 193 Crohn Disease....................................................................................................... 193 Imaging Techniques ............................................................................................. 194 Ulcerative Colitis .................................................................................................. 198 Imaging Techniques ............................................................................................. 198 Indeterminate Colitis ............................................................................................ 200 Other Radiologic Modalities in IBD.................................................................... 200 Evaluation of Complications ................................................................................ 202 Extraintestinal Disease ......................................................................................... 205 Hepatobiliary Disease........................................................................................... 205 Bone and Joint Disease ........................................................................................ 205 Future Trends........................................................................................................ 206
Contents
xv
Chapter 18. Endoscopic Modalities in Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . 211 Krishnappa Venkatesh and Mike Thomson Introduction........................................................................................................... 211 Endoscopy – Background History ....................................................................... 211 Patient Preparation................................................................................................ 212 Bowel Preparation ................................................................................................ 213 Monitoring and Sedation ...................................................................................... 214 Endoscopic Techniques in Inflammatory Bowel Disease ................................... 215 Ileocolonoscopy .................................................................................................... 217 Ileocolonoscopy Basic Technique........................................................................ 218 Complications of Ileocolonoscopy ....................................................................... 226 Endoscopic Findings in Inflammatory Bowel Disease........................................ 227 Follow-up and Surveillance Ileocolonoscopy ...................................................... 228 Enteroscopy........................................................................................................... 229 Double Balloon Enteroscopy................................................................................ 231 Endosonography ................................................................................................... 233 New Endo-diagnostic Methods ............................................................................ 234 Summary ............................................................................................................... 235 Chapter 19. The Pathology of Chronic Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . 241 Pierre Russo Introduction........................................................................................................... 241 Major Histologic Features Noted in Mucosal Specimens ................................... 241 Pathologic Features of Ulcerative Colitis and Crohn Disease ............................ 243 Ulcerative Colitis .................................................................................................. 245 Crohn Disease....................................................................................................... 248 Backwash Ileitis.................................................................................................... 254 Upper GI Tract Involvement in UC..................................................................... 255 Chapter 20. Video Capsule Endoscopy in Pediatric Inflammatory Bowel Disease . . . . . . . . . 263 Marc Girardin and Ernest G. Seidman Introduction........................................................................................................... 263 Potential Uses of Capsule Endoscopy for Inflammatory Bowel Disease ........... 265 Detection of Post-operative Recurrence............................................................... 267 Indeterminate Colitis ............................................................................................ 267 Experience in Pediatric Inflammatory Bowel Disease ........................................ 267 Specificity of Capsule Findings ........................................................................... 267 Practical Issues in Pediatric Patients.................................................................... 268 Conclusions........................................................................................................... 271 Chapter 21. Bone Health Assessment in Pediatric Inflammatory Bowel Disease . . . . . . . . . . 275 Meena Thayu, Edisio Semeao and Mary B. Leonard Introduction........................................................................................................... 275 Skeletal Modeling and Bone Accrual During Childhood.................................... 276 Changes in Cortical and Trabecular Bone with Growth ..................................... 277 Potential Threats to Bone Health in Pediatric IBD ............................................. 278 Assessment of Bone Status in Children and Adolescents ................................... 280 Clinical Studies of Bone Health in Pediatric IBD............................................... 283 Potential Therapies for Bone Health in Pediatric IBD........................................ 285 Summary ............................................................................................................... 287
xvi
Contents
Chapter 22. Assessment of Growth and Nutritional Status in Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295 Babette Zemel Introduction........................................................................................................... 295 Medical History and Laboratory Evaluation........................................................ 295 Anthropometry...................................................................................................... 296 Skeletal Maturation............................................................................................... 302 Sexual Maturation................................................................................................. 303 Summary ............................................................................................................... 304 Section 4
Medical Therapy
Chapter 23. Pharmacogenetics in Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . 309 Marla C. Dubinsky Introduction........................................................................................................... 309 A Historical Perspective of TPMT Pharmacogenetics ........................................ 309 Pharmacology of Thiopurines .............................................................................. 311 The Clinical Application of TPMT Pharmacogenetics ....................................... 312 Pharmacokinetics: The Role of Metabolite Monitoring ...................................... 313 Conclusion ............................................................................................................ 314 Chapter 24. 5-Aminosalicylate Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 M. Susan Moyer Introduction........................................................................................................... 317 Pharmacokinetics .................................................................................................. 317 Mechanism of Action ........................................................................................... 320 Indications and Efficacy ....................................................................................... 320 Safety and Side Effects ........................................................................................ 323 Adherence ............................................................................................................. 324 Future Directions .................................................................................................. 324 Chapter 25. Antibiotic Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329 Douglas Jacobstein and Howard Kader Introduction........................................................................................................... 329 Antibiotic Use in Crohn Disease.......................................................................... 330 Antibiotics in Ulcerative Colitis........................................................................... 332 Emerging Therapies.............................................................................................. 333 Summary ............................................................................................................... 334 Chapter 26. Nutritional Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337 Wael El Matary and Mary Zachos Introduction........................................................................................................... 337 Nutritional Impairment in Pediatric Inflammatory Bowel Disease..................... 337 General Management of Nutrition in Inflammatory Bowel Disease .................. 339 Adverse Effects of Enteral Nutrition ................................................................... 345 Mechanisms of Enteral Nutrition ......................................................................... 346 Conclusions........................................................................................................... 347 Chapter 27. Probiotic Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351 David R. Mack Introduction........................................................................................................... 351 Ulcerative Colitis .................................................................................................. 352 Pouchitis................................................................................................................ 354
Contents
xvii
Crohn’s Disease .................................................................................................... 355 Associated Conditions .......................................................................................... 357 Summary ............................................................................................................... 357 Chapter 28. Corticosteroid Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363 Johanna C. Escher Introduction........................................................................................................... 363 The Working Mechanism of Corticosteroids....................................................... 363 Systemic Corticosteroids ...................................................................................... 364 Topical Corticosteroids......................................................................................... 364 Efficacy of Oral Budesonide Treatment in Crohn Disease ................................. 365 Side Effects of Budesonide in Children............................................................... 366 Maintenance Treatment in Crohn Disease........................................................... 368 Budesonide Enemas in Ulcerative Colitis............................................................ 368 Conclusion ............................................................................................................ 368 Chapter 29. 6-Mercaptopurine Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371 Carmen Cuffari Introduction........................................................................................................... 371 Clinical Indication ................................................................................................ 371 Drug Monitoring................................................................................................... 373 6-MP Toxicity....................................................................................................... 376 Conclusions........................................................................................................... 376 Chapter 30. Methotrexate Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379 Joel R. Rosh Introduction........................................................................................................... 379 Mechanism of Action ........................................................................................... 380 Dose and Administration...................................................................................... 381 Efficacy ................................................................................................................. 382 Toxicity and Monitoring ...................................................................................... 383 Summary ............................................................................................................... 384 Chapter 31. Infliximab Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387 Séverine Vermeire, Gert Van Assche and Paul Rutgeerts Introduction........................................................................................................... 387 Efficacy of Infliximab in Adult Crohn Disease................................................... 388 Efficacy of Infliximab in Paediatric Crohn Disease............................................ 389 Infliximab for Paediatric Ulcerative Colitis......................................................... 392 Side Effects and Safety Profile of Infliximab...................................................... 393 Summary ............................................................................................................... 397 Chapter 32. Biologic Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403 Jeanne Tung and William J. Sandborn Introduction........................................................................................................... 403 Anti-tumor Necrosis Factor.................................................................................. 403 Anti-adhesion........................................................................................................ 410 Anti-interleukin 12/23 .......................................................................................... 413 Anti-interleukin-2 Receptor (Anti-CD25)............................................................ 414 Miscellaneous Biotechnology Agents .................................................................. 414
xviii
Contents
Chapter 33. Treatment of Perianal Crohn Disease Fistulae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429 Mark T. Osterman and Gary R. Lichtenstein Introduction........................................................................................................... 429 Background ........................................................................................................... 429 Medical Treatment................................................................................................ 431 Summary ............................................................................................................... 439 Chapter 34. Treatment of Fulminant Colitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447 Harland Winter Case....................................................................................................................... 447 Discussion ............................................................................................................. 449 Section 5
Surgical Therapy
Chapter 35. Surgical Management of Crohn’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 455 Daniel von Allmen Introduction........................................................................................................... 455 History of Surgical Therapy................................................................................. 455 Operative Indications............................................................................................ 456 Surgical Emergencies ........................................................................................... 457 Elective Surgery ................................................................................................... 458 Surgical Therapy................................................................................................... 459 Stricturoplasty ....................................................................................................... 461 Laparoscopy.......................................................................................................... 462 Colonic Disease .................................................................................................... 462 Perineal Disease.................................................................................................... 463 Rectal Strictures.................................................................................................... 463 Impact of Medical Therapy .................................................................................. 464 Post-operative Recurrence .................................................................................... 464 Adjuvant Procedures............................................................................................. 464 Chapter 36. Surgical Treatment of Ulcerative Colitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 469 Peter Mattei and John L. Rombeau Introduction........................................................................................................... 469 Indications for Surgery ......................................................................................... 469 Surgical Procedures .............................................................................................. 471 Preparation for Surgery ........................................................................................ 475 Outcomes of Surgery............................................................................................ 476 Complications ....................................................................................................... 477 Current Trends and Future Considerations .......................................................... 479 Summary ............................................................................................................... 480 Chapter 37. Pouchitis After Ileal Pouch-Anal Anastomosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 485 Christine Carter-Kent and Robert Wyllie Introduction........................................................................................................... 485 Definition and Incidence ...................................................................................... 486 Etiology and Pathogenesis.................................................................................... 486 Diagnosis............................................................................................................... 488 Classification......................................................................................................... 489 Treatment .............................................................................................................. 490 Outcome................................................................................................................ 491 Summary ............................................................................................................... 493
Contents
xix
Chapter 38. Enteral Feeding Devices and Ostomies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495 Susan N. Peck Gastrostomy .......................................................................................................... 495 Complications of Gastrostomy/Gastrojejenunostomy Tubes............................... 496 Ostomy Education and Management ................................................................... 501 Section 6
Research
Chapter 39. Clinical Indices for Pediatric Inflammatory Bowel Disease Research . . . . . . . . . 507 Angela Noble and Dan Turner Introduction........................................................................................................... 507 Assessment of Instruments Used in Clinical Research ....................................... 507 Outcomes for Clinical Research in Paediatric Inflammatory Bowel Disease .... 509 Gastrointestinal Endoscopy Indices ..................................................................... 515 Quality of Life Instruments.................................................................................. 516 Summary ............................................................................................................... 516 Appendix A........................................................................................................... 521 Appendix B........................................................................................................... 525 Appendix C........................................................................................................... 526 Appendix D........................................................................................................... 530 Chapter 40. Clinical Trials (Clinical Perspective) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 531 Salvatore Cucchiara and Osvaldo Borrelli Introduction........................................................................................................... 531 Markers and Indexes of Disease Activity............................................................ 531 Quality of Life ...................................................................................................... 536 Summary ............................................................................................................... 537 Chapter 41. Clinical Trials (Industry Perspective) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 541 Allan David Olson Introduction........................................................................................................... 541 Key Players in the Drug Development Process................................................... 541 Drug Development Process .................................................................................. 543 Key Clinical Trial Design Features...................................................................... 545 The Regulatory Agencies and the Regulatory Process........................................ 545 Good Clinical Practice.......................................................................................... 545 Practicing Physicians and Conduct of Clinical Trials ......................................... 547 Economics of Drug Development ........................................................................ 548 Unique Issues in Pediatric Research: Dosing and Consent/Assent..................... 549 Impact of the Pediatric Rule(s) ............................................................................ 549 Summary ............................................................................................................... 549 Glossary of acronyms ........................................................................................... 550 Websites................................................................................................................ 551 Section 7
Special Considerations
Chapter 42. Psychological Aspects of Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . 555 Laura M. Mackner and Wallace V. Crandall Introduction........................................................................................................... 555 Behavioral/Emotional Functioning....................................................................... 555 Social Functioning ................................................................................................ 558 Family Functioning............................................................................................... 559
xx
Contents
Body Image and Self-esteem ............................................................................... 559 Stress and Coping ................................................................................................. 560 Eating Problems.................................................................................................... 560 Education .............................................................................................................. 560 Psychotherapy and Other Resources .................................................................... 561 Summary ............................................................................................................... 561 Chapter 43. Measurement of Quality of Life in Pediatric Inflammatory Bowel Disease . . . 565 Anthony Otley Introduction........................................................................................................... 565 Quality of Life: Concepts/Definitions.................................................................. 565 Health-related Quality of Life Assessment in Pediatrics .................................... 568 Health-related Quality of Life Assessment in Inflammatory Bowel Disease: Adult IBD Perspective .....................................................................569 Health-related Quality of Life Assessment in Pediatric Inflammatory Bowel Disease.................................................................................................571 IMPACT ............................................................................................................... 572 Deficiencies in Current Knowledge and Areas for Future Research .................. 576 Chapter 44. Irritable Bowel Syndrome and Functional Gastrointestinal Disorders in Pediatric Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581 Manu R. Sood Introduction........................................................................................................... 581 Epidemiology........................................................................................................ 581 Clinical Features ................................................................................................... 582 Pathophysiology.................................................................................................... 583 Diagnosis............................................................................................................... 586 Treatment .............................................................................................................. 587 “Irritable” Pouch Syndrome ................................................................................. 589 Summary ............................................................................................................... 589 Chapter 45. Inflammatory Bowel Disease in Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 593 Sunanda Kane Introduction........................................................................................................... 593 Onset and Diagnosis During Pregnancy .............................................................. 593 Contraception........................................................................................................ 593 Fertility.................................................................................................................. 594 Effect of IBD on Pregnancy................................................................................. 595 Effect of Pregnancy on IBD................................................................................. 595 Management of IBD During Pregnancy .............................................................. 596 Medical Therapies ................................................................................................ 596 Immunomodulators ............................................................................................... 599 Breastfeeding ........................................................................................................ 602 Mode of Delivery ................................................................................................. 603 Surgery and Pregnancy......................................................................................... 604 Transition of Care................................................................................................. 604 Summary Points.................................................................................................... 605 Chapter 46. Malignant Tumors Arising in Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . 611 Thomas A. Ullman Introduction........................................................................................................... 611 Pathogenesis and Molecular Basis of Cancer in IBD ......................................... 611
Contents
xxi
Colorectal Cancer in Ulcerative Colitis: Epidemiology and Clinical Practice ... 613 Colorectal Cancer in Crohn Disease .................................................................... 622 Crohn Disease and Adenocarcinoma of the Small Intestine ............................... 624 Other Malignancies............................................................................................... 624 Summary ............................................................................................................... 625 Chapter 47. Quality Improvement in Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . 631 Richard B. Colletti and Peter A. Margolis Introduction........................................................................................................... 631 Variation in Care .................................................................................................. 632 The Chronic Illness Care Model .......................................................................... 633 The Need for Quality Improvement in IBD ........................................................ 634 The Improvement Model...................................................................................... 635 The Improvement Collaborative .......................................................................... 636 Collaborative Networks ........................................................................................ 638 Chapter 48A. Advocacy for Pediatric Patients with Inflammatory Bowel Disease . . . . . . . . . . 641 Janis Arnold, Athos Bousvaros, and Jennifer C. Jaff Introduction........................................................................................................... 641 Advocacy Directed at Schools ............................................................................. 641 Advocacy Directed at Insurance Companies ....................................................... 644 Social Security Disability ..................................................................................... 648 Family and Medical Leave for Caregivers .......................................................... 649 Summary ............................................................................................................... 650 Appendix 1. Sample Letter for Patient’s Student File Regarding Educational Accommodations Needed for an IBD Diagnosis ......................650 Appendix 2. Preparing an Effective Insurance Company Letter of Medical Necessity ......................................................................................651 Appendix 3. Sample Letter for Appeal of Denial of Mental Health Benefits ..............................................................................652 Appendix 4. Social Security Listing of Impairments for Children with IBD .... 652 Appendix 5. Preparing an Effective Letter for Family Medical Leave Act Provisions.................................................................................................653 Chapter 48B. Legislative Advocacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 655 Suzanne Rosenthal Introduction........................................................................................................... 655 Legislative Initiatives ........................................................................................... 656 Looking Back One Could Ask............................................................................. 658 Chapter 49. Transition from Pediatric to Adult Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661 George D. Ferry and M. Susan Moyer Introduction........................................................................................................... 661 Background ........................................................................................................... 662 Who is the Target ................................................................................................. 662 Goals/objectives.................................................................................................... 662 Transition Steps .................................................................................................... 663 Monitoring the Process......................................................................................... 664
Contributors
Janis Arnold, LICSW Pediatric Clinical Social Worker Inflammatory Bowel Disease Center Division of Gastroenterology and Nutrition Boston Children’s Hospital Boston, Massachusetts Robert N. Baldassano, MD Professor University of Pennsylvania School of Medicine Attending Physician and Director, Inflammatory Bowel Disease Center The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania Cheryl Blank, DO Assistant Professor of Pediatrics University of Pittsburgh School of Medicine Department of Gastroenterology Children’s Hospital of Pittsburgh of UMPC Pittsburgh, Pennsylvania Osvaldo Borrelli, MD Pediatric Gastroenterology and Liver Unit Pediatric Inflammatory Bowel Disease Center University of Rome “La Sapienza” Rome, Italy Athos Bousvaros, MD, MPH Associate Director, Inflammatory Bowel Disease Center Boston Children’s Hospital Boston, Massachusetts Christine Carter-Kent, MD Pediatric Gastroenterology Cleveland Clinic Foundation Cleveland, Ohio
xxiii
xxiv
Contributors
Judy H. Cho, MD Associate Professor of Medicine and Pediatrics Director, Inflammatory Bowel Disease Center Yale University New Haven, Connecticut Richard B. Colletti, MD Professor and Vice-Chair Department of Pediatrics Associate Chief, Vermont Children’s Hospital University of Vermont Burlington, Vermont Wallace V. Crandall, MD, FAAP Associate Professor of Clinical Pediatrics The Ohio State University Director, The Center for Pediatric and Adolescent IBD Columbus Children’s Hospital GI & Nutrition Columbus, Ohio Salvatore Cucchiara, MD, PhD Division of Pediatric and Liver Unit, Head Pediatric Inflammatory Bowel Disease Center, Director University Hospital Umberto 1 University of Rome “La Sapienza” Rome, Italy Carmen Cuffari, MD The Johns Hopkins Hospital Department of Pediatrics, Division of Gastroenterology Baltimore, Maryland Edwin F. de Zoeten, MD, PhD Division of Gastroenteroloyg, Hepatology and Nutrition The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania Marla C. Dubinsky, MD Assistant Professor of Pediatrics David Geffen School of Medicine University of California at Los Angeles Director Pediatric IBD Center Cedars-Sinai Medical Center Los Angeles, California Wael El Matary, MBBCH, MD, MRCP Assistant Professor of Pediatrics University of Alberta
Contributors
Division of Gastroenterology – Department of Pediatrics Stollery Children’s Hospital Edmonton, Alberta Canada Johanna C. Escher, MD, PhD Erasmus MC-Sophia Children’s Hospital University Medical Center Department of Pediatric Gastroenterology Rotterdam, The Netherlands William A. Faubion, Jr, MD Department of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota George D. Ferry, MD Professor of Pediatrics Baylor College of Medicine Director, IBD Center Texas Children’s Hospital Houston, Texas Claudio Fiocchi, MD The Cleveland Clinic Foundation Department of Gastroenterology and Hepatology Department of Pathobiology, Lerner Research Institute Cleveland, Ohio Ivan J. Fuss, MD National Institute of Allergy Immunology and Infectious Disease Mucosal Immunity Section National Institutes of Health Bethesda, Maryland Marc Girardin, MD Research Fellow McGill Center for IBD Division of Gastroenterology Faculty of Medicine McGill University Montreal, Quebec Canada Benjamin D. Gold, MD Professor of Pediatrics and Microbiology Marcus Professor and Director Division of Pediatric Gastroenterology, Hepatology and Nutrition Emory University School of Medicine Atlanta, Georgia
xxv
xxvi
Contributors
Richard J. Grand, MD Center for Inflammatory Bowel Disease Treatment and Research Division of Gastroenterology and Nutrition Children’s Hospital Boston and Department of Pediatrics Harvard Medical School Boston, Massachusetts Anne M. Griffiths, MD, FRCP (C) Professor of Paediatrics Division of Gastroenterology/Nutrition The Hospital for Sick Children Toronto, Ontario Canada Neera Gupta, MD, MAS Department of Pediatrics Pediatric Gastroenterology, Hepatology and Nutrition University of California, San Francisco San Francisco, California Melvin B. Heyman, MD, MPH Department of Pediatrics Pediatric Gastroenterology, Hepatology and Nutrition University of California, San Francisco San Francisco, California Jeffrey S. Hyams, MD Professor of Pediatrics University of Connecticut School of Medicine Head, Division of Digestive Diseases and Nutrition Connecticut Children’s Medical Center Hartford, Connecticut Douglas Jacobstein, MD Division of Pediatric Gastroenterology Sinai Hospital of Baltimore Baltimore, Maryland Jennifer C. Jaff, Esq. Executive Director Advocacy for Patients with Chronic Illness, Inc. Farmington, Connecticut Howard Kader, MD Division of Pediatric Gastroenterology Sinai Hospital of Baltimore Baltimore, Maryland
Contributors
Sunanda Kane, MD Department of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota Michael D. Kappelman, MD, MPH Assistant Professor of Pediatrics University of North Carolina Chapel Hill 5143 Bioinformatics Bldg; CB#7229 Chapel Hill, NC 27599 E-mail:
[email protected] David J. Keljo, MD, PhD Professor of Pediatrics University of Pittsburgh School of Medicine Director, Inflammary Bowel Disease Center Department of Gastroenterology Children’s Hospital of Pittsburch of UMPC Pittsburgh, Pennsylvania Barbara S. Kirschner, MD Professor of Pediatrics Section of Pediatric Gastroenterology, Hepatology & Nutrition Department of Pediatrics The University of Chicago The University of Chicago Corner Children’s Hospital Chicago, Illinois Email:
[email protected] Subra Kugathasan, MD Associate Professor of Pediatrics Department of Pediatrics Medical College of Wisconsin Milwaukee, Wisconsin Thierry Lamireau, MD, PhD Division of Pediatric Gastroenterology Children’s Hospital Victor Segalen University of Badeaux2 Bordeaux, France Mary B. Leonard, MD, MSCE Department of Pediatrics The Children’s Hospital of Philadelphia Department of Biostatistics and Epidemiology University of Pennsylvania School of Medicine Philadelphia, Pennsylvania
xxvii
xxviii
Contributors
Gary R. Lichtenstein, MD Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Division of Gastroenterology Philadelphia, Pennsylvania David R. Mack, MD, FAAP, FRCPC Professor, Department of Pediatrics University of Ottawa Head, Pediatric Gastroenterology, Hepatology & Nutrition Children’s Hospital of Eastern Ontario Ottawa, Ontario Canada Laura M. Mackner, PhD Division of Psychology Department of Pediatrics Columbus Children’s Hospital and The Ohio State University Petar Mamula, MD Assistant Professor of Pediatrics University of Pennsylvania School of Medicine Attending Physician, Division of G.I. and Nutrition The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania Peter A. Margolis, MD, PhD Professor and Co-Director, Center for Health Care Quality Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio James Markowitz, MD Professor of Pediatrics New York University School of Medicine Attending Pediatrician North Shore – LIJ Health System Division of Pediatric Gastroenterology Schneider Children’s Hospital New Hyde Park, New York Jonathan E. Markowitz, M.D., M.S.C.E Associate Professor of Clinical Pediatrics University of South Carolina School of Medicine Attending Physician, Children’s Center for Digestive Health Greenville Hospital System University Medical Center Greenville, South Carolina
Contributors
Peter Mattei, MD Department of General, Thoracic and Fetal Surgery The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania Nancy McGreal, MD Fellow, Medicine and Pediatrics University of Chicago Chicago, Illinois M. Susan Moyer, MD Cincinnati Children’s Hospital Medical Center Division of GI, Hepatology & Nutrition Cincinnati, Ohio Angela Noble, MD Clinical Instructor in Pediatrics Department of Gastroenterology, Hepatology and Nutrition St. Justine Hospital University of Montreal Montreal, Canada Benedict C. Nwomeh, MD, FACS, FAAP Assistant Professor of Surgery The Ohio State University Surgical Director, The Center for Pediatric and Adolescent IBD Columbus Children’s Hospital Columbus, Ohio Maria Oliva-Hemker, MD Division of Pediatric Gastroenterology and Nutrition The Johns Hopkins University School of Medicine Baltimore, Maryland Allan David Olson, MD, MS, MBA Director Immunology Centocor, Inc. Horsham, Pennsylvania Mark T. Osterman, MD Division of Gastroenterology Department of Medicine Pennsylvania Presbyterian Medical Center University of Pennsylvania School of Medicine Philadelphia, Pennsylvania Anthony Otley, MD, MSc, FRCPC Division of Gastroenterology, Department of Pediatrics Associate Professor, Dalhousie University Halifax, Nova Scotia Canada
xxix
xxx
Contributors
Susan N. Peck, MSN, CRNP Division of GI, Hepatology and Nutrition The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania Shervin Rabizadeh, MD, MBA Division of Pediatric Gastroenterology and Nutrition The Johns Hopkins University School of Medicine Baltimore, Maryland Barry H. Rich, MD Associate Professor Section of Pediatric Endocrinology Department of Pediatrics The University of Chicago Chicago, Illinois John L. Rombeau, MD University of Pennsylvania School of Medicine Department of Surgery Division of Colon and Rectal Surgery Philadelphia, Pennsylvania Suzanne Rosenthal Crohn’s & Colitis Foundation of America, Inc. Co-Founder, Chairman of the Board Emerita Joel R. Rosh, MD Director, Pediatric Gastroenterology Atlantic Health/Goryeb Children’s Hospital Associate Professor of Pediatrics UMD – New Jersey Medical School Morristown, New Jersey Pierre Russo, MD Chief, Anatomic Pathology Department of Pathology The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania Paul Rutgeerts, MD, PhD, FRCP Division of Gastroenterology University Hospital Leuven Leuven, Belgium Shehzad A. Saeed, MD Associate Professor of Pediatrics Department of Pediatrics and Nutrition Sciences Division of Gastroenterology and Nutrition
Contributors
The University of Alabama at Birmingham and The Children’s Hospital of Alabama Birmingham, Alabama William J. Sandborn, MD Professor of Medicine Mayo College of Medicine Vice Chairman, Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota Ernest G. Seidman, MD, FRCPC, FACG Bruce Kaufman Chair in IBD at McGill Professor of Medicine & Pediatrics McGill University Health Center Montreal Children’s Hospital Montreal, Quebec Canada Edisio Semeao, MD Department of Pediatrics The Children’s Hospital of Philadelphia University of Pennsylvania School of Medicine Philadelphia, Pennsylvania Manu R. Sood, MD Associate Professor of Pediatrics Department of Pediatrics Medical College of Wisconsin Milwaukee, Wisconsin Jennifer Strople, MD Division of Pediatric Gastroenterology, Hepatology and Nutrition Children’s Memorial Hospital Chicago, Illinois Francisco Sylvester, MD Associate Professor of Pediatrics University of Connecticut School of Medicine Connecticut Children’s Medical Center Hartford, Connecticut Meena Thayu, MD Department of Pediatrics The Children’s Hospital of Philadelphia University of Pennsylvania School of Medicine Philadelphia, Pennsylvania
xxxi
xxxii
Contributors
Dr. Mike Thomson Centre for Pediatric Gastroenterology Sheffield Children’s NHS Foundation Trust Sheffield, United Kingdom Jeanne Tung, MD Division of Gastroenterology and Hepatology Department of Pediatrics Mayo Clinic Rochester, Minnesota Dan Turner, MD Department of Gastroenterology, Hepatology and Nutrition St. Justine Hospital University of Montreal Montreal, Canada Thomas A. Ullman, MD Assistant Professor of Medicine The Dr. Henry D. Janowitz Division of Gastroenterology The Mount Sinai School of Medicine New York, New York Gert Van Assche, MD, PhD Division of Gastroenterology University Hospital Leuven Leuven, Belgium Dr. Krishnappa Venkatesh Centre for Pediatric Gastroenterology Sheffield Children’s NHS Foundation Trust Sheffield, United Kingdom Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Leuven Leuven, Belgium Daniel von Allmen, MD Division of Pediatric Surgery The University of North Carolina Chapel Hill Chapel Hill, North Carolina Thomas D. Walters, MBBS, FRACP The Hospital for Sick Children University of Toronto Toronto, Canada
Contributors
Harland Winter, MD Pediatric GI Unit-MGH 175 Cambridge Street-CPZS-560 Boston, MA 02114 Robert Wyllie, MD Cleveland Clinic Foundation Chair, Department of Pediatric GI and Nutrition Cleveland, Ohio Mary Zachos, MD, FRCPC Assistant Professor Department of Pediatrics University of Toronto Clinical Director – Inflammatory Bowel Disease Program Staff Gastroenterologist, Hospital for Sick Children The Hospital for Sick Children Toronto, Ontario Canada Babette Zemel, PhD Director, Nutrition and Growth Laboratory Division of Gastroenterology, Hepatology and Nutrition The Children’s Hospital of Philadelphia Associate Professor of Pediatrics University of Pennsylvania School of Medicine Philadelphia, Pennsylvania
xxxiii
Section 1 Etiology and Pathogenesis
1 Genetics of Inflammatory Bowel Diseases Nancy McGreal and Judy H. Cho∗
Introduction The inflammatory bowel diseases (IBD), Crohn disease and ulcerative colitis, are immune-mediated disorders resulting in chronic, relapsing inflammation of the gastrointestinal tract. While no specific etiology has been defined, the complex nature of IBD supports the notion that its origin is likely multi-factorial. Current theory suggests that in genetically predisposed individuals, environmental factors and maladaptive immune responses to gastrointestinal flora generate a dysregulated inflammatory cascade creating mucosal injury. Over the last decade, considerable interest and research has focused on the genetic aspect of IBD. The identification of linkage between Crohn disease and the pericentromeric region of chromosome 16 (IBD1) by Hugot in 1996, spawned a series of genome scans and linkage analyses in search of susceptibility and phenotypic modifier genes [1]. In 2001, the discovery that specific polymorphisms in the CARD15/NOD2 gene at the IBD1 locus were associated with Crohn disease engendered a new era of genotype-phenotype investigations [2, 3]. The advent of genome-wide association studies has resulted in the successful identification of new, well-replicated disease associations. The heterogeneity of IBD phenotypes suggests that it is a polygenic disorder in which susceptibility loci act in epistasis with other disease-modifying genes and the environment to produce disease. The field of IBD genetics is of special interest to pediatric gastroenterologists for both practical and investigational reasons. From a clinical practice standpoint, pediatric gastroenterologists are often faced with questions from concerned parents regarding the risk of IBD among current or future siblings, as well as the eventual offspring of the affected child. Understanding genetic associations of IBD can provide patients and their families with useful information that may help them cope with the disease. Furthermore, as our knowledge of genotype-phenotype associations grows, it is anticipated that genotyping at the onset of disease may enable physicians to predict disease course and tailor medical therapies specific for each patient. In terms of advancing the field of gastroenterology through research, studies of pediatric IBD genetics are of significance because children have been exposed to fewer environmental confounders of disease than their adult counterparts. Examining the disease of young individuals could provide us with keys to unlock intrinsic genetic mechanisms in IBD that may not otherwise be detected in adult studies. This may be of special importance in individuals with very early
*Associate Professor of Medicine and Pediatrics, Director, Inflammatory Bowel Disease Center, Yale University, Phone: 203-785-4138
3
4
Nancy McGreal and Judy H. Cho
onset IBD (< 5 years), whose disease course and phenotypes are the most discordant with those of adult-onset IBD.
Crohn Disease and Ulcerative Colitis: Genetic Epidemiology Ethnic and Racial Variations of Disease That IBD has a genetic component is supported by ethnic and racial variations in disease prevalence. The highest rates of IBD are found in Caucasian individuals, especially those of Jewish heritage. Among Jewish sub-groups, Ashkenazi Jews have a 2 to 9 fold greater prevalence of IBD over non-Jewish counterparts [4]. This increased occurrence has been noted to be stable over time and geographic distribution, substantiating the important role of genetics in IBD. African Americans and Asians are believed to have a lower risk of IBD; although there appears to be a trend towards growing prevalence in these populations. In a study of the impact of race and ethnicity on IBD, Basu et al. found that African Americans and whites were more likely to have Crohn disease, whereas ulcerative colitis predominated among Mexican Americans [5]. While intestinal manifestations did not appear to vary based upon race or ethnicity, there were differences in extraintestinal manifestation between groups. Among Crohn patients, African Americans were more likely to evidence arthritis and uveitis than whites, whereas, joint symptoms and osteoporosis were more common among whites with UC than Mexican Americans. Family Studies The concept that IBD may, in part, be hereditary has been well-established through observations of familial disease aggregation. Family studies have demonstrated that 5–30% of probands with Crohn disease and ulcerative colitis identify the presence of IBD in a family member [4]. This association appears to be stronger for Crohn disease than ulcerative colitis. Phenotypically, relatives of probands with IBD are more likely to develop the same form of disease as the affected family member. Furthermore, there is literature to suggest that within families with IBD, there is a concordance between family members in terms of localization of disease, but not disease severity. With regard to age of disease onset, patients with a family history of IBD are thought to be more likely to develop disease at an earlier age than affected individuals lacking a family history [6]. Among family members, the risk of developing IBD is greatest among first degree relatives, especially siblings. The relative risk (RR) for a sibling of a Crohn patient developing disease is 13–26 and 7–17 for siblings of ulcerative colitis patients [7]. Parents of children with IBD are at a lower risk of developing disease than siblings [7]. With regard to the offspring of affected individuals, Orholm et al. found that 6.2% of children born to a parent with ulcerative colitis developed IBD and 9.2% of children born to a parent with Crohn disease developed IBD [8]. In the rare instance that both parents have IBD, studies estimate that their children have a 33% chance of developing IBD by age 28 [7]. Although, second and third degree relatives of IBD probands have a lower likelihood of disease, their risk is still elevated compared to the background population. Twin Studies Investigations of monozygotic and dizygotic twins have provided strong evidence that genetics play an integral role in the etiology of IBD. Twin studies are based upon the premise that in the setting of a similar environmental milieu, rates of disease concordance between twins correlate with the influence of genetic factors. To date, three large studies of twin pairs with IBD from Scandinavia and the United Kingdom have consistently identified higher concordance rates among monozygotic twins with Crohn disease and ulcerative colitis than dizygotic twins [9–11]. The
Chapter 1 Genetics of Inflammatory Bowel Diseases
5
influence of genetics appears to be greater in Crohn disease than ulcerative colitis with reported cumulative monozygotic concordance rates of 36% and 16%, respectively [12]. Concordance rates for dizygotic twins are approximately 4% in both Crohn disease and ulcerative colitis. Similar to data from family studies, co-twins with IBD are likely to develop the same disease type, however, mixed pairs of dizygotic twins with ulcerative colitis and Crohn disease have been reported. With regard to disease-specific characteristics, Scandinavian twin registries demonstrated concordance of 40–77% for disease location, however, there appeared to be no association of disease behavior or extent among co-twins [9, 11]. Furthermore, a trend towards concordance for age at diagnosis was identified with 40–67% receiving a diagnosis of IBD within 2 years of one another. Taken together, the data from twin studies regarding concordance between monozygoytes provides evidence that genetic influences are important in the development of IBD. However, the fact that monozygotic concordance is not 100%, and the low concordance between dizygotes suggests that genotype alone is not sufficient for disease evolution.
Identifiable Gene Variants in Crohn Disease NOD2/CARD15 Gene and Crohn Disease The NOD2/CARD15 gene located on the IBD1 locus of chromosome 16 is associated with an increased susceptibility to Crohn disease but not ulcerative colitis. Among the more than 30 known amino acid polymorphisms identified in the NOD2/CARD15 gene [13], the most common variants are two missense mutations, R702W and G908R, and one frameshift mutation L1007fsinsC. From a disease pathogenesis perspective, NOD proteins (NOD1 and NOD2) are mammalian pattern recognition receptors which serve the innate immune system as bacterial sensing molecules. NOD2 is a cytosolic protein found in a variety of cells including monocytes, macrophages, B and T lymphocytes, dendritic cells, and intestinal epithelial cells. Stimulation of NOD2 by its ligand, muramyl dipeptide (MDP), propagates signal transduction pathways leading to nuclear factor B (NF-B) and mitogen activated protein kinase (MAPK) activation. Functional Effects of NOD2 Mutations How mutations in NOD2/CARD15 contribute to the pathogenesis of IBD remains an active area of research. In mice which lacked NOD2 [14, 15], no spontaneous intestinal inflammation was identified and bone marrow macrophage response to MDP was impaired. Further investigation into the impact of bacterial infection on NOD2 mutations showed that knockouts had increased susceptibility to infection with administration of oral Listeria monocytogenes compared to control mice. When Listeria was administered systemically, however, there was no difference in bacterial clearance between controls and NOD2 deficient mice. These findings substantiated the importance of NOD2 in bacterial recognition and activation of inflammatory pathways. They also served to identify a key antibacterial role for NOD2 in the intestinal epithelial layer which has been linked to -defensin deficiency in human Crohn disease [15]. Epidemiology of NOD2 Mutations Possession of one NOD2/CARD15 allele confers a two-three fold relative risk of developing Crohn disease; this risk is increased to 17-fold if two alleles are present [16]. Ten to thirty percent of patients with Crohn disease are heterozygous for one of the three mutations, while 3–15% are homozygous or compound heterozygotes [17]. Although these variants are associated with an increased risk of Crohn disease, 8–15% of the healthy population possesses at least one of these mutations and 1% of healthy individuals are homozygous or compound heterozygotes. That genotypic variants are found in individuals without known Crohn suggests phenotypic expression of disease is subject to polygenic factors, variable penetrance, and other environmental mediators.
6
Nancy McGreal and Judy H. Cho
Studies of patients with Crohn disease world-wide have revealed that the association of NOD2/CARD15 polymorphisms with Crohn varies between different ethnic populations. North American adult Caucasian cohorts report carriage rates of 10–30% for the three common NOD2/CARD1 variants, while minority groups were found to have lower allele frequencies. A North American, multi-center study of pediatric patients with Crohn disease identified NOD2/CARD15 polymorphisms among 25% White, 1.6% African American, and 1.6% Hispanic participants [18]. Significant diversity in allele carriage has been described among Crohn patients in European countries and background control populations. NOD2/CARD15 variants are virtually absent in Japanese, Korean, Chinese, and sub-Saharan African individuals. High rates of NOD2/CARD15 mutations have been seen in the Jewish Ashkenazim with one Israeli group reporting the presence of variants in 51% of pediatric and 37.5% of adult Crohn patients studied [19]. SLC22A4/A5 Variants at the IBD5 Locus The IBD5 locus on chromosome 5 contains genes SLC22A4 and SLC22A5, also known as OCTN1 and OCTN2 (organic cation transporter proteins), respectively. While variants of these genes have been associated with both ulcerative colitis and Crohn disease, the linkage with Crohn appears stronger [20, 21]. Similar to the differential distribution of NOD2/CARD15 polymorphisms among various ethnic backgrounds, the OCTN variants also appear more prevalent in the Caucasian population than Asian populations [22]. Studies of Caucasian individuals demonstrate that possession of one OCTN allele increases the risk of Crohn disease by 2.5 fold and two copies raises the risk by 4 fold [23, 24]. Some studies have demonstrated an interactive effect between NOD2/CARD15 polymorphisms, however, these findings have not been consistently observed. Phenotypic correlates have been reported for perianal disease [25, 26], colonic location [27], disease complications and progression [21, 28], extensive disease in UC [20], as well as for decreased height and weight at diagnosis in pediatric cohorts [29]. In contrast, some studies have not observed clear genotype-phenotype correlations [30, 31]. DLG5 Gene Variants and IBD Polymorphisms of the DLG5 (Drosophila Discs Large Homolog 5) gene on chromosome 10q22–23 were reported to have an association with IBD by Stoll et al. [32] DLG5 is a member in the MAGUK (membrane-associated guanylate kinase) family which mediates protein-protein interactions and adhesion of epithelial cell junctions. DLG5 has been postulated to play a role in maintenance of the intestinal epithelial barrier and permeability. Given the known increase in intestinal permeability of Crohn patients and their family members, mutations in the DLG5 gene have been conceptualized to result in impaired barrier function predisposing to a disease state. In a case control cohort it was demonstrated that variants, G113A and C4136A, resulted in amino acid substitutions that conferred a relative modest risk of disease, 1.6 and 1.5, respectively [32]. A different DLG5 variant was found to be weakly associated with Crohn disease in the Japanese population [22]. German and Hungarian investigators, however, were unable to replicate disease susceptibility with any DLG5 polymorphisms [33], nor did they find evidence to suggest that DLG5 variants were associated with increased intestinal permeability in patients with Crohn disease. Thus, further investigation is needed to understand what role DLG5 mutations may play in the pathogenesis of IBD. HLA Type and IBD Susceptibility The IBD3 locus on chromosome 6p encodes genes in the HLA region which serve an immunoregulatory role and contribute to lymphocyte function. Associated polymorphisms between HLA types and IBD have included: HLA-B, HLA-DRB1, HLADQB1, HLA-DP, tumor necrosis factor
Chapter 1 Genetics of Inflammatory Bowel Diseases
7
(TNF), heat shock protein (HSP)-70, and MICA [34]. The polymorphic nature of the HLA region as well as its complex linkage disequilibrium has resulted in heterogeneous findings among investigators. Of the greater than 100 association studies of IBD and HLA performed to date, stronger evidence exists for an association with class II alleles than class I alleles. Class II alleles DRB1*0103, DRB*1502, and DRB*401 have been consistently associated with ulcerative colitis [35]. Phenotypic analyses have identified DRB1*0103 to be predictive of a more aggressive form of ulcerative colitis with shorter time to colectomy than those without the allele. Polymorphisms of a TNF promoter resulting in a low TNF- producing haplotype have also been associated with limited ulcerative colitis that remains distal over the disease course [34]. In Crohn patients, a particular link between DRB1*0103 and isolated colonic disease has been reported [36]. The correlation of DRB1*0103 with both colonic Crohn disease and ulcerative colitis has been postulated to provide a unifying molecular mechanism for colonic involvement in IBD. The relatively low frequency of this allele, however, makes it less likely to be a true susceptibility gene. Rather, it probably functions as a disease modifying gene in epistasis with other genetic and environmental factors. HLA associations with extraintestinal manifestations have also been evaluated. One small study of both ulcerative colitis and Crohn disease identified a connection between TNF promoter variants and erythema nodosum [37]. HLA-B27, HLA-B35 and HLA-DRB*103 have been associated with type I peripheral arthropathy, whereas, HLA-B*44 is associated with type II peripheral arthropathy [38, 39]. Symptoms of uveitis have been linked with HLA-B27 and DRB*0103.
Genome-wide Association Studies in Crohn Disease A major new development in the field of complex human genetics has been the capacity to perform dense genotyping across the genome. This technological development has made possible the performance of genome-wide association studies. These genome-wide association studies have the capacity to assay a large fraction of the common human genetic variation throughout the genome and have the potential to markedly increase understanding of the genetic basis for complex, multigenic disorders. Thus far, a number of novel gene associations have been reported in Crohn disease which have demonstrated promising results in early studies. Association of IL23R (Interleukin 23 Receptor) Polymorphisms to Crohn Disease and Ulcerative Colitis A genome-wide association study in a North American ileal Crohn disease cohort identified multiple new gene associations, notably to multiple polymorphisms within the IL23R gene on chromosome 1p31 [40]. In particular, an amino acid polymorphism, Arg381Gln, located in the cytoplasmic domain of the IL23R protein, demonstrated highly significant evidence for association. The less common glutamine allele conferred significant protection against developing IBD in non-Jewish and Jewish Crohn disease cohorts, a well as in non-Jewish ulcerative colitis cohorts. Additional independent association signals were observed indicating the presence of multiple associations within the IL23R gene [40]. Since the initial report, the IL23R associations have been replicated in a childhood onset IBD cohort from Scotland [41], as well as in a Belgian CD cohort [42]. The functional IL-23 heterodimeric receptor is comprised of the IL23R (chromosome 1p31) and IL12RB2 (chromosome 19p13) [43] subunits, with the latter subunit shared with the functional IL-12 receptor (Figure 1.1). Similarly, the IL-23 cytokine is comprised of a unique subunit, p19 (chromosome 12q13), as well as the p40 subunit which is common to the IL-12 functional cytokine. Significant recent progress has been reported in understanding the role of the IL-23 pathway in mediating end-organ inflammation. Prior work with mouse models has demonstrated a requirement for IL-23 in murine colitis [44–47], experimental autoimmune encephalitis [48], and
8
Nancy McGreal and Judy H. Cho IL-23 signaling p40 p19 chr12q13 chr5q33
IL-12 signaling p40 p35 chr5q33 chr3q25
Cytokine
Receptor
IL23R chr1p31
IL12RB1 chr19p13
IL12RB1 IL12RB2 chr19p13 chr1p31
Figure 1.1. Interleukin 23 and interleukin 12 signaling. Both pathways are comprised of heterodimeric cytokines and receptors and share common subunits of both the cytokine (p40) and receptor (IL12RB1).
collagen-induced arthritis. Similar IL23R gene associations have been reported in human psoriasis [49]. Taken together, these findings would suggest that blocking the IL-23 pathway may be efficacious in the treatment of IBD. In support of this, anti-p40 antibodies (which would block both IL-12 and IL-23 pathways) [50] have been effective in the treatment of Crohn disease. Whether specific targeting of the p19 pathway to achieve IL-23 specific effects [51] will be more efficacious will be the focus of future studies. Association of the ATG16L1 Autophagy Gene to Crohn Disease A genome-wide association study focusing on coding region polymorphisms identified association of the amino acid polymorphism, Thr197Ala. The ATG16L1 gene is part of the autophagosome pathway and has been implicated in the processing of intracellular bacteria [52]. ATG16L1 is expressed in intestinal epithelial cells, as well as in CD4+ , CD8+ and CD19+ primary human lymphocytes [53]. Since the initial report in a German cohort, this association has been confirmed in independent Belgian [42] and North American cohorts [53]. Of interest is that no association was observed to ulcerative colitis, suggesting that ATG16L1, like the NOD2/CARD15 associations, represent CD-specific risk alleles. Taken together, the ATG16L1 association suggests that autophagy and host cell responses to intracellular microbes are involved in the pathogenesis of CD. Association of a Gene Desert on Chromosome 5p13 to Crohn Disease A genome-wide association study in a Belgian CD cohort demonstrated association to a broad genomic region on chromosome 5p13 not containing any genes [42]. The closest flanking gene is the prostaglandin receptor, EP4 (PTGER4). Of great interest is that some of the genetic variants in this region were demonstrated to regulate PTGER4 mRNA expression. PTGER4 represents a very strong candidate gene to account for the statistical association because PTGER4-deficient mice demonstrating increased susceptibility to dextran sodium sulfate-induced colitis [54]. These promising findings will need to be replicated in independent IBD association cohorts.
Genetic Studies in Ulcerative Colitis The search for genetic variants associated with ulcerative colitis has yielded fewer candidate genes than Crohn disease. One potential candidate, the interleukin-1 receptor antagonist (IL1RA) gene, was first identified in 1994 and remains controversial. Data from the primary investigators reported
Chapter 1 Genetics of Inflammatory Bowel Diseases
9
an association between IL1RA and increased susceptibility to ulcerative colitis with an odds ratio (OR) of 1.3. Subgroup analysis showed that this relationship was strongest for individuals with extensive disease (OR 1.5), those undergoing colectomy (OR 1.5), and patients who developed pouchitis [55, 56]. Other researchers studying cohorts from the same region, however, failed to replicate an association between IL1RA and Crohn disease or ulcerative colitis suggesting the connection may be weak [57]. The multi-drug resistance gene, MDR1, which resides in a region of linkage on chromosome 7 has also been postulated to play a role in colitis. Encoding a set of membrane transporters, variants of the MDR1 gene modulate epithelial transport and barrier function. Animal studies have shown that murine MDR1 knockouts develop spontaneous colitis reminiscent of inflammatory bowel disease [58]. In humans, diminished mRNA expression of MDR1 from intestinal tissue of patients with IBD implies this pathway may be involved in disease pathogenesis [59]. Genetic analyses in humans, however, have exhibited contradictory results regarding susceptibility to UC and SNP C3435T. Taken together, this data suggests that variants of the MDR1 gene may warrant further study in relation to ulcerative colitis [60]. Recent studies have also identified associations between ulcerative colitis and polymorphisms of the NFB1 promoter and IBD2 susceptibility locus. Genes in the NFB pathway merit special interest based upon the integral role the signal transduction pathway plays in inflammatory processes. Murine models of colitis have demonstrated strong linkage between a locus on chromosome 3 that contains the NFB1 gene. Translated to humans, a Dutch study found allele frequency for the 94ins/delATTG variant was significantly higher in UC patients as compared to controls or those with Crohn. Individuals homozygous for the deletion also appeared to have younger age at onset of disease [61]. The IBD2 locus located on chromosome 12 has also been implicated in the pathogenesis of ulcerative colitis. In a linkage study of 904 affected relative pairs, the IBD2 locus was associated with a subset of patients manifesting extensive ulcerative colitis [62].
Genotype-Phenotype Correlations in Pediatric IBD Disease Type and Location The discovery of genetic polymorphisms in IBD has afforded investigators with the opportunity to identify predictive correlations between specific variants and phenotypic disease characteristics. Analyses of adult populations have demonstrated that carriage of NOD2/CARD15 risk alleles predicts disease onset at an earlier age and ileal disease location in a dose-dependent manner. Subsequently, a meta-analysis of 16 case-control studies confirmed the association of NOD2/CARD15 carriage with ileal disease location, and also identified a correlation with fibrostenosing behavior and family history of IBD [16]. The majority of pediatric studies have concurred with findings from adult counterparts that carriage of NOD2/CARD15 variants is associated with ileal disease. Estimates suggest that 20–65% of children with ileal Crohn disease possess at least one NOD2/CARD15 mutation; consistent phenotypic associations have not been seen for other regions of the gastrointestinal tract [63–68]. In contradistinction to the adult literature, correlates of NOD2/CARD15 variants with fibrostenosing disease have demonstrated conflicting results [19, 63, 64, 67, 68]. Two large studies from the US and Scotland found that 34–45% of Crohn patients possessing NOD2/CARD15 polymorphisms had evidence of fibrostenosing disease, especially the 1007fs and R720W variants [64, 68]. Three other pediatric studies, however, found no correlation of NOD2/CARD15 with fibrostenosing disease [19, 63, 67].
10
Nancy McGreal and Judy H. Cho
Disease Age at Onset Previous literature has suggested that individuals with a family history of IBD are more likely to have early onset disease. This would imply a greater influence of genetic factors in those diagnosed with IBD at an earlier age. Analysis of age of disease onset with respect to NOD2 carriage, however, has not shown a clear association between age and these allelic variants [19, 64, 68]. Russell et al. reported a median age at diagnosis of 11 years for carriers of NOD2 variants and 11.3 years for non-carriers [68]. Similar results were published by Kugathasan et al. who found no difference in the mean age of disease onset among Caucasian children with Crohn disease possessing NOD2 mutations versus those who did not (11.98 years vs. 12.76 years, respectively) [64]. Only one study of 55 German pediatric Crohn patients showed a higher frequency of two NOD2 mutations among children than adults (35% vs. 17%) [65]. Thus, while genetic factors may predispose individuals to developing IBD at a young age, there is insufficient evidence at this time to conclude that NOD2 variants are associated with earlier onset disease in pediatric IBD.
Growth Parameters As growth failure is an important feature of pediatric IBD, several groups have investigated the relationship between anthropometric parameters and NOD2/CARD15 status. A study of 101 Crohn patients demonstrated that 44% of participants possessing a NOD2/CARD15 polymorphism were <5% for weight at the time of diagnosis, while only 15% of those without a genetic variant were <5% for weight at the time of diagnosis [63]. Although similar trends were seen for height, these results did not reach statistical significance. Another study of 93 Crohn patients, however, did not show any correlation between NOD2/CARD15 status and height or weight Z scores at disease onset or for the lowest Z score during childhood [67]. Rather disease severity was the strongest predictor for impaired growth and ileal involvement was associated with height retardation at disease onset and the lowest Z-score during follow-up. Finally, a German group did not find any statistically significant difference in mean body mass index (BMI) or mean height percentiles at diagnosis between patients with and without NOD2/CARD15 variants [69]. The authors did note a non-significant trend of greater numbers of patients possessing NOD2/CARD15 polymorphisms being below the 3% for BMI. Taken together, these data imply that while NOD2/CARD15 variants may be associated with poor growth, this effect may be more a reflection of malnutrition secondary to ileal location and disease severity as opposed to an inherent genetic effect.
Association with Risk of Surgery Results of pediatric studies correlating NOD2/CARD15 status with the need for small bowel surgical resection have consistently delineated a positive association. Russell et al estimated an odds ratio for risk of surgery among children with Crohn possessing any NOD2 mutation to be 4.45 [68]. Pediatric Crohn patients with the 1007fsInsC variant appeared to have a greater likelihood of requiring surgery with an odds ration of 4.8. Among US Caucasian Crohn patients, hazard ratios for surgery indicate that children possessing the 3020insC variant are at 6-fold greater risk of requiring surgical intervention [64]. Furthermore, these children also showed a trend toward a need for earlier surgery at median of 14 months versus 23 months after diagnosis. Finally, it has been suggested that there is a positive correlation between the number mutations possessed by an individual and increased risk of surgery [65].
Chapter 1 Genetics of Inflammatory Bowel Diseases
11
Summary That there is a genetic basis for IBD had been previously theorized through observations of racial/ethnic variations in disease, as well as family and twin studies. The recent advent of genome-wide association studies has markedly advanced the identification of well-replicated IBD association, and has substantiated this concept at a molecular level and catapulted the field of IBD genetics into a new realm of discovery.
References 1. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn disease on chromosome 16. Nature 1996;379(6568):821–3. 2. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn disease. Nature 2001;411(6837):599–3. 3. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn disease. Nature 2001;411(6837):603–6. 4. Duerr RH. The genetics of inflammatory bowel disease. Gastroenterology clinics of North America 2002;31(1):63–76. 5. Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. The American Journal of Gastroenterology 2005;100(10):2254–1. 6. Weinstein TA, Levine M, Pettei MJ, Gold DM, Kessler BH, Levine JJ. Age and family history at presentation of pediatric inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition 2003;37(5):609–3. 7. Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001;120(4):816–9. 8. Orholm M, Fonager K, Sorensen HT. Risk of ulcerative colitis and Crohn disease among offspring of patients with chronic inflammatory bowel disease. The American Journal of Gastroenterology 1999;94(11):3236–8. 9. Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scandinavian Journal of Gastroenterology 2000;35(10):1075–1. 10. Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996;312(7023):95–6. 11. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29(7):990–6. 12. Russell RK, Satsangi J. IBD: a family affair. Best practice & research 2004;18(3):525–39. 13. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. American Journal of Human Genetics 2002;70(4):845–57. 14. Pauleau AL, Murray PJ. Role of nod2 in the response of macrophages to toll-like receptor agonists. Molecular and Cellular Biology 2003;23(21):7531–9. 15. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307(5710):731–4. 16. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn disease risk and phenotype in diverse populations: a metaanalysis. The American Journal of Gastroenterology 2004;99(12):2393–04. 17. Cummings JR, Jewell DP. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflammatory Bowel Diseases 2005;11(1):56–1. 18. Kugathasan S, Loizides A, Babusukumar U, et al. Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and White children with Crohn disease. Inflammatory Bowel Diseases 2005;11(7):631–8.
12
Nancy McGreal and Judy H. Cho
19. Weiss B, Shamir R, Bujanover Y, et al. NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared with adults with Crohn disease. The Journal of Pediatrics 2004;145(2):208–2. 20. Latiano A, Palmieri O, Valvano RM, et al. Contribution of IBD5 locus to clinical features of IBD patients. The American Journal of Gastroenterology 2006;101(2):318–5. 21. Noble CL, Nimmo ER, Drummond H, et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn disease. Gastroenterology 2005;129(6):1854–64. 22. Yamazaki K, Takazoe M, Tanaka T, et al. Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease. Journal of human genetics 2004;49(12):664–8. 23. Newman B, Gu X, Wintle R, et al. A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn disease. Gastroenterology 2005;128(2):260–9. 24. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004;36(5):471–5. 25. Pierik M, Yang H, Barmada MM, et al. The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. Inflamm Bowel Dis 2005;11(1):1–7. 26. Armuzzi A, Ahmad T, Ling KL, et al. Genotype-phenotype analysis of the Crohn disease susceptibility haplotype on chromosome 5q31. Gut 2003;52(8):1133–9. 27. Torok HP, Glas J, Tonenchi L, et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn disease. Gut 2005;54(10):1421–7. 28. Palmieri O, Latiano A, Valvano R, et al. Variants of OCTN1–2 cation transporter genes are associated with both Crohn disease and ulcerative colitis. Alimentary Pharmacology & Therapeutics 2006;23(4):497–6. 29. Russell RK, Drummond HE, Nimmo ER, et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut 2006;55(8):1114–3. 30. Babusukumar U, Wang T, McGuire E, Broeckel U, Kugathasan S. Contribution of OCTN variants within the IBD5 locus to pediatric onset Crohn disease. The American Journal of Gastroenterology 2006;101(6):1354–1. 31. Silverberg MS, Duerr RH, Brant SR, et al. Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn disease. European Journal of Human Genetics 2007;15(3):328–5. 32. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nature genetics 2004;36(5):476–80. 33. Buning C, Geerdts L, Fiedler T, et al. DLG5 variants in inflammatory bowel disease. The American Journal of Gastroenterology 2006;101(4):786–92. 34. Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Current Opinion in Gastroenterology 2003;19(4):327–35. 35. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta- analysis. Gut 1999;45(3):395–1. 36. Silverberg MS, Mirea L, Bull SB, et al. A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflammatory Bowel Diseases 2003;9(1):1–9. 37. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002;123(3):714–8. 38. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000;118(2):274–8. 39. Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Practice & Research 2004;18(3):577–96. 40. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461–3. 41. Van Limbergen JE, Russell RK, Nimmo ER, et al. IL23R Arg381Gln is associated with childhood onset inflammatory bowel disease in Scotland. Gut 2007.
Chapter 1 Genetics of Inflammatory Bowel Diseases
13
42. Libioulle C, Louis E, Hansoul S, et al. A novel susceptibility locus for Crohn disease identified by whole genome association maps to a gene desert on chromosome 5p13.1 and modulates the level of expression of the prostaglandin receptor EP4. Plos Genetics 2007. 43. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL12Rbeta1 and a novel cytokine receptor subunit, IL-23R. Journal of Immunology 2002;168(11):5699–8. 44. Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. The Journal of Experimental Medicine 2006;203(11):2473–83. 45. Kullberg MC, Jankovic D, Feng CG, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. The Journal of Experimental Medicine 2006;203(11):2485–4. 46. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006;25(2):309–18. 47. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. The Journal of Clinical Investigation 2006;116(5):1310–6. 48. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421(6924):744–8. 49. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. American Journal of Human Genetics 2007;80(2):273–90. 50. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn disease. The New England Journal of Medicine 2004;351(20):2069–79. 51. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends in immunology 2006;27(1):17–3. 52. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature Genetics 2007;39(2):207–11. 53. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nature Genetics 2007. 54. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. The Journal of Clinical Investigation 2002;109(7):883–93. 55. Carter MJ, Di Giovine FS, Cox A, et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001;121(4):805–11. 56. Carter MJ, di Giovine FS, Jones S, et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001;48(4):461–7. 57. Craggs A, West S, Curtis A, et al. Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England. Scandinavian Journal of Gastroenterology 2001;36(11):1173–8. 58. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. Journal of Immunology 1998;161(10):5733–44. 59. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004;127(1):26–40. 60. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124(1):26–33. 61. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. International Journal of Immunogenetics 2005;32(6):401–5. 62. Achkar JP, Dassopoulos T, Silverberg MS, et al. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. The American Journal of Gastroenterology 2006;101(3):572–80. 63. Tomer G, Ceballos C, Concepcion E, Benkov KJ. NOD2/CARD15 variants are associated with lower weight at diagnosis in children with Crohn disease. The American Journal of Gastroenterology 2003;98(11):2479–84. 64. Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn disease. Clinical Gastroenterology and Hepatology 2004;2(11):1003–9. 65. Sun L, Roesler J, Rosen-Wolff A, et al. CARD15 genotype and phenotype analysis in 55 pediatric patients with Crohn disease from Saxony, Germany. Journal of Pediatric Gastroenterology and Nutrition 2003;37(4):492–7.
14
Nancy McGreal and Judy H. Cho
66. Meinzer U, Idestrom M, Alberti C, et al. Ileal involvement is age dependent in pediatric Crohn disease. Inflammatory Bowel Diseases 2005;11(7):639–44. 67. Wine E, Reif SS, Leshinsky-Silver E, et al. Pediatric Crohn disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 2004;114(5):1281–6. 68. Russell RK, Drummond HE, Nimmo EE, et al. Genotype-phenotype analysis in childhood-onset Crohn disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflammatory Bowel Diseases 2005;11(11):955–64. 69. Roesler J, Thurigen A, Sun L, et al. Influence of CARD15 mutations on disease activity and response to therapy in 65 pediatric Crohn patients from Saxony, Germany. Journal of Pediatric Gastroenterology and Nutrition 2005;41(1):27–32.
2 Gut Immunity and Inflammatory Bowel Disease William A. Faubion∗ and Claudio Fiocchi
Introduction Gut Immunity and Inflammatory Bowel Disease: A Pediatrician’s Perspective Inflammation is by far the single most common response that the body mounts in response to a variety of challenges. The vast majority of these challenges comes from the external environment and, in the specific case of the gastrointestinal tract, they include foods, the commensal flora, microbial pathogens and xenobiotics. What protects the intestine from such a large and permanent antigenic load is the mucosal immune system, explaining why this makes up the largest and most varied collection of immune cells of the body. Not only the antigenic challenge to the gut is massive and continuous, but it also occurs at the largest area of interface with the external milieu, as the total surface of the gastrointestinal tract is roughly equal to that of a tennis court (400 m2 ). Therefore, an effective immune response in the gut must adapt not only to the type and size of the challenge, but also the location where the challenge occurs. To be fully effective mucosal immunity sets in motion an assortment of cellular and molecular mechanisms, transforming a relatively quiescent immune system into an active one. The degree of such activation varies considerably, ranging from a perfectly controlled inflammatory response that eliminates potential dangers without even alerting the host, to an uncontrolled full-blown inflammation that results in structural tissue damage and overt clinical symptoms. Within this wide range of performance, mucosal immunity must transit from a physiological to a pathological response, but the boundaries between a protective and a deleterious response are not clearly delineated. A child with inflammatory bowel disease (IBD) has often already reached the pathological extreme end of the immune response, inflicting damage rather than affording protection. To understand what goes wrong in pediatric IBD it is necessary first to understand how the intestinal immune system works. Much is known about both its composition and function, including its anatomical basis [1], its cellular and secretory components [2], and its critical interaction with the enteric flora [3]. Unfortunately, most of this information derives from studies carried out in adult murine species and humans, and whether the derived knowledge also applies to children, and to what degree, is uncertain. As it will be discussed later on in this chapter, some information on neonatal mucosal
*Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, Phone: 507-284-2468, Fax: 507-266-0335
15
16
William A. Faubion and Claudio Fiocchi
immunity is also available, but this derives almost entirely from newborn mice, raising again the issue of relevance and reproducibility in younger humans. Thus, when a pediatrician aims at better comprehending the inflammatory events occurring in the gut of a patient affected by Crohn disease or ulcerative colitis, he or she will have to rely on a mix of information on mucosal immunity gathered primarily from human adults and animal models. Despite these limitations, most of the knowledge on the intestinal immunity is likely to apply to children, with the exclusion of the short neonatal period, when limited exposure to external antigens and a status of relative immune immaturity creates special conditions. This chapter will review currently accepted concepts of physiological intestinal immunity with selected references to dysfunctions found in IBD.
Innate Intestinal Immunity and IBD Epithelial Barrier The cellular barrier of the gastrointestinal tract is formed by a continuous single layer of epithelial cells sealed with tight junctions. The competency of these tight junctions depends upon the regulation of a meshwork of proteins such as occludin, claudin family members and the junctional adhesion molecule JAM [4]. On the luminal surface, a thick and resilient layer of mucus, rich in secreted IgA antibodies [5], proteins with antibacterial activity (i.e., - and -defensins) [6], and proteolytic and glycolytic enzymes [7], offers the first line of defense against invasion by a variety of potential pathogens. Despite this protective barrier, luminal antigens and gut bacteria do enter the subepithelial lamina propria, a large extracellular matrix compartment which contains a variety of immune and nonimmune cellular components. Although some entry occurs through unwanted breaks in the barrier, under physiological circumstances much of the entry occurs by design through specialized, follicle-associated epithelium (FAE) that overlies the organized lymphoid tissue of the gut (Gut-Associated Lymphoid Tissue - GALT). The FAE overlies large lymphoid aggregates called Peyer’s patches. When compared to the rest of the intestinal epithelium, the FAE is deficient in goblet cells and has a lower concentration of brush border enzymes. These conditions facilitate the controlled transport of selected luminal macromolecules into the underlying lymphoid follicle through unique M (microfold) cells. M cells are highly specialized epithelial cells that differ from enterocytes in regard to characteristics required to facilitate transepithelial transport of antigen. Such characteristics include fewer microvilli, decreased alkaline phosphatase activity, and no IgA secretory component [8]. Antigen transported through the M cells is then captured below by underlying dendritic cells, which then present antigenic peptides to interfollicular T cells or naïve T cells within the mesenteric lymph nodes (Figure 2.1).
Evidence for barrier dysfunction in the pathogenesis of IBD Several lines of investigation indicate that disruption of the epithelial barrier may either instigate or perpetuate chronic intestinal inflammation. Abnormal intestinal permeability has been established among patients with Crohn disease and their healthy first-degree relatives, and may represent a primary abnormality predisposing to excessive antigen uptake, continuous immune stimulation, and eventually mucosal inflammation. Potential etiologic factors for barrier dysfunction in Crohn disease may be environmental or genetic. Smoking and non-steroidal anti-inflammatory drugs both potentially affect gut permeability and are variably associated with IBD [9]. Mutations in two genes recently found to be potentially associated with Crohn disease (OCTN and DLG5) appear to affect epithelial permeability and may lead to inappropriate exposure of the mucosal immune system to luminal antigen [10, 11].
Chapter 2 Gut Immunity and Inflammatory Bowel Disease
17
Gut lumen FAE M cell
APC DC T cell T cell
B cell zone
Germinal center
Figure 2.1. Basic organizational structure of the follicular associated epithelium (FAE). The main functional component of the FAE is the M (microfold) cell, which is specialized in transepithelial antigen transport. Transported antigen is taken up and processed by dendritic cells (DCs) and antigen-presenting cells (APC) which present it to naïve T cells.
Innate Immune Cells The immune system can be divided into two main branches: innate and adaptive immunity, characterized by differences in regard to specificity and timing of response. In contrast to adaptive immune cells, typically represented by T cells, which require some time for priming and clonal expansion for full effectiveness, cells of the innate immune system rapidly seize upon potential threats to the host. The rapidity of response occurs because the receptors used to quickly detect invading microorganisms or toxic macromolecules are germ-line encoded, invariable, and predetermined to recognize a repertoire of bacterially/virally associated carbohydrate and lipid structures. These pathogen recognition receptors may be membrane-bound (i.e., Toll-Like Receptors–TLRs) or cytoplasmic (i.e., Nucleotide-binding Oligomerization Domain family members–NODs). Innate immune cells primarily responsible for immediate bactericidal activity include professional phagocytic cells (macrophages and neutrophils), eosinophils, and lymphoid cells that have evolved to fulfill innate rather than adaptive immune functions. As a prelude to the discussion of the relationship between luminal bacteria and lymphocytes, background information regarding the macrophage, dendritic cell, and the atypical lymphocytes (NKT and T cell) will be presented. Macrophages Macrophages are phagocytic cells present in large numbers throughout the gastrointestinal mucosa. In fact, the GALT contains the largest reservoir of macrophages within the body [12]. Macrophages mature continuously from peripheral blood monocytes that are recruited to sites of mucosal inflammation [13], while neutrophils are produced and lost in large numbers each day. In the non-inflamed intestine macrophages differ from peripheral monocytes in their hyporesponsiveness to TLR ligands, diminished ability to prime adaptive immune responses, yet preserved capacity for phagocytosis and intracellular killing [13]. However, in the setting of pathogen invasion and inflammation, intestinal macrophages freshly recruited from blood monocytes, instead of developing a primarily scavenger function, rapidly display a pro-inflammatory phenotype marked by abundant cytokine production and accessory cell function. The conversion to this pro-inflammatory phenotype is stimulated by ligation of their pathogen recognition receptors.
18
William A. Faubion and Claudio Fiocchi
Activated macrophages express membrane-bound receptors specific for opsonized particles and pathogens, complement, and common bacterial proteins (i.e., mannose receptor, TLR, NOD). The complement receptor for C5a is largely responsible for the movement of macrophages to sites of inflammation, and reduced expression as seen in patients with acquired immunodeficiency syndrome results in susceptibility to mycobacterial infection [14]. Recognition of pathogens through these receptors leads to phagocytosis and intracellular degradation. Activation of macrophages also results in the secretion of bioactive molecules called cytokines. Cytokines are proteins produced and secreted by one cell that affect the function of another cell, thus allowing cell-cell communication in the absence of cell contact. The cytokine TGF- produced by activated macrophages is also a potent chemoattractant leading to the further recruitment of macrophages and neutrophils to the area of inflammation [15]. Not only is cytokine secretion important for the augmentation of phagocytic intracellular killing, but it also represents a critical link between innate and adaptive immunity, a topic discussed more fully below. Dendritic cells are also phagocytic cells, but their most important role is that of antigen presentation and activation of T cells. Dendritic Cells The dendritic cell (DC) is the most potent inducer of adaptive immune responses. Current evidence supports the model that intestinal DCs continuously migrate in an immature or tolerogenic form scavenging apoptotic cells and acquiring antigen sampled either directly from the lumen [16] or shuttled from the lumen through M cells (Figure 2.1) [17]. T cells activated by Peyer’s patchderived DCs (intestinal DCs) produce IL-4, IL-10, and TGF-, three cytokines that promote the induction of T cells with regulatory function (discussed more fully below). This cytokine profile indicates that intestinal DCs may have a role in the induction of regulatory T cells and/or B cell responses. Upon activation through microbial products or pro-inflammatory molecules, mature DCs migrate to T cell areas of the GALT where they induce effector rather than tolerogenic T cell responses. Intestinal DCs can induce the mucosal homing receptor 47 on T cells, suggesting that they can instruct a T cell to home back to the original site of activation [18]. Upon acquisition of antigen, DCs process the antigen within the cell and load antigenic peptide onto MHC class II molecules displayed on the surface membrane. DCs fully loaded with antigen migrate to the draining mesenteric lymph nodes where the greatest opportunity exists for presentation of a particular MHC-peptide complex to T cells bearing the T cell receptor (TCR) specific for the antigen being presented. Under normal circumstances, these antigen-loaded DCs express low levels of co-stimulatory molecules and cytokines, stimulating preferentially the differentiation of regulatory T cells. As opposed to these tolerogenic DCs isolated from non-inflamed bowel, DCs stimulated with pathogenic bacteria or isolated from sites of inflammation are strongly immunogenic, expressing on the cell surface high levels of co-stimulatory molecules, adhesion molecules, and abundantly produce cytokines. The resultant T cell activation will be discussed further below. Atypical Lymphocytes The atypical lymphocytes NKT (Natural Killer T) cells and T cells also play a role in the innate immune response. NKT cells mature in the thymus and recognize lipid antigen (presumably bacterial) presented on the “MHC-like” complex Cd1d. NKT cells secrete large amounts of proinflammatory cytokines and readily kill infected cells or tumor cells. The potential importance of these cells to the pathogenesis of ulcerative colitis has been recently described. Pro-inflammatory cytokine-producing NKT cells isolated from patients with ulcerative colitis have cytotoxic activity against colonic epithelial cells in culture and produce large amounts of IL-13 [19]. T cells that express gamma and delta TCR chains (T cells), rather than the typical TCR chains, are atypical lymphocytes that only exist in significant quantity in epithelial tissues. In the
Chapter 2 Gut Immunity and Inflammatory Bowel Disease
19
intraepithelial space, T cells make up approximately 10% of the total number of T cells, the remaining majority being CD8+ T cells [20]. Unlike conventional T cells, T cells do not require the thymus for development [21], do not recognize antigen in association with MHC class I or II [22], and do not participate in adaptive immune responses [23]. While their precise function in humans remains enigmatic, experimental evidence suggests that T cells perform different functions depending upon tissue distribution and the local microenvironment [24].
Development of the Epithelial Barrier and Innate Immune Cells While the functional properties of the fetal intestinal epithelial barrier are unknown, progressive maturation of epithelial tight junctions has been identified histologically [25]. It is apparent that neonatal intestinal permeability is higher than that in adulthood [26]; yet, its relationship to the development of a an efficient mucosal immune system by facilitating exchange of dietary antigen, enteric colonizing bacteria, and maternal antibody or trophic factors is unknown. Interspersed within the intestinal epithelium, M cells sample the lumen and deliver antigen to DCs positioned below the FAE. M cells are present by week 17 of gestation following the appearance of lymphoid aggregates. Indeed, it appears that lamina propria lymphocytes and luminal bacteria promote M cell differentiation from enterocytes [27]. A second form of differentiated enterocyte is the Paneth cell, a specialized epithelial cell present within small intestinal crypts and dedicated to the production of various anti-bacterial peptides, like defensins. The Paneth cell is also present by 17 weeks of gestation [28]. Macrophages and CDs appear in the fetal intestine by 12 weeks, but little is known about their functional maturational state [29]. Data available on neonatal macrophages document defective production of pro-inflammatory cytokines such as IL-12 and TNF- [30]. Evidence for Innate Immune Cellular Dysfunction in the Pathogenesis of IBD At least three pieces of evidence exist indicating a major role for innate immune cells in the perpetuation of human chronic intestinal inflammation. First, the strongest genetic association to date with small bowel Crohn disease is the loss of function polymorphisms in the bacterial sensing gene CARD15/NOD2. Whether the ultimate pathogenic dysfunction rests in Paneth cells [31] or monocytes, [32] it appears certain that dysregulation in the detection of and/or responsiveness to enteric bacteria by innate immune cells promotes chronic inflammation in this subgroup of patients. The second piece of evidence rests in the efficacy of immune therapy targeted against pro-inflammatory cytokines produced by innate immune cells. Activated macrophages produce large amounts of TNF- and IL-12, two cytokines responsible for the recruitment and activation of pathogenic effector T cells. The efficacy of anti-TNF- therapy is established [33], and promising anti-IL-12 studies are currently ongoing [34]. The third piece of evidence is the presence of a defective acute inflammatory response to injury and bacterial products in Crohn disease patients, demonstrated by reduced neutrophilic infiltration, IL-8 production and vascular flow [35], and corroborated by the clinical improvement provided by the administration of GM-CSF, supposedly by improving macrophage and neutrophilic function [36].
Adaptive Intestinal Immunity and IBD T Cells Within the lamina propria of the intestine CD4+ and CD8+ T cells bearing the conventional TCR are roughly equally represented. The intraepithelial space contains unusual and enigmatic T cell populations bearing the TCR and CD8+ cells with homodimeric expression of TCR (discussed briefly above). As current understanding of both human and experimental IBD
20
William A. Faubion and Claudio Fiocchi
emphasizes the primary importance of activated CD4+ TCR T cells to disease pathogenesis, the discussion below will focus on activation of CD4+ T cells and the homing pattern that ensues. Upon maturation in the thymus, naïve T cells (cells which have yet to experience antigen exposure) circulate the lymphatic tissues in search of its cognate MHC-peptide complex. Constitutive expression of the selectin CD62L (L-selectin) and the chemokine receptor 7 (CCR7) ensures that naïve T cells bind to glycosylated CD34 and the chemokine ligand 21 expressed on endothelial cells of high endothelial venules [37]. The interaction of CD62L and CD34 (among other glycosylated endothelial molecules) promotes a rolling action of the T cell across the endothelial surface. The T cell surface adhesion molecule LFA-1 binds to ICAM-1 and ICAM-2 promoting firm adhesion and crossing of the endothelial lining into the lymphoid tissue. Within the underlying lymphatics await DCs loaded with antigen in variable states of activation. Naïve T cells search the DC selection for a recognizable MHC-peptide complex. If none is found the cells exit the lymph node, return to the circulation, and reenter other nodes to repeat this process. Eventually, a naïve T cell finds its specific antigenic mate and receives the appropriate activation signals upon ligation of its TCR (Figure 2.2). A full T cell activation requires two signals: signal 1 is delivered by TCR stimulation and signal 2 is a co-stimulatory signal provided by secondary accessory pathways. Among the latter, co-stimulation through CD28 by B7.1 or B7.2 results in T cell activation; in contrast, co-stimulation through CTLA-4 by B7.1 or B7.2 results in T cell inhibition. In addition, TCR signaling in the absence of co-stimulation results in anergy, defined as a lack of response upon re-exposure to the same antigen in the future. A key consequence resulting from activation of CD4+ T cells is cytokine secretion, and the particular pattern of cytokines secreted orchestrates the type of the ensuing immune response (i.e., directed against intracellular pathogens, parasites, etc). The phenotype of the mature effector T cell depends upon in large part the cytokine milieu available to the T cell while undergoing the activation and differentiation program. While insight into these complex events is in constant evolution, current understanding is as follows (Figure 2.3). Activation of CD4+ T cells in the presence of IL-12 and absence of IL-4 results in a T helper 1 (Th1) phenotype, resulting in IFN-producing cells effective in the control of intracellular pathogens. Cells activated in the presence of IL-4 acquire a T helper 2 (Th2) phenotype, generating IL4-, IL5-, and IL13-producing cells effective in allergic responses and clearance of parasitic infections. Finally, activation in the presence of IL6, TGF and IL-23 result in cells expressing the recently described Th17 phenotype, i.e., IL17 and IL6-producing T cells responsible for acute inflammation and recruitment of granulocytes [38, 39]. Full activation of T cells takes 4-5 days and is accompanied by clonal expansion and remarkable changes in the homing behavior of these cells.
CD28
B7.1/.2
T cell + signal 2
APC
MHC II
Ag
TCR
+ signal 1 - signal
B7.1/.2
CTLA-4
Figure 2.2. Major molecular receptor-ligand pairs and co-stimulatory / inhibitory signals involved in antigenspecific stimulation of a T cell. APC, antigen-presenting cell; MHC II, major histocompatibility complex class II; Ag, antigen; TCR, T cell receptor; CTLA-4, cytotoxic T lymphocyte antigen-4.
Chapter 2 Gut Immunity and Inflammatory Bowel Disease
Th1
IFN-γ
Th2
IL-4 IL-5 IL-13
Th17
IL-17
21
IL-12 IL-4 APC
TGF-β IL-6
Figure 2.3. Current understanding of the pathways mediating differentiation of naïve T cells into the three major types of effector Th cells (Th1, Th2 and Th17). The ultimate functional phenotype of mature effector T cells depends upon the type and amount of antigen, and the cytokine milieu present at the time of activation. APC, antigen-presenting cell.
Once activated, these effector T cells leave the lymph node returning to the circulation, thus allowing a locally generated immune response to promote defense at distance throughout the gastrointestinal tract [40]. Activated T cells express unique adhesion molecules that direct the cells to sites of inflammation, and indeed T cells primed by mucosal DCs are destined to return to the gut through the upregulation of two surface molecules, 47 integrin and the chemokine receptor CCR9 [18]. The integrin 4 binds to the vascular adhesion molecule VCAM-1, a molecule expressed on vascular endothelium only at sites of inflammation. The 47 integrin recognizes the more ubiquitous vascular endothelial molecule MAdCAM-1, directing migration to the intestinal lamina propria [41, 42], while E7 is uniquely expressed on T cells destined to the intestinal intraepithelial space. MAdCAM-1 has been shown to be upregulated during exacerbations of IBD, and thus represents a promising target for therapeutic intervention [42]. Effector T cells appear to enter nearly all tissues in limited numbers. Recognition of cognate antigen within the tissue results in T cell cytokine production. Pro-inflammatory cytokines, such as TNF-, stimulate endothelial cells to upregulate adhesion molecules such as E-selectin (that recruits monocytes and neutrophils), and VCAM-1 and ICAM-1 (both of which recruit activated T cells). TNF- and IFN- likewise act to alter the vascular permeability, endothelial cell shape, and blood flow, resulting in enhanced infiltration of inflammatory cells into the tissue. These inflammatory cascades set in motion by activated T cells and the significant structural alterations they cause in the inflamed tissue eventually trigger the signs and symptoms characteristic of active IBD. Thus, naïve T cells circulate nearly all tissues due to the expression of CD62L, CCR7, and LFA-1. Activation of T cells in the GALT leads to expression of 47 and CCR9 expression, two molecules that produce selective homing to the intestine through endothelial expression of MAdCAM-1 and CCL-25. Mucosal inflammation results in upregulation of MAdCAM-1, in addition to other endothelial ligands, and enhanced recruitment of pro-inflammatory T cells to the inflamed organ. T Regulatory Cells (TREG) It is now well established that subpopulations of CD4+ T cells with regulatory potential exist in both mice and humans. Current models describe three major and not necessarily mutually exclusive subtypes of Tregs: the “naturally occurring” CD4+CD25+ cell, the IL-10- and TGF-producing Tr1 cell, and the TGF--producing Th3 cell derived through oral tolerance [43]. While accurate description of this rapidly evolving field is a moving target, the more studied and
22
William A. Faubion and Claudio Fiocchi
better understood Treg cell type is the CD4+CD25+ T cell expressing the transcription factor FOXP3. The importance of this cell type to murine colitis and its capacity to suppress mucosal inflammation are well established [44, 45]. However, although this type of Treg has also been described in IBD [46], the function of these cells in the periphery and the gut of patients with IBD has yet to contribute to a better understanding of IBD pathogenesis.
B Cells B cells of the GALT work in close collaboration with the epithelium to export secretory IgA (sIgA) and to some extent secretory IgM (sIgM) to enhance mucosal defense from intestinal pathogens. Mucosal B cells exhibit a predominant IgA class switch and, upon differentiation to mature plasma cells, produce approximately 3 grams of sIgA per day [47]. Over 80% of all human plasma cells are found in the gut, and nearly all these plasma cells produce IgA [48]. Mucosal plasma cells produce primarily dimeric or polymeric forms of IgA. The joining or “J” chain of polymeric IgA spontaneously interacts with the polymeric Ig receptor expressed on the basolateral surface of epithelial cells facilitating exportation of the sIgA to the gastrointestinal lumen [49]. Once in the lumen, sIgA coats commensal and potentially pathogenic bacteria. This coating may promote M cell-mediated bacterial uptake and target presentation to intestinal DCs and macrophages, providing a barrier to bacterial penetration as well as a positive feedback loop to enhance secretory immunity [50].
Development of Adaptive Immune Cells Lymphocytes begin to populate the lamina propria by 12 weeks of gestation (after the thymus matures) and are primarily CD4+ cells [51]. Organized lymphoid tissue of the small bowel (Peyer’s patches) consisting of B cell follicles, and interfollicular CD4+ and CD8+ T cells are detected by 16–18 weeks of gestation [51]. Dendritic cells are detected at 19 weeks, representing the last of the required cellular components of an adaptive immune response [52]. Neither the T cells nor the B cells of the Peyer’s patch exist in an activated state within the fetal intestine. Indeed, the number of Peyer’s patches increases from 80–120 at birth to 250 by adolescence [53]. Without antigenic stimulation, there are no IgA secreting cells; yet, within 2 weeks of birth IgA and IgM secreting plasma cells are present within the lamina propria [54].
Evidence for Adaptive Immune Cellular Dysfunction in the Pathogenesis of IBD There are multiple lines of evidence strongly supporting the notion that activated CD4+ T cells are a central feature of human IBD. First, T cell-driven animal models of colitis mimic human IBD in both histologic features and susceptibility to similar treatment regimens [19, 55–57]. In human IBD, Crohn disease displays all the major features of a well defined Th1 response pattern [58], while ulcerative colitis represents an atypical Th2 response [19]. As mentioned previously, established and emerging therapy for human IBD is directed towards the destruction or deterrence of activated effector T cells, or blockade of Th1-driving cytokines [59] Third, clonal populations of T cells have been described in patients with Crohn disease [60]. A similar development of T cell clones has been described in an animal model of IBD. Importantly, these T cell clones specifically recognize endogenous gut bacteria and are proven pathogenic in their ability to mediate colitis when transferred into non-colitic recipient mice [61]. Finally, the presence of antibodies unique to patients with IBD directed against microbial antigen signifies a potentially pathogenic adaptive immune responses against the intestinal flora [62].
Chapter 2 Gut Immunity and Inflammatory Bowel Disease
23
Putting it all Together: Integrating Gut Microbes, Epithelial Cells, and Lymphocytes in the Pathogenesis of IBD With rare exception, murine models of IBD require the presence of intestinal bacteria for the development of colitis. The presence of antibodies to bacterial antigen in most patients with IBD and the beneficial effects of antibiotics and probiotics suggest an important role of bacteria in the instigation or perpetuation of human IBD. Thus, understanding the interaction between gut flora, epithelial cells, and adaptive immune cells is important. Intestinal epithelial cells encounter commensal and pathogenic bacteria routinely, and constitutively express membrane-bound and intracellular receptors to sense gut microbes. The membrane bound TLR2 and 4 have been described in mouse and human intestinal epithelial cells lines [63]. Experimental evidence suggests that interaction between commensal gut flora and TLRs protects against colitis and enhances the mucosal barrier [64, 65]. An additional set of intracellular bacterial sensing receptors, NOD1 and NOD2, exists to detect intracellular pathogens. Experimental evidence indicates an anti-bacterial effect of the NOD2 protein in infected intestinal epithelial cell lines [66]. The importance of NOD2 in epithelial cell defense systems (particularly Paneth cells of the terminal ileum) underscores the relevance of polymorphisms in the NOD2/CARD15 gene in the pathogenesis of Crohn disease [67, 68]. It is established that the downstream signaling pathways of TLRs and NODs lead to activation of NF-B responsive genes mediating inflammatory responses, but the precise details of these important cascades are beyond the scope of this chapter. Thus, intestinal epithelial cells directly sense enteric bacteria, and this interaction is essential to normal barrier function. Potential pathogenic and probably commensal bacteria may contact immune cells of the GALT in at least three ways (Figure 2.4). First, infected epithelial cells may undergo apoptosis (either spontaneously or killed by effector immune cells), and apoptotic fragments containing bacteria may be ingested by resident phagocytic cells (macrophages and DCs) and subsequently presented to host T cells. In this fashion, bacterial antigen may be presented to CD4+ T cells through MHC class II-TCR interaction and/or CD8+ cytotoxic T cells, as antigen from apoptotic fragments may be presented as “self” on MHC class I molecules [69]. Second, DCs and macrophages may acquire bacteria directly from the environment. DCs have been shown to directly sample intestinal antigen from the lumen, and both cell types engulf and kill whole bacteria, presenting bacterial antigen Gut lumen
Bacteria
DC
Apoptotic infected cell
TLR
Macrophage T cell
T cell T cell
1
2
3
Figure 2.4. Potential pathways through which bacterial antigens can activate mucosal T cells. 1) Apoptosis of infected epithelial cells; 2) Luminal sampling and acquisition of bacteria by mucosal dendritic cells (DC); 3) Direct contact of translocated bacteria with T cells mediated by Toll-like receptor (TLR) recognition.
24
William A. Faubion and Claudio Fiocchi
on MHC class II to CD4+ T cells. Third, lymphocytes may contact bacterial antigen directly in the absence of antigen presenting cells. T lymphocytes have been shown to express TLRs and in certain model systems, respond by proliferation and cytokine secretion [70]. Thus, multiple pathways exist with the potential of presenting enteric bacterial products to CD4+ T lymphocytes. As previously pointed out, the T cell response to recognition of bacterial antigen on MHC class II molecules through the TCR depends upon the expression of co-stimulatory molecules on the antigen-presenting cell (Figure 2.2). Activation of the CD4+ T cell results in cytokine secretion and the pattern of cytokines secreted determines the type of the ensuing immune response (i.e., directed against intracellular pathogens, parasites, etc). These pro-inflammatory cytokines incite and amplify a vigorous immune response through many factors including increased blood flow, increased vascular permeability, and recruitment of effector immune cells. Activated CD4+ T cells also stimulate B cells through expression of the cell surface molecule CD40 ligand. CD40-CD40 ligand interaction results in B cell proliferation, variation in the class of antibody secretion (i.e., IgG, IgA, etc), and initiation of antibody secretion. Following this multifactorial antigen-driven immune response, a series of secondary events also unfolds, including the production of proteolytic enzymes, like matrix metalloproteinases that digest the extracellular matrix [71], and oxygen reactive metabolites which are directly toxic to the cells in the surrounding microenvironment [72], ultimately leading to necrosis and structural tissue damage.
Innate and Adaptive Immune Responses Unique to Pediatrics Maturation of the mucosal immune system is a continuum with no definitive markers defining a “mature” and “immature” status. The only evidence available from which to draw conclusions unique to the pediatric mucosal immune system is from studies of human neonates or animal studied at the time of weaning. The most noticeable difference between developing (neonatal) and established immune responses would appear to be in adaptive immunity. The rationale for this assumption is that adaptive immune responses are antigen-specific and thus require post-natal exposure to dietary and microbial antigen to develop immunologic memory. On the contrary, as pointed out above, innate immune responses are for the most part germline-encoded through recognition of microbial ligands by pathogen recognition receptors. Indeed, fetal intestinal epithelial cell lines exhibit responsiveness to inflammatory stimuli and bacterial products [73]. Thus, this section will briefly address three established differences in adaptive immune responses between pediatric and adult populations. Neonates are capable of humoral and cellular immune responses at the time of birth. Immediately upon leaving the birth canal the gastrointestinal tract encounters microbes resident in the birth canal and the surrounding environment. Within hours the gastrointestinal tract is colonized with facultative and strict anaerobic bacteria. Specific secretory IgA responses to organisms such as Escherichia coli are produced within the first week of life [74, 75]. Infants and young children are capable of generating the full spectrum of functional T cells (Th1, Th2, etc.) and T celldependent B cell responses [76]; yet, T cell-independent B cell immune responses do not reach full maturity for several years. It is possible that this impaired B cell response to T cell-independent antigens (i.e., polysaccharides) that leaves young children susceptible to encapsulated bacteria (i.e., Haemophilus influenzae type b) [77]. The second major difference is the tendency of the young mucosal immune system to generate systemic immune responses to oral antigen. The evidence for this exists in epidemiologic studies of neonatal protein intolerance [78] as well as animal data demonstrating antigen-feeding and the induction of systemic antibody responses [79]. The third point commonly highlighted is the propensity of neonatal effector T cell responses to be preferentially Th2 polarized [80]. The significance of this observation is unclear, but it has been suggested that this may represent a “default” pathway aimed at keeping inflammatory reactions controlled at an early stage of life when vigorous Th1 polarization could lead to damaging
Chapter 2 Gut Immunity and Inflammatory Bowel Disease
25
inflammatory responses [81]. How any of the three aforementioned neonatal adaptive immune features relate to human IBD remains to be explored.
Summary As discussed in other chapters of this book dealing with treatment of pediatric IBD, it is obvious that all recent advances in the field of novel therapeutic approaches, notably biological therapies, are directly derived from knowledge harnessed by studies of mucosal immunity in the normal and inflamed intestine [82]. In spite of these striking advances, some aspects of gut immunity remain unclear. Perhaps the most critical one is how the mucosal immune system interacts with the endogenous commensal flora under physiological and pathological conditions, a fundamental issue considering the widely accepted notion that IBD is an abnormal immune response to the autologous enteric bacteria in genetically susceptible individuals [83]. The problem in understanding the mutual relationship between the gut and its luminal flora resides more in the latter than the former. In fact, the immune cells and the molecular tools the gut uses to communicate with intestinal microorganisms are reasonably understood, but far less knowledge exists on the composition and the function of the commensal flora. This is due in part to the limited attention paid to classical enteric microbiology for several decades, but in even greater part to the unrecognized complexity of the gut flora and the practical observation that most of it cannot be identified by traditional culture techniques. New perceptions of the gut microbiota are needed as well as new tools to dissect and classify it, and some of these are being now implemented, such as fluorescence in situ hybridization (FISH), terminal restriction length polymorphism (T-RFLP), polymerase chain reaction combined with denaturing gradient or temperature gradient gel electrophoresis (PCR/DGGE and PCR/TGEE), and 16S rRNA gene libraries [84]. These new methodologies do not necessarily allow the isolation of the actual microbes, but provide a far more detailed molecular classification of the hundreds of bacterial strains that populate the gut, and permit to get closer to the identification of bacteria against which the gut mucosal immune system reacts and induces inflammation. Another critical aspect of gut immunity is the nature of the mucosal immune response mediating inflammation during the course of a chronic disease, as typically found in IBD. It is plausible, if not probable, that long lasting intestinal inflammatory processes like Crohn disease and ulcerative colitis undergo substantial changes of the underlying biological response regardless of the initial triggering events. This point is fundamentally important for pediatric IBD, when the disease is at its earliest possible stages of detection and there is perhaps an opportunity to change the natural history of the disease, a far more difficult goal to attain in adult IBD patients with a long clinical history. Studying early events of IBD pathogenesis and follow them up during disease evolution into chronicity is obviously difficult in humans and more so in children, but this can be accomplished in animal models, which are starting to generate concrete evidence of substantial changes in the gut immune response from the early to the chronic stages of inflammation. Switches from a Th1 to a Th2 pattern occur in at least two models of experimental IBD. In the colitis of IL-10-deficient mice and the ileitis of SAMP1/YitFc mice, both of which are Th1-mediated initially, there is a marked increase in disease-mediating Th2 cytokines in late disease, e.g., IL-4 and IL-13 in the colitis model, and IL-5 and IL-13 in the ileitis model [85, 86]. The lesson here is that, even though the clinical manifestations of IBD remain constant, the underlying pathogenic immunopathology changes rather dramatically over time. Therefore, immunomodulators that are effective in early disease may no longer be effective in chronic disease, as again exemplified by the above animal models where blockade of Th1 cytokines is therapeutically effective in early but not late inflammation, a period when blockade of Th2 cytokines ameliorates disease. When these observations and concepts are translated into the human situation it is reasonable to assume that different immunomodulatory approaches should be used at different stages of IBD. Preliminary
26
William A. Faubion and Claudio Fiocchi
evidence for the existence of a differential susceptibility to immune modulation in children with IBD comes from both clinical and in vitro studies. Children with early onset Crohn disease have a significantly longer remission in response to TNF- blockade than children with late disease [87], and the cytokine secretory pattern of mucosal T cell clones derived from children with IBD can be modulated only in patients with early but not late disease (Kugathasan et al., submitted). In summary, investigation of gut immunity in IBD has been and still is extremely rewarding, as it has provided not only new information on the biology of its components and overall function, but also practical new ways to exploit this new information for current and future therapeutic applications. References 1. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003;3:331–41. 2. Johansen FE, Brandtzaeg P. Transcriptional regulation of the mucosal IgA system. Trends Immunol 2004;25:150–7. 3. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004;4:478–85. 4. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2:416–22. 5. Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol 2003;3:63–72. 6. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3:710–20. 7. Harwig SS, Tan L, Qu XD, Cho Y, Eisenhauer PB, Lehrer RI. Bactericidal properties of murine intestinal phospholipase A2. J Clin Invest 1995;95:603–10. 8. Newberry RD, Lorenz RG. Organizing a mucosal defense. Immunol Rev 2005;206:6–21. 9. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn disease. Immunol Rev 2005;206:277–95. 10. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G, Griffiths AM, St George-Hyslop PH, Siminovitch KA. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004;36:471–5. 11. Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJ, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004;36:476–80. 12. Lee SH, Starkey PM, Gordon S. Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J Exp Med 1985;161:475–89. 13. Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 2005;206:149–59. 14. Smith PD, Ohura K, Masur H, Lane HC, Fauci AS, Wahl SM. Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis. J Clin Invest 1984;74:2121–8. 15. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A 1987;84:5788–92. 16. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, Fox JG, Littman DR, Reinecker HC. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005;307:254–8. 17. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685–711. 18. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, Von Andrian UH. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature 2003;424:88–93. 19. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490–7.
Chapter 2 Gut Immunity and Inflammatory Bowel Disease
27
20. Hayday A, Theodoridis E, Ramsburg E, Shires J. Intraepithelial lymphocytes: exploring the Third Way in immunology. Nat Immunol 2001;2:997–1003. 21. Kanamori Y, Ishimaru K, Nanno M, Maki K, Ikuta K, Nariuchi H, Ishikawa H. Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lymphohemopoietic progenitors develop. J Exp Med 1996;184:1449–59. 22. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gamma delta T cells. Science 1998;279:1737–40. 23. Boismenu R, Havran WL. An innate view of gamma delta T cells. Curr Opin Immunol 1997;9:57–63. 24. Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002;2:336–45. 25. Polak-Charcon S, Shoham J, Ben-Shaul Y. Tight junctions in epithelial cells of human fetal hindgut, normal colon, and colon adenocarcinoma. J Natl Cancer Inst 1980;65:53–62. 26. Udall JN, Pang K, Fritze L, Kleinman R, Walker WA. Development of gastrointestinal mucosal barrier. I. The effect of age on intestinal permeability to macromolecules. Pediatr Res 1981;15:241–4. 27. Kerneis S, Bogdanova A, Kraehenbuhl JP, Pringault E. Conversion by Peyer’s patch lymphocytes of human enterocytes into M cells that transport bacteria. Science 1997;277:949–52. 28. Trier JS. The Paneth cells: an enigma. Gastroenterology 1966;51:560–2. 29. Teitelbaum JE, Allan Walker W. The development of mucosal immunity. Eur J Gastroenterol Hepatol 2005;17:1273–8. 30. Marodi L. Innate cellular immune responses in newborns. Clin Immunol 2006;118:137–44. 31. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA. Nod2dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731–4. 32. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M. Nod2 mutation in Crohn disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005;307:734–8. 33. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn disease. Crohn Disease cA2 Study Group. N Engl J Med 1997;337:1029–35. 34. Orenstein R. Anti-interleukin-12 antibody for active Crohn disease. N Engl J Med 2005;352:627–8. 35. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW. Defective acute inflammation in Crohn disease: a clinical investigation. Lancet 2006;367:668–78. 36. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn disease. N Engl J Med 2005;352:2193–201. 37. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 1998;95:258–63. 38. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006;116:1218–22. 39. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677–88. 40. Johansson-Lindbom B, Svensson M, Pabst O, Palmqvist C, Marquez G, Forster R, Agace WW. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005;202:1063–73. 41. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74:185–95. 42. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97–110. 43. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006;25:195–201. 44. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151–64. 45. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003;170:3939–43.
28
William A. Faubion and Claudio Fiocchi
46. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868–78. 47. Conley ME, Delacroix DL. Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense? Ann Intern Med 1987;106:892–9. 48. Brandtzaeg P, Farstad IN, Johansen FE, Morton HC, Norderhaug IN, Yamanaka T. The B-cell system of human mucosae and exocrine glands. Immunol Rev 1999;171:45–87. 49. Brandtzaeg P, Prydz H. Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 1984;311:71–3. 50. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004;303:1662–5. 51. Spencer J, Dillon SB, Isaacson PG, MacDonald TT. T cell subclasses in fetal human ileum. Clin Exp Immunol 1986;65:553–8. 52. Spencer J, MacDonald TT, Isaacson PG. Heterogeneity of non-lymphoid cells expressing HLA-D region antigens in human fetal gut. Clin Exp Immunol 1987;67:415–24. 53. Cornes JS. Peyer’s patches in the human gut. Proc R Soc Med 1965;58:716. 54. Perkkio M, Savilahti E. Time of appearance of immunoglobulin-containing cells in the mucosa of the neonatal intestine. Pediatr Res 1980;14:953–5. 55. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553–62. 56. Totsuka T, Kanai T, Uraushihara K, Iiyama R, Yamazaki M, Akiba H, Yagita H, Okumura K, Watanabe M. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2003;284:10. 57. Sugawara K, Olson TS, Moskaluk CA, Stevens BK, Hoang S, Kozaiwa K, Cominelli F, Ley KF, McDuffie M. Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn disease. Gastroenterology 2005;128:351–60. 58. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F. Interleukin 12 is expressed and actively released by Crohn disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169–78. 59. Van Assche G, Vermeire S, Rutgeerts P. Emerging biological treatments in inflammatory bowel diseases. Dig Dis 2006;24:131–6. 60. Probert CS, Chott A, Turner JR, Saubermann LJ, Stevens AC, Bodinaku K, Elson CO, Balk SP, Blumberg RS. Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol 1996;157:3183–91. 61. Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH, Sundberg JP, Elson CO. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998;187:855–64. 62. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113:1296–306. 63. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004;4:953–64. 64. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229–41. 65. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004;127:224–38. 66. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124: 993–1000. 67. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K, Stange EF. NOD2 (CARD15) mutations in Crohn disease are associated with diminished mucosal alpha-defensin expression. Gut 2004;53:1658–64. 68. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nunez G, Keshav S. Crohn disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003;125:47–57. 69. Bevan MJ. Cross-priming. Nat Immunol 2006;7:363–5.
Chapter 2 Gut Immunity and Inflammatory Bowel Disease
29
70. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 2006;27:387–93. 71. Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000;47:57–62. 72. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002;33:311–22. 73. Nanthakumar NN, Fusunyan RD, Sanderson I, Walker WA. Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis. Proc Natl Acad Sci U S A 2000;97:6043–8. 74. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 1999;69:1035S–1045S. 75. Mellander L, Carlsson B, Jalil F, Soderstrom T, Hanson LA. Secretory IgA antibody response against Escherichia coli antigens in infants in relation to exposure. J Pediatr 1985;107:430–3. 76. Fadel S, Sarzotti M. Cellular immune responses in neonates. Int Rev Immunol 2000;19:173–93. 77. Rijkers GT, Dollekamp EG, Zegers BJ. The in vitro B-cell response to pneumococcal polysaccharides in adults and neonates. Scand J Immunol 1987;25:447–52. 78. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow’s milk allergy. J Exp Med 2004;199:1679–88. 79. Hanson DG. Ontogeny of orally induced tolerance to soluble proteins in mice. I. Priming and tolerance in newborns. J Immunol 1981;127:1518–24. 80. Rowe J, Macaubas C, Monger TM, Holt BJ, Harvey J, Poolman JT, Sly PD, Holt PG. Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infect Immun 2000;68:3873–7. 81. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol 2004;4:553–64. 82. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005;307:1920–5. 83. Oliva-Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis 2002;8:112–28. 84. Tannock GW. New perceptions of the gut microbiota: implications for future research. Gastroenterol Clin North Am;2005 Sep;34:361–82. 85. Spencer DM, Veldman GM, Banerjee S, Willis J, Levine AD. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002;122:94–105. 86. Bamias G, Martin C, Mishina M, Ross WG, Rivera-Nieves J, Marini M, Cominelli F. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 2005;128:654–66. 87. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn disease. Am J Gastroenterol 2000;95:3189–94.
3 Cytokines and Inflammatory Bowel Disease Edwin F. de Zoeten∗ and Ivan J. Fuss
Introduction The etiology of inflammatory bowel diseases (IBD) is generally described as multifactorial including genetic predisposition, environmental insult and a dysregulated immune response. The immune response is the only one of these that is currently amenable to therapy. Understanding the factors that go into the activation of inflammation, and those that perpetuate this effect is improving greatly. With this mastery we are able to define the cytokines that are important in the etiology of IBD. Over the past 15 years many of the newest and arguably the most successful therapies for Crohn disease (CD) and ulcerative colitis (UC) have been developed due to an increased understanding of the immune response and specifically the cytokines essential to this response. As stated above, IBD is in part due to a dysregulated or an inappropriate immune reaction, which has been thought in part to be against the microflora of the gut. Upon activation of the immune system, cytokines and chemokines, which are proteins produced by the cells involved in the immune response, are produced, and trigger a cascade of downstream reactions. These cytokines are increasingly being defined as important molecules in the pathogenesis of IBD as well as putative and known targets for the therapy of IBD. With the advent of murine models of mucosal inflammation a great deal of knowledge has been acquired which has advanced our understanding of inflammation in IBD. In these models it has been initially noted that the inflammation is due either to an excessive Th1 T cell response or an excessive Th2 T cell responses, with the former characterized by increased interleukin 1 (IL-1), IL-2, IL-6, IL-12, IL-18, interferon gamma (IFN-) and tumor necrosis factor alpha (TNF-) production and the latter by increased IL-4, IL-5, IL-10, and/or IL-13 production. An example of a murine Th1 colitis is that induced by the haptenating agent trinitrobenzesulfonic acid (TNBS) [1], a colitis in which the predominant immune response is dominated by IL-12, IFN- and TNF-. This correlates with human studies, which have shown increased levels of TNF-, IFN-, IL-1 and IL-6 in the intestinal tissues and the peripheral blood of patients with CD [2]. Similar to what has been observed in patients with UC [3, 4] the oxazolone model of colitis in mice, which has similar histologic features as those seen in UC is associated with a Th2 response that is dominated by IL-13. These murine models have given important insights into the
*Division of Gastroenterology, Hepatology and Nutrition, The Children’s Hospital of Philadelphia, 34th Street and Civic Ctr. Blvd., Philadelphia, PA 19104, Phone: 215-590-9146, Fax: 215-590-3606, E-mail:
[email protected]
31
32
Edwin F. de Zoeten and Ivan J. Fuss
IBD entities; however, questions of whether CD and UC are “true” Th1 or Th2 mediated disease processes remain. This will be discussed later. In the immune cascade, cytokines help to determine the nature of the immune response, and they can act in a dual nature as either pro- (IL-1, IL-6, TNF-) or anti-inflammatory (IL-4, IL-5, IL-10, transforming growth factor beta (TGF-)) molecules. They can affect the synthesis or secretion of reactive oxygen species, nitric oxide, leukotrienes, platelet-activating factor, and prostaglandins. In addition, they can have differing qualities depending on when they are present in the inflammatory cascade. Finally, it is important to understand that pro- and anti- inflammatory responses are required to maintain the integrity of the intestinal mucosa due to the environment in which it exists. The intestinal mucosa is constantly bombarded with antigen from food, comensal and pathogenic bacteria and therefore it is important to be able to mount an inflammatory response to rid itself of harmful bacteria. At the same time, the mucosal immune system must be able to regulate itself either by the action of specific regulatory cells or by the action of cytokines such as IL-4, IL-5, IL-10, TGF-, IL-1ra, and TNF-.
Pro-inflammatory Cytokines Tumor Necrosis Factor Alpha For most gastroenterologists TNF- is the most recognized cytokine due to the increasing use of the chimeric monoclonal anti-TNF- antibody, infliximab, for the treatment of CD and UC. TNF- is secreted by macrophages, monocytes, neutrophils, T cells, and NK cells following their stimulation by bacterial lipopolysaccharides. CD4+ T lymphocytes secrete TNF- while CD8+ T cells do not. The synthesis of TNF- is induced by many different stimuli including interferons, IL-2, and granulocyte macrophage colony stimulating factor (GM-CSF). The production of TNF- is inhibited by IL-6, and TGF-. TNF- is an agonist of the p38 and c-jun N terminal kinase cascades, two important signaling pathways of the mitogen activated protein (MAP) kinase family involved in the generation of the inflammatory responses [5]. It is a potent proinflammatory cytokine that exerts its stimulatory effect on cells which produce IFN-. Indeed, in synergy with factors from non-lymphocyte lamina propria mononuclear cells it can act with prostaglandin E2 to stimulate IL-12- mediated T cell production of IFN-. ˜In resting macrophages, TNF- induces the synthesis of IL-1 and prostaglandin E2 which can act in concert to potentiate the inflammatory cascade. TNF- can also enhance the proliferation of T cells induced by various stimuli in the absence of IL-2, in fact some subpopulations of T cells only respond to IL-2 in the presence of TNF-. Beyond its effect on the immune response, TNF- activates osteoclasts and thus induces bone resorption and this effect is associated to one of the theories of why patients with CD may have decreased bone mineral density. Although TNF- is required for normal host immune responses the overexpression can have severe pathologic consequences as exemplified by mice in which the overexpression of TNF by a transgene is associated with a severe colitis [6]. In animal models TNF- knockout mice do not develop significant colitis [7] and as proof of principle that TNF- is important for the pathogenesis of IBD TNF- neutralizing antibodies have been shown to be effective in ameliorating intestinal inflammation. Associated human studies have reported elevated levels of TNF- in serum, stool and mucosal tissue [8, 9] correlating with clinical and laboratory indices of intestinal activity. Furthermore, dramatic effects have been noted in clinical studies in patients with Crohn disease treated with infliximab [10, 11]. These effects have been observed in both disease amelioration and induction of clinical remission. Important for the understanding of some of the critical side effects of infliximab, TNF- mediates a part of the cell-mediated immunity against obligate and facultative bacteria and parasites by stimulating
Chapter 3 Cytokines and Inflammatory Bowel Disease
33
phagocytosis and the synthesis of superoxide dismutase in macrophages. It confers protection against Listeria monocytogenes infections and tuberculosis. Anti-TNF- antibodies have been shown to weaken the ability of mice to cope with these infections. Infection with these organisms is a possible risk of using anti-TNF monoclonal antibody therapy in the treatment of IBD and a reason that patients are screened for tuberculosis prior to initiation of therapy with infliximab. Interferon-gamma Interferon gamma is produced mainly by CD4+ , CD8+ T-lymphocytes and natural killer cells activated by antigens, and mitogens. IFN- synergises with TNF- in inhibiting the proliferation of various cell types, however, the main biological activity of IFN- appears to be immunomodulatory in contrast to the other interferons (IFN- or ) which are mainly antiviral. IL-2 and IFN- appear to be intricately interwoven in their functions. In T-helper cells IL-2 induces the synthesis of IFN- and other cytokines. IFN- acts synergistically with IL-1 and IL-2 and appears to be required for the expression of IL-2 receptors (CD25) on the cell surface of T-lymphocytes. Blocking of the IL-2 receptor by specific antibodies inhibits the synthesis of IFN-. IFN- is a modulator of T-cell growth and functional differentiation, it is a growth-promoting factor for T-lymphocytes and it potentiates the response of these cells to growth factors. Most importantly, IFN- can increase the expression of MHC class molecules allowing greater antigenic recognition. Furthermore, it can increase permeability at epithelial tight junction barriers, thereby allowing further antigenic exposure [12]. Finally, in concert with TNF-, IFN- can cause direct tissue destruction as it increases local inflammation. [13] IFN- is one of the few cytokines that correlates with severity of disease in patients with Crohn disease. As a known proinflammatory cytokine it would appear to be an obvious choice to target for treatment of IBD. IFN- has been targeted in Crohn disease using, fontolizumab, a humanized monoclonal antibody against IFN- [14, 15]. In studies using these antibodies positive results were found in patients with moderate to severe Crohn disease when compared to placebo. Although the studies did not reach statistical significance the results did indicate a trend toward effect. This suggests a potential benefit of blocking IFN- in patients with Crohn disease. Interleukin -1 This cytokine consists of IL-1 and IL-1 subunits which are both produced by monocytes, macrophages and endothelial cells. In addition to these pro-inflammatory cytokines there is an IL-1 receptor antagonist (IL-1ra) produced by intestinal epithelial cells which is capable of inhibiting the proinflammatory actions of IL-1 by binding the IL-1 receptor and competitively blocking the interaction with IL-1. IL-1ra is considered to be one intestinal mechanism for down regulation of the immune response and has been shown to be elevated in the serum of patients with CD. Stimulation of IL-1ra secretion has been shown to be activated by IL-1 itself, therefore forming a negative feedback loop. IL-1- and – are essential biologically equivalent pleiotropic factors that act locally and systemically. IL-1 has a multitude of effector functions, some of which are mediated indirectly by the induction of the synthesis of other mediators including adrenocorticotropic hormone (ACTH), prostaglandin E2 , IL-6 and IL-8 (a chemotactic cytokine in the chemokine family). The main biological activity of IL-1 is the stimulation of T-helper cells, which are induced to secrete IL-2 and to express IL-2 receptors. IL-1 can also act on B-cells, promoting their proliferation and the synthesis of immunoglobulins. IL-1 stimulates the proliferation and activation of other immune cells such as NK-cells, fibroblasts, and thymocytes. The IL-1 mediated proliferative effects can be inhibited by the suppressive cytokine, TGF-. The synthesis of IL-1 can be induced by other cytokines including TNF-, IFN-, , or and also by bacterial endotoxins, and viruses. Furthermore IL-1 activity is not limited to stimulation
34
Edwin F. de Zoeten and Ivan J. Fuss
of T cells but it also promotes the adhesion of neutrophils, monocytes, T-cells, and B-cells by enhancing the expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and endothelial leukocyte adhesion molecule (ELAM) all of which can contribute to the pathogenesis of CD. IL-1 is also a strong chemoattractant for leukocytes as demonstrated by the local accumulation of neutrophils at the site of injection of tissue with IL-1. Finally, in combination with TNF- IL-1 appears to be involved in the generation of lytic bone lesions. IL-1 activates osteoclasts thereby suppressing the formation of new bone. Low concentrations of IL-1, however, promote new bone growth. IL-1 was one of the first cytokines targeted for therapy in animal colitis models. In these studies, administration of IL-1ra led to amelioration of colitis, in a rabbit model. Thus, it was also one of the first demonstrations that blockade of a single cytokine could be effective in therapy of colitis [16]. In patients with IBD, increased serum levels of IL-1 are seldom detected. However, in intestinal lesions in patients with both CD and UC, IL-1 levels are elevated [17]. IL-1ra is a possible intestinal mechanism for down regulation of the immune response and is elevated in the serum of patients with CD. IL-1 receptor antagonist determines the biological effects of IL-1, as increased concentrations of this mediator will decrease IL-1 activity. In the inflammatory lesions of patients with IBD, levels of this mediator are increased, although not as much as IL-1, leading to a disproportionate increase in IL-1 activity. Interleukin-2 IL-2 is a major T cell growth factor, secreted by activated T cells acting via the high-affinity IL-2 receptor (CD25) on T cells. This binding to CD25 promotes cell proliferation. Under physiologic conditions IL-2 is produced mainly by CD4+ T lymphocytes following cell activation. Resting cells do not produce IL-2. In T-helper cells IL-2 induces the synthesis of IFN- and other cytokines. IFN- acts synergistically with IL-1 and IL-2 and appears to be required for the expression of IL-2 receptors on the cell surface of T-lymphocytes. Blocking of the IL-2 receptor by specific antibodies also inhibits the synthesis of IFN-. IFN- in return is a modulator of T-cell growth and functional differentiation. It is a growth-promoting factor for T-lymphocytes and potentiates the response of these cells to growth factors IL-2 is a growth factor for all subpopulations of T-lymphocytes including importantly suppressive T regulatory cells. It is an antigen-unspecific proliferation factor for T-cells that induces cell cycle progression in resting cells and thus allows clonal expansion of activated T-lymphocytes. In patients with CD it has been demonstrated in many studies that IL-2 secretion from lamina propria cells is decreased as compared to normal patient samples. Daclizumab, a humanized monoclonal antibody to CD25, produced in an effort to block the binding of IL-2 to the IL-2R was tested in patients with UC and initially appeared promising in a small open label study [18], but upon testing in a placebo controlled study the therapy did not show efficacy [19]. This effect could be related to the fact that IL-2R (CD25) is also present on T regulatory cells. The inhibition of binding of IL-2 to its receptor present on T regulatory (T reg) cells, thereby inhibits the proliferation of these cells which are important in down regulation of the immune response. This highlights a common problem in the targeting of the cytokine pathway for treatment of inflammatory diseases, in that, cytokines frequently have multiple effects and can function in both a pro-inflammatory as well as an anti-inflammatory capacity. Interleukin-6 IL-6 is a pleiotropic cytokine considered to be a major cytokine in inflammation, regulation of T cell responses and apoptosis. IL-6 is produced by many different cell types. The main sources in vivo are stimulated monocytes, fibroblasts, endothelial cells, macrophages, T-cells, and
Chapter 3 Cytokines and Inflammatory Bowel Disease
35
B-lymphocytes. IL-6 is a B-cell differentiation factor in vivo and in vitro and an activation factor for T-cells. In the presence of IL-2, IL-6 induces the differentiation of mature and immature T-cells into cytotoxic T-cells. IL-6 also induces the proliferation of thymocytes and likely plays a role in the development of thymic T-cells. Most significantly IL-6 and TGF- together can induce the development of the inflammatory Th17 cell lineage. Finally, in opposition, if IL-6 is present, there is decreased propensity to development of FOXP3 positive T reg cells. Interestingly IL-6 levels are increased in the serum of patients with active CD and UC compared to normal controls. A study looking at a known functional polymorphism of the IL-6 gene and the site of disease in CD patients did not demonstrate an association of IL-6 functional polymorphisms with CD or protection from CD. It did demonstrate that patients with the high producer genotype were more likely to have ileocolonic disease, while those with the low producer genotype had primarily colonic type disease, whereas those with intermediate producer genotype were more likely to have isolated ileal disease. These studies indicated an association of IL-6 production and site of disease [20]. The activity of IL-6 has made it an obvious target for clinical trials not only due to its proinflammatory effects but due to its involvement in T cell apoptosis cell death [21]. A pilot study was performed [22] to investigate safety and efficacy of a humanized anti-IL-6R monoclonal antibody in patients with Crohn disease. This target appeared to be promising with 80% of the patients treated for 12 weeks demonstrating clinical improvement as compared to 31% treated with placebo. Interleukin-12 IL-12 is a heterodimeric molecule composed of IL-12 p40 and IL-12 p35 subunits. IL-12 is secreted by antigen presenting cells such as monocytes, macrophages, dendritic cells, and to a lesser extent by NK cells. The most powerful inducers of IL-12 are bacteria, bacterial products, and parasites. IL-12 is a proinflammatory cytokine that is important in the differentiation of naïve T cells into IFN- producing pathogenic CD4+ Th1 cells [13, 23]. In peripheral lymphocytes of the Th1 T-helper cell type, IL-12 induces the synthesis of IFN-, IL-2, and TNF-. TNF- also appears to be involved in mediating the effects of IL-12 on natural killer cells since the effects of IL-12 are inhibited by an antibody directed against TNF-. IL-12 and TNF- are co-stimulators for IFN- production with IL-12 maximizing the IFN-g response; the production of IL-12, TNF-, and IFN- is inhibited by IL-10. In Th2 T-helper cells IL-12 reduces the synthesis of IL-4 IL-5, and IL-10. This cytokine is considered a driving force behind chronic intestinal inflammation. Evidence for this is derived from murine models of colitis demonstrating that disease development could be inhibited by treatment with anti IL-12p40 monoclonal antibodies [23]. In human studies, this master T cell differentiating cytokine has been shown to be produced in large amounts in the intestines of patients with CD [24]. In addition, this cytokine has been targeted in human CD using an anti-IL-12p40 monoclonal antibody and found to be effective in early studies [25]. The long lasting clinical effect observed may be due in part to the induction of apoptosis of the inflammatory effector cells. These studies suggest that in addition to IL-2, IL-12 is a necessary growth and survival factor for T cells [26]. It also brings about the point that the mechanism of action of the various anti-biologic therapies lies not only in their capability to neutralize their respective cytokines but due to their ability to induce cell death of the inciting inflammatory effector cells. Interestingly, the p40 subunit is also found to be a portion of another significant proinflammatory master cytokine, IL-23. The positive effects observed of the anti IL-12 p40 antibody may indeed have been due to both the effect on IL-12 and IL-23 [24]. Further studies in models of colitis indicate that IL-23 is important in the inflammatory response in IBD in that it plays a significant role in the maintenance of Th-17 effective inflammatory cells [27].
36
Edwin F. de Zoeten and Ivan J. Fuss
Interleukin-23 IL-23 is a proinflammatory cytokine that has become a recent focus of attention. IL-23 is secreted by activated dendritic cells and macrophages. It is a proinflammatory cytokine that shares structural homology with IL-12, specifically it is composed of the p40 subunit and a unique p19 chain. Initial studies indicating an ameliorating effect of an anti-p40 antibody in murine models of inflammation was felt to be due to its effect on IL-12. However, recently this effect has been reevaluated and studies indicate that this ameliorating effect may be due to a decrease in IL-23 mediating effect. In these studies, mice deficient in the p19 subunit of IL-23 displayed attenuated inflammation in colitis models, whereas mice deficient in the p35 chain of IL-12 (therefore deficient in IL-12, but not IL-23) had no effect on colitis. These studies together suggest that the initial effects observed with anti-p40 in a variety of animal models may have been due to a decrease in IL-23. IL-23 promotes a novel subset of CD4+ T cells (Th17 cells) that is characterized by the production of IL-17, IL-6, and TNF- and has been associated with autoimmune tissue inflammation [28]. The exact mechanism by which IL-23 promotes the Th17 response has not been defined but it appears TGF- and IL-6 are important for the commitment into a Th17 cell and IL-23 is important for the proliferation of this cell type [29, 30]. IL-23 effect is not limited to Th17 cells but appears to have an effect of the innate immune system inducing monocytes and macrophages to produce proinflammatory cytokines such as IL-1, IL-6 and TNF- as well. In addition, in a genome wide association study in adults [31] as well as in a pediatric population (Baldassano, personal communication) the IL-23 receptor (IL-23R) gene on chromosome 1p31 has been shown to have a highly significant association with CD specifically, and an uncommon coding variant of the IL-23R gene was shown to confer protection. These data indicate that the IL-23 pathway may have a causal link to CD. Interleukin-17 IL-17 has been associated with multiple immune regulatory functions. Most notably, IL-17 is involved in inducing and mediating proinflammatory responses. IL-17 induces the production of many other cytokines, such as IL-6, granulocyte colony stimulating factor (G-CSF), GM-CSF, IL-1, TGF-, TNF-, chemokines including IL-8, growth regulated oncogene alpha (GRO-) and monocyte chemotractic protein 1 (MCP-1) and prostaglandins (e.g. PGE2 ) from many cell types (fibroblasts, endothelial cells, epithelial cells, and macrophages). IL-17 expression is currently believed to be stimulated by IL-23 expression. IL-23 appears to activate expression of IL-17 by subset of CD4+ T-cells called T-Helper-17 (Th17) cells, monocytes, and neutrophils [32]. Increased expression of IL-17 has been reported in the intestinal mucosa of patients with IBD [33]. Some reports suggest that IL-17 alone is capable of inducing autoimmune tissue reactivity whereas other groups suggest that IL-17 and IFN- synergize to stimulate this autoimmune reactivity [28, 34]. In these studies it was indicated that IL-17 was produced by T cells and monocytes in the intestinal mucosa. IL-17 binds to the IL-17 receptor on endothelial cells and epithelial cells to promote secretion of proinflammatory substances that recruit inflamatory cells to the site [35]. As a result of these roles, the IL-17 family has been linked to many immune/autoimmune related diseases including rheumatoid arthritis, asthma, and lupus. IL-17 expression is increased in patients with a variety of allergic and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, IBD, and asthma, suggesting the contribution of IL-17 to the induction and/or development of such diseases. This work identifies IL-17 as another possible target for IBD therapy. Interleukin-18 This cytokine initially identified as interferon- inducing factor (IGIF) is similar to the IL-1 family in structure, processing, receptor, and proinflammatory properties. It has been found to be
Chapter 3 Cytokines and Inflammatory Bowel Disease
37
produced by intestinal epithelial cells and appears to induce other proinflammatory cytokines and Th1 polarization. IL-12 and IL-18 have a synergistic relationship. Their production by activated macrophages appears to drive the development of Th1 CD4+ T cell predominance in the intestinal mucosa. Recombinant IL-18 alone is able to induce a proliferative response in vitro in freshly isolated mucosal lymphocytes from patients with CD. The synergistic effect is likely due to the upregulation of the IL-18 receptor by IL-12. Intestinal mucosa from patients with CD have been evaluated and found to have increased expression of IL-18 [36] and this was also noted in experimental murine colitis [37]. Tissues from patients with CD have been shown in vitro to have decreased suppressive cytokine IL-10 expression after treatment with IL-18 indicating one possible effector mechanism. IL-12 and IL-18 together appear to synergize to drive the lamina propria lymphocytes into a Th1 type response. IL-12 appears to induce increased IL-18 expression thus the synergistic effect [38, 39]. Using models of colitis multiple laboratories have tried to block IL-18 and the results indicate that IL-18 may have a role in the initiation of intestinal inflammation, while others have shown that IL-18 acts to reduce inflammation. Interleukin-13 IL-13 can have a dual functional role in that it can down-modulate macrophage activity, reducing the production of pro-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, IL-12) and chemokines (macrophage inflammatory protein 1 (MIP-1), MCP) in response to IFN- or bacterial lipopolysaccharides. IL-13 can also enhance the production of the IL-1 receptor antagonist and decrease the production of nitric oxide by activated macrophages, leading to a decrease in parasiticidal activity. Yet interestingly it appears that IL-13 is important in the development of Th2 type colitis such as the murine model of colitis oxazolone and its human counterpart, UC. In these studies it was found that IL-13 produced by natural killer T cells, when neutralized led to decreased inflammation in the oxazolone model of colitis. Furthermore, most importantly, in human studies, these IL-13 secreting NK T cells exhibited an increased cytolytic function against epithelial cell lines. Finally, IL-13 itself has been shown to be directly toxic to epithelial cells as well as to cause increased permeability barrier functional defects [40, 41]. Thus, in the oxazolone model of colitis and its human counterpart ulcerative colitis it is believed that IL-13 secreting NK T cells plays an important role in the etiology of this disease entity. This is in contrast to the Th1/Th17 disease process discussed in the pathogenesis of Crohn disease. Finally, although IL-13 can function as a pro inflammatory molecule in UC it stills retains anti-inflammatory effects as mentioned above, its role in Th1 disease entities remains uncertain.
Anti-inflammatory Cytokines As the host requires a pro-inflammatory response in the presence of a stimulating antigen, so too, the host requires an anti-inflammatory response once the antigen has been dealt with or the offending infection has been cleared. Without the ability to turn off or down-regulate the immune response the inflammation becomes overwhelming and can be detrimental to the host. This issue is exemplified in patients with the disease known as IPEX (immune dysregulation, polyendocrinopathy, and enteropathy, X-linked). This syndrome is characterized by the development of overwhelming systemic autoimmunity in the first year of life. It is associated with mutations identified in the FoxP3 gene. FoxP3 is a member of the forkhead/winged-helix family of transcriptional regulators known to be specific to regulatory T cells and important for their function. Without functional T reg cells the activated immune system has little or no halt to the inflammatory process. Tolerance, in normal hosts, is mediated by these regulatory T cells, as well as, B lymphocytes, natural killer T cells and dendritic cells that secrete TGF-, IL-10, IFN-/
38
Edwin F. de Zoeten and Ivan J. Fuss
and prostaglandin J2. Another mechanism for regulation is the secretion of anti-inflammatory cytokines. As these cytokines are defined they are being evaluated for methods to increase their secretion or for systemic therapy with the cytokine itself to treat IBD. Transforming Growth Factor Beta TGF- belongs to a family of multi-functional polypeptides produced by a wide variety of lymphoid and non-lymphoid cells. They exist in five different isoforms, three of which are expressed in mammals and designated as TGF-1, TGF-2 and TGF-3 [1]. TGF- can act in both autocrine and paracrine modes to control the differentiation, proliferation and state of activation of immune cells. TGF- can inhibit the production of and response to cytokines associated with CD4+ Th1 T cells and CD4+ Th2 T cells. TGF- inhibits the proliferation of T-lymphocytes by down-regulating predominantly IL-2 mediated proliferative signals. It also inhibits the growth of natural killer cells in vivo and deactivates macrophages. Of significance, TGF- has been shown to be important in stimulating the development of Foxp3+ T regulatory cells. These activities have been verified in animal models of IBD [42]. These studies indicate that TGF- production is relevant in the pathogenesis of experimental colitis. In two different models of Th1-mediated murine experimental colitis, it has been shown that protection from colitis development is strictly associated with the presence of increased numbers and/or up-regulation of TGF-1 producing cells [1, 43]. In humans, the data pertaining to regulatory cells remains sparse. In a single study, Maul et al. [44] have shown that there exists a decrease in FoxP 3 expressing cells in the periphery of patients with IBD. However, examination of mucosal tissue reveals that as compared to controls, patients with IBD had a relative increase in these cells albeit this increase was less than that seen in other inflammatory disorders such as diverticulitis. The authors postulated that there is a relative lack of counter-regulation at the mucosal level in IBD and therefore, an ability to increase the number of local resident regulatory cells in the face of inflammation. The theory that IBD may be due to a defect in regulatory cells number or suppressive function still requires further investigation. Interleukin-4 IL-4 is produced mainly by a subpopulation of activated T-cells (Th2) which are the biologically most active helper cells for B-cells and which also secrete IL-5 and IL-6. Another subpopulation, Th1 also produces IL-4 albeit to a lesser extent. IL-4 is a stimulatory molecule for both B and T cells that has known immunosuppressive effects in the intestine where it promotes the proliferation and differentiation of activated B-cells, and the expression of major histocompatibility complex (MHC) class 2 antigens. IL-4 enhances expression of MHC class 2 antigens on B-cells. It can promote their capacity to respond to other B-cell stimuli and to present antigens for T-cells. While IL-4 is frequently described as an anti-inflammatory cytokine, recent studies have shown its capacity to perpetuate inflammatory diseases. Specifically, in a murine model of ileitis a monoclonal antibody against IL-4 was shown to suppress disease severity [45]. Interestingly, IL-4 mediated disease in certain animals models appears to be most important in inflammation limited to the ileum and small intestine [46]. In the aforementioned oxazolone model of colitis, IL-4 is the predominant initial cytokine to appear in the mucosal lesions, however this is subsequently superceded by an IL-13 response. This coincided with what one sees in the IBD entities as no significant measurable secreted levels of IL-4 have been found in either UC or CD patients to suggest a pathogenic role. Thus, IL-4 as IL-13 displays both anti-inflammatory and inflammatory cytokine properties. Its targeting for therapy in animal studies has had some beneficial effects. Targeting in human disease is not as clear.
Chapter 3 Cytokines and Inflammatory Bowel Disease
39
Interleukin-10 IL-10 is produced by activated CD8+ peripheral blood T-cells, by T-helper CD4+ T-cell clones after both antigen-specific and polyclonal activation. IL-10 has been defined as having multiple biologic effects all acting to down regulate the inflammatory response. IL-10 inhibits the synthesis of a number of cytokines such as IFN-, IL-2 and TNF- in Th1 T-helper subpopulations of T-cells but not of Th2 T-helper cells. This activity is antagonized by IL-4. The inhibitory effect on IFN- production is indirect and appears to be the result of a suppression of IL-12 synthesis by accessory cells. In the human system, IL-10 is produced by, and down-regulates the function of, Th1 and Th2 cells. In macrophages stimulated by bacterial lipopolysaccharides IL-10 inhibits the synthesis of IL-1, IL-6 and TNF- by promoting, among other things, the degradation of cytokine mRNA. It also leads to an inhibition of antigen presentation. The activation of macrophages can be prevented by IL-10. In human monocytes, IFN- and IL-10 antagonize each other’s production and function. IL-10 has been shown also to be a physiologic antagonist of IL-12. In macrophages stimulated with bacterial lipopolysaccharides IFN- increases the synthesis of IL-6 by inhibiting the production of IL-10. In B-cells activated via their antigen receptors or via CD40 IL-10 induces the secretion of IgG, IgA, and IgM. This effect is synergised by IL-4 while the synthesis of immunoglobulins induced by IL-10 is antagonized by TGF-. It has been shown that human IL-10 is a potent and specific chemoattractant for human T-lymphocytes. Finally, IL-10 also inhibits the chemotactic response of CD4(+) cells, but not of CD8(+) cells, towards IL-8. In support of its role in IBD, mice deficient in IL-10 (IL-10-/-) gene spontaneously develop chronic colitis. Using this information recombinant IL-10 has been used as therapy in patients with CD. While initial studies appeared red positive, upon further evaluation in larger clinical trials results were not noted to be significant. Due to the concern that IL-10 was not delivered in significant quantitites at the local mucosal level, another approach was attempted using “Turbo Probiotics”. This was done by engineering Lactobacillus Lactis to secrete IL-10 specifically at the intestinal level. A similar construct has been tried in patients with IBD. This novel approach has shown some promising results.
Summary As is evidenced above, there are many cytokines that are involved in the inflammatory response of the mucosa in inflammatory bowel disease. These cytokines can have either pro-, anti- or both pro and anti-inflammatory effects and are important in the pathogenesis of this and other autoimmune diseases. The above-described cytokines are those that were deemed most significant to inflammatory bowel disease but there are multiple other cytokines that are currently being evaluated (IL-22, IL-32, IL-33, IL-35, TL1A, IL-15) or are as yet unknown, that may be targets for IBD therapy in the future. References 1. Neurath, M.F., et al., Experimental granulomatous colitis in mice is abrogated by induction of TGFbeta-mediated oral tolerance. J Exp Med, 1996. 183(6): pp. 2605–16. 2. Reinecker, H.C., et al., Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn disease. Clin Exp Immunol, 1993. 94(1): pp. 174–81. 3. Camoglio, L., et al., Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis, 1998. 4(4): pp. 285–90. 4. Boirivant, M., et al., Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med, 1998. 188(10): pp. 1929–39.
40
Edwin F. de Zoeten and Ivan J. Fuss
5. Shetty, A. and A. Forbes, Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn disease. Am J Pharmacogenomics, 2002. 2(4): pp. 215–21. 6. Strober, W., et al., Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today, 1997. 18(2): pp. 61–4. 7. Neurath, M.F., et al., Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol, 1997. 27(7): pp. 1743–50. 8. Murch, S.H., et al., Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut, 1991. 32(8): pp. 913–7. 9. Reimund, J.M., et al., Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn disease. J Clin Immunol, 1996. 16(3): pp. 144–50. 10. Targan, S.R., et al., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn disease. Crohn Disease cA2 Study Group. N Engl J Med, 1997. 337(15): pp. 1029–35. 11. Hanauer, S.B., et al., Maintenance infliximab for Crohn disease: the ACCENT I randomised trial. Lancet, 2002. 359(9317): pp. 1541–9. 12. Bruewer, M., et al., Proinflammatory cytokines disrupt epithelial barrier function by apoptosisindependent mechanisms. J Immunol, 2003. 171(11): pp. 6164–72. 13. Strober, W., I.J. Fuss, and R.S. Blumberg, The immunology of mucosal models of inflammation. Annu Rev Immunol, 2002. 20: pp. 495–549. 14. Reinisch, W., et al., A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn disease. Gut, 2006. 55(8): pp. 1138–44. 15. Hommes, D.W., et al., Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn disease. Gut, 2006. 55(8): pp. 1131–7. 16. Cominelli, F. and T.T. Pizarro, Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther, 1996. 10 Suppl 2: p. 49–53; discussion 54. 17. Mahida, Y.R., K. Wu, and D.P. Jewell, Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn disease. Gut, 1989. 30(6): pp. 835–8. 18. Van Assche, G., et al., A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol, 2003. 98(2): pp. 369–76. 19. Van Assche, G., et al., Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut, 2006. 55(11): pp. 1568–74. 20. Cantor, M.J., P. Nickerson, and C.N. Bernstein, The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol, 2005. 100(5): pp. 1134–42. 21. Atreya, R. and M.F. Neurath, Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol, 2005. 28(3): pp. 187–96. 22. Ito, H., et al., A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn disease. Gastroenterology, 2004. 126(4): pp. 989–96; discussion 947. 23. Bouma, G. and W. Strober, The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol, 2003. 3(7): pp. 521–33. 24. Fuss, I.J., et al., Both IL-12p70 and IL-23 are synthesized during active Crohn disease and are downregulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis, 2006. 12(1): pp. 9–15. 25. Mannon, P.J., et al., Anti-interleukin-12 antibody for active Crohn disease. N Engl J Med, 2004. 351(20): pp. 2069–79. 26. Fuss, I.J., et al., Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology, 1999. 117(5): pp. 1078–88. 27. Harrington, L.E., et al., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 2005. 6(11): pp. 1123–32. 28. Langrish, C.L., et al., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med, 2005. 201(2): pp. 233–40. 29. Mangan, P.R., et al., Transforming growth factor-beta induces development of the T(H)17 lineage. Nature, 2006. 441(7090): pp. 231–4.
Chapter 3 Cytokines and Inflammatory Bowel Disease
41
30. Bettelli, E., et al., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006. 441(7090): pp. 235–8. 31. Duerr, R.H., et al., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science, 2006. 314(5804): pp. 1461–3. 32. Hue, S., et al., Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med, 2006. 203(11): pp. 2473–83. 33. Fujino, S., et al., Increased expression of interleukin 17 in inflammatory bowel disease. Gut, 2003. 52(1): pp. 65–70. 34. Kullberg, M.C., et al., IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med, 2006. 203(11): pp. 2485–94. 35. Kolls, J.K. and A. Linden, Interleukin-17 family members and inflammation. Immunity, 2004. 21(4): pp. 467–76. 36. Pizarro, T.T., et al., IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn disease: expression and localization in intestinal mucosal cells. J Immunol, 1999. 162(11): pp. 6829–35. 37. Reuter, B.K. and T.T. Pizarro, Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur J Immunol, 2004. 34(9): pp. 2347–55. 38. Okamura, H., et al., Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol, 1998. 10(3): pp. 259–64. 39. Nakanishi, K., et al., Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev, 2001. 12(1): pp. 53–72. 40. Fuss, I.J., et al., Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest, 2004. 113(10): pp. 1490–7. 41. Heller, F., et al., Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology, 2005. 129(2): pp. 550–64. 42. Powrie, F., et al., A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med, 1996. 183(6): pp. 2669–74. 43. Duchmann, R. and M. Zeitz, T regulatory cell suppression of colitis: the role of TGF-beta. Gut, 2006. 55(5): pp. 604–6. 44. Maul, J., et al., Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology, 2005. 128(7): pp. 1868–78. 45. Bamias, G., et al., Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology, 2005. 128(3): pp. 654–66. 46. Dohi, T., et al., T helper type-2 cells induce ileal villus atrophy, goblet cell metaplasia, and wasting disease in T cell-deficient mice. Gastroenterology, 2003. 124(3): pp. 672–82.
Section 2 Epidemiology and Clinical Features
4 Epidemiology of Pediatric Inflammatory Bowel Disease Shehzad Saeed and Subra Kugathasan∗
Introduction Inflammatory bowel disease (IBD), one of the most serious chronic gastrointestinal conditions affecting growth, social well-being, education, and employment, is increasing in incidence among children. It is increasing comprised of two distinct entities – Crohn disease (CD) and Ulcerative colitis (UC). Although the exact details of disease pathogenesis remain unknown, the general accepted hypothesis is that IBD occurs as the result of an inappropriate and exaggerated mucosal immune response to ubiquitous environmental factors including commensal microflora in a genetically susceptible host. Although only about 25% of all IBD occurs in the pediatric age group, continued assessment of epidemiology among children is important since it may facilitate better understanding of the disease etiology since in childhood the disease is “Pure” and not complicated by long standing environmental exposures. Studies of epidemiology in children may therefore provide better clues as to the progression, predictors and outcomes of IBD. Various and seemingly unrelated environmental factors such as diet, breastfeeding, drugs, socioeconomic status, and stress have been implicated in the rapid worldwide spreading of IBD. In principle, epidemiology holds that each factor deserves credit, but the strength of the supporting data varies considerably for each factor with only a few factors emerging as clinically associated with disease. The first is smoking. Despite an obscure mechanism of action, the epidemiological evidence that smoking is related to disease is too strong and reproducible to be dismissed. The second factor is the gut commensal flora. Backed by an impressive amount of experimental evidence from animal models, reasonable patient clinical data, and the recently established link between CD and abnormal NOD2-mediated bacterial sensing, gut commensal flora appears to be clearly associated with IBD. In fact, currently efforts are devoted to better understanding which enteric bacteria may have a pathogenic potential, and why their recognition by the mucosal immune system leads to inflammation in IBD subjects but not the general population. The third factor to consider is appendectomy which has been demonstrated to reduce risk of UC by 69%. This inverse relationship between UC and appendectomy is particularly strong in pediatric population. In this chapter, we will discuss not only the descriptive epidemiology of childhood IBD, but also the emerging and exciting areas of growth (“new epidemiology”) including as-yet-unidentified environmental risk factors, clinical epidemiology (outcome of IBD), IBD in emerging populations
*Department of Pediatrics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee WI 53226, Phone: 414 266 3690, Fax: 414 266 3676, E-mail:
[email protected]
45
46
Shehzad Saeed and Subra Kugathasan
and the need for studies to understand the complex interplay between environmental and genetic risk factors.
Descriptive Epidemiology Descriptive epidemiology refers to the study of disease incidence, prevalence, temporal and geographical trends, and demographic factors, such as age, gender and race/ethnicity which may influence disease. Although emerging data from Asia, Pacific regions and South America suggest the incidence of IBD in children is increasing worldwide, most of the data regarding the descriptive epidemiology of IBD (including childhood onset) is derived from European and North American cohorts. The United States prevalence of CD and UC combined is estimated to be 400 cases per 100,000 persons, or 0.4%. Based on the current US population of 320 million, there are approximately 1.4 million Americans with IBD [1]. Accordingly, the age-specific incidence rates of IBD in North America for children aged 1 to 17 years old is approximately 2/100,000 for UC and 4.5/100,000 for CD [2]. About 30% of all patients with CD present before the age of 20 years. In addition, only 4% of pediatric IBD cases occur before the age of 5 years, and 20% before the age of 10 years with a peak age of onset in the adolescent years [3]. Although there are no prevalence data of IBD among children available from North America, extrapolations of available data suggest that anywhere between 45,000–100,000 children and adolescents in North America are suffering from IBD and about 10,000 new cases are diagnosed annually [4]. In fact, IBD is one of the most common chronic gastrointestinal conditions being managed by gastroenterologists in the US. The incidence and prevalence data from available pediatric studies from around the world is summarized in Table 4.1. Time Trends in Pediatric IBD Several studies from Europe have reported an increasing incidence of CD and UC. For instance, a Scottish cohort of hospitalized pediatric IBD patients noted a 3 fold increase in incidence of CD from 1968 to 1983, with essentially no change in incidence of UC [5]. A follow up study aimed at documenting the incidence of pediatric-onset IBD between 1981 and 1995 examined the temporal trends of IBD in scotland between 1968 and 1995 [6]. The incidence of pediatric-onset CD was noted to rise with the prevalence increased by 30% since 1983. The authors further concluded that unlike the previous reports, the incidence of childhood-onset UC was also increasing. Whether this represents a real rise in incidence, or merely the inclusion of milder cases remains uncertain. Additional evidence of the increasing incidence of CD comes from Sweden where the incidence of CD increased from 2.4/100,000 in 1990–92 to 5.4 between 1996–98. In contrast, the incidence of UC remained stable over the same time period [7]. Furthermore, the incidence of pediatric IBD almost doubled in Finland from 1987 to 2003 [8], and data from Eastern Europe is similar with a Czech cohort [9], reporting an increased incidence from 0.25/100,000 to 1.25/100,000 in CD patients aged less than 15 years between 1990 and 2001. This increasing incidence of IBD has been contradicted by other studies such as a cohort from Northern France, which documented no significant change in the incidence of CD over a 10 year period [10]. Geographic Trends of Pediatric IBD Several studies have noted higher predisposition of IBD in northern latitudes than southern regions [11, 12]. This gradient difference is even seen within countries. The study populations with the highest incidence and prevalence rates are reported from the northern latitudes. Few pediatric studies have assessed this trend, a Scottish report noted a higher incidence of CD in northern
Table 4.1. Available world-wide epidemiological data from pediatric studies. Authors and reference
Country
Year
IBD incidence IBD 7.1 CD 4.5 UC 2.2 IBD 3.9 CD 2.3 UC 1.6 IBD 3.81 CD 3.1 UC 0.71 IBD 6.9 CD 3.8 UC 2.1 IC 1.1 1.25 CD IBD 3.1 CD 2.3 UC 0.8 CD 8.5 IBD 2.6 CD 2.1 UC 0.5 IBD 4.7 CD 2.7 UC 2.0
Kugathasan et al. [2]
USA
2003
Barton et al. [5]
UK
1989
Cosgrove et al. [67]
UK
1996
Askling et al. [7]
Sweden
1999
Pozler et al. [9] Auvin et al. [10]
Czech Republic France
2006 2005
Bjornsson et al. [68] Gottrand et al. [69]
Iceland France
2000 1991
Størdal et al. [70]
Norway
2004
IBD prevalence
Other comments
N/A
Prospective Population based
N/A
Retrospective Population based
CD-16.6 UC3.4
Retrospective
N/A
Retrospective
N/A
Partly retrospective and partly prospective
N/A N/A
Prospective Population based Published in French
N/A
Prospective
(Continued)
Table 4.2. (Continued) Authors and reference
Country
Year
IBD incidence IBD 6.8 CD 2.5 UC 4.3 IBD 4.5 CD1.3 UC3.2 IBD 7.4 CD 4.9 UC 2.2 IBD 2.6 CD 1.36 UC 0.75 UC 6.02 IBD 3.8 CD 2.5 UC 1.3 CD 2.0
Olafsdottir et al. [71]
Norway
1989
Lindberg et al. [72]
Sweden
2000
Hildebrand et al. [73]
Sweden
2003
Hassan et al. [74]
UK / Wales
2000
Sood et al. [75] Armitage et al. [6]
India / Punjab UK / Scotland
2003 2001
Phavichitr et al. [76]
Australia
2003
N/A – not available, IC indeterminate colitis
IBD prevalence
Other comments
N/A
Prospective
N/A
Prospective
N/A
Prospective
N/A
Prospective
UC 44.3 N/A
Prospective Retrospective
N/A
Retrospective
Chapter 4 Epidemiology of Pediatric Inflammatory Bowel Disease
49
Scotland than in the southern regions of the country; this trend was not replicated for UC [13]. Data is lacking from North America with no prospective multicenter assessment of this observation. A retrospective review of all hospitalized patients in the US (including adults) over a two year period (1986–87) noted higher frequencies of both CD and UC in northern regions and in urban areas [11]. Racial/Ethnicity Trends Traditionally, IBD is thought to be less prevalent in non-Caucasian populations. This is most probably related to under-representations of non-Caucasians in the study populations/centers. An assessment of the epidemiology of these disorders in non-Caucasians is complicated by a wide range of factors including the absence of population based registries in ethnically diverse regions, the use of retrospective data, and highly variable clinical presentations which may delay or obscure the diagnosis [14, 15]. In addition, two pediatric studies have also shown comparable incidence and disease characteristics in African American compared with Caucasian populations in two different geographical locations of the US – Wisconsin [2] and Georgia [16]. These studies demonstrate differing proportions of African Americans afflicted with IBD and therefore, suggest IBD among African-Americans is not rare among pediatric populations. Jewish ancestry is thought to confer increased susceptibility to IBD. One study showed life time risk of developing IBD in offspring of an affected non-Jewish parent to be 5 and 2% for CD and UC, respectively [17]. The risk increased to 8 and 5% if the affected parent happened to be Jewish. In addition, if both parents are affected, life-time risk of developing IBD increases to 33% by age 28. Gender and Pediatric IBD Although previous studies have not found gender to be a significant variable in the incidence, prevalence or outcome of IBD, recent epidemiological data suggest overall incidence and prevalence of CD among adult females slightly exceeds that of adult males [18]. In sharp contrast, however, population based studies of pediatric onset CD in the US [2], Canada [19] and the United Kingdom [20] demonstrate a nearly 1.5:1 male-to-female incidence of pediatric onset CD. This “male excess” in incidence among childhood onset CD remains unexplained, but genetic predisposition and other intrinsic factors are suspected to play a role. Furthermore, no gender differences in the epidemiology is seen for UC.
Hygiene Hypothesis and Other Epidemiological Observation in IBD A remarkable change in the types of diseases affecting humans has occurred in the developed world over the last century [21] The most common illnesses responsible for the majority of morbidity and mortality have shifted from infectious diseases to chronic inflammatory diseases and cancer. This was initially noted in Northern Europe and North America (Figure 4.1), but since the end of World War II this phenomenon has been observed in other parts of the world, such as, Japan, Eastern Europe, and some South American countries. The emergence of chronic autoimmune disorders and chronic inflammatory diseases (including IBD) throughout the world has been closely linked to social and economical progress. Keeping with this trend, the emergence of IBD has most recently be observed in the Asian Pacific Region (Figure 4.1). The “hygiene hypothesis” has been proposed as the probable underlying reason for the switch from infectious to chronic inflammatory diseases such as IBD, and postulates that there has been a fundamental lifestyle change from one associated with high microbial exposure to one with low microbial exposure [23]. The lack of microbial antigens in infancy and childhood, therefore, leads
50
Pre-World War II
1950-1970
1970-1990
1990-present
Legend: Light grey indicates low incidence of Inflammatory Bowel Disease isease Medium grey indicates moderate incidence of Inflammatory Bowel Disease Black indicates high incidence of Inflammatory Bowel Disease
Shehzad Saeed and Subra Kugathasan
Figure 4.1. Changing distribution of IBD is shown here with World-wide distribution. Black area indicate high prevalence, light grey indicate low prevalence and medium grey indicate moderate prevalence of IBD.
World-wide distribution of IBD since its description
Chapter 4 Epidemiology of Pediatric Inflammatory Bowel Disease
51
Figure 4.2. Environmental risk factors and proposed etiology of IBD.
to a less educated and weaker immune system unequipped to properly handle new challenges later on in life. This leads then to generating an ineffective immune response that is prolonged and inappropriate because it is powerless to eliminate the offending agent. Many environmental modifications have been ascribed to the hygiene hypothesis, including better and bigger housing, safe food and water, improved hygiene and sanitation, vaccines, widespread use of antibiotics leading to lack of parasites, fewer infections, and better nutrition [24]. While contributing to the progressive decline of infectious diseases these changes may have simultaneously contributed to a surge in allergic and autoimmune diseases [25].
Environmental Risk Factors Smoking The most indisputable example of the influence of the environment on IBD is tobacco use, specifically, cigarette smoking. Smoking has a strikingly opposite effect on CD as compared to UC, supporting the notion that distinct mechanisms underlie the pathogenesis of these two forms of chronic inflammatory disease [26]. Notably, UC patients are frequently non-smokers, and furthermore, cessation of smoking is noted to increase the risk of developing UC. In fact, nicotine patches are currently being studies to treat UC, supporting its protective role in this disease. In sharp contrast, however, cigarette use is an important risk factor for CD, increasing the frequency of disease relapse and need for surgery, while discontinuation improves disease course [27]. The role of passive smoking, particularly in children, as either a risk factor or protective factor for CD and/or UC is still a matter of controversy with none of the studies having quantitatively assessed the passive smoke exposure. The mechanisms underlying the differential effect of smoking in CD or UC remain obscure. However, smoking has been demonstrated to affect both systemic and mucosal immunity, as well as alter a wide range of both innate and adaptive immune functions [28]. For instance, smoking alters the ratio of T-helper to T-suppressor cells, reduces T cell proliferation, modulates apoptosis, and significantly decreases serum and mucosal immunoglobulin levels. In animal models, smoking reduces mucosal cytokine production and promotes adhesion of leukocytes to endothelial cells. Furthermore, it enhances small bowel permeability and colonic
52
Shehzad Saeed and Subra Kugathasan
mucus production. Interestingly, transdermal nicotine shows some beneficial effect in patients with mild to moderate UC. On the other hand, nicotine may be detrimental in CD by contributing to the hypercoagulability state present in this condition. Taken together, these divergent effects of smoking in human IBD indicate a complex interaction between smoking and IBD [29]. In childhood IBD, a concerted effort should be made to study smoking exposure and the risks of IBD development, progression, as well as its interaction with an individual’s genes in determining the eventual outcome. Microbial Factors; Specific Infectious Agents Search for specific infectious organisms as a cause of IBD has remained very attractive. The history of IBD is dotted by cyclic reports on the isolation of specific infectious agents thought to be responsible for CD or UC. Unfortunately, none of these initial reports have ever been reproduced. Several microorganisms have been proposed as having a potential etiologic role, such as Listeria monocytogenes, Chlamydia trachomatis, Escherichia coli, Cytomegalovirus, Saccharomyces cerevisiae, and others. Among those, the role of Mycobacterium Avium paratuberculosis (MAP) in CD has been the center of major controversy. This bacterium is the causative agent of Johne’s disease, a chronic granulomatous ileitis in ruminants that closely resembles CD. MAP was initially isolated from a few CD tissues[30], but follow-up studies that tried to culture Mycobacterium paratuberculosis, looked for specific DNA sequences in intestinal samples, or measured serum antibodies against M. paratuberculosis yielded conflicting or inconclusive results. In addition, controlled trials have repeatedly failed to show a therapeutic effect of antituberculous therapy in CD patients [31]. Recently, however, there has been a renewed interest in MAP as a cause of CD following the isolation of MAP by PCR in milk sold in supermarkets of California and Wisconsin [32]. In addition to bacteria, a few have proposed a viral etiology as the cause of IBD and specifically for CD. The finding of paramixovirus-like particles in CD endothelial granulomas has led to the suggestion that CD is a chronic vasculitis caused by the persistence of the measles virus in the mucosa [33]. In support of this hypothesis, an association between perinatal measles and predisposition to CD was also advanced based on some epidemiological and serologic data [34]. Despite these preliminary findings none were confirmed by later investigations [35]. Importantly, the progressive decline of measles virus infection in the last decades with the concomitant rise of CD during the same period of time speaks largely against an etiologic role of measles in CD. The hypothesis that measles vaccination, rather than measles infection, might be a risk factor for CD has also been raised, but again subsequent studies failed to confirm any association [36]. Microbial Factors; Intestinal Commensal Flora Over the past decade, there has been an exponential increase in interest about commensal bacteria as etiological agents of IBD (Figure 4.2). Based on fairly solid data, a substantial body of evidence has accumulated suggesting that the normal enteric flora plays a key role in the development of IBD [37]. Additionally, the following clinical observations support this hypothesis: 1) that the beneficial effect of antibiotics in the treatment of CD, and to a lesser extent UC, has been appreciated for years, 2) diversion of the fecal stream from inflamed bowel loops has been known to induce symptomatic improvement in CD patients, while relapse often occurs upon restoration of intestinal continuity, and 3) pouchitis, a chronic inflammation of a surgically constructed ileoanal pouch, develops in a considerable proportion of UC patients after proctocolectomy, and is associated with a dysbiosis caused by the contact of the once near sterile small bowel mucosa with a rich colon-like flora repopulating the pouch after surgery [38]. Furthermore, more recent data demonstrating that probiotics (primarily lactic acid bacteria), defined as live microbial feeds,
Chapter 4 Epidemiology of Pediatric Inflammatory Bowel Disease
53
beneficially affect the host by modulating gut microbial balance, and improve both human IBD and experimental colitis, adds an important dimension to the role of gut flora in IBD. In addition, it has been observed that much larger numbers and concentrations of bacteria make up the biofilm covering the intestinal epithelium of IBD patients compared to the epithelium of healthy subjects [39], and loss of immune tolerance against the autologous enteric aerobic and anaerobic flora has been reported [40]. Finally, and probably most convincingly, the majority of animal models of IBD fail to develop intestinal inflammation when kept in a germ-free environment [41]. Why there is an abnormal response to normal endogenous gut bacteria in IBD is not clear, but the recent discovery that CD is genetically associated with mutations of the NOD2 gene, whose products are bacteria-recognizing proteins, points to a link between gut inflammation and abnormal bacterial sensing [42].
Appendectomy Protective effects of appendectomy upon UC have been well established in a number of adult and pediatric studies. A meta-analysis of seventeen case control studies showed a 69% reduction in risk of subsequent development of UC in cases with appendectomy [43, 44]. This negative association is more pronounced in pediatric onset UC. Duggan et al. [45] also noted a protective effect of appendectomy on development of UC, especially if performed during childhood. On the other hand, risk for CD is reported to be increased after appendectomy [46]. The reasons for these observed differences remain ill defined with altered mucosal immunity in response to appendectomy as one of the proposed hypothesis.
Breast Feeding Breast feeding is thought to provide protection against infections and minimizes allergic triggers to a developing gut. It has also been suggested to provide long term beneficial effects like improved cognitive functioning, prevention of chronic disease like type I diabetes, celiac disease, lowering of blood pressure and improved cholesterol profile [47]. The role of breast feeding (or lack thereof) has been reported to be associated with development of Crohn disease in a few pediatric studies. A metanalysis by Klement et al. suggested a protective effects of breast feeding on later development of IBD [48]. This has been contradicted by a population based case control study which reported an increased risk of CD among breast fed infants [49]. They also reported increased risk of CD with eczema and BCG vaccines, but a protective effect of drinking tap water. Meanwhile, the risk of developing UC increased with family history of IBD, disease during pregnancy, and bedroom sharing, but appendectomy conferred a protective effect.
Dietary Factors The gastrointestinal tract is constantly being exposed to dietary antigens, and hence, this exposure has generated a number of observations relating to the potential role of different dietary components in the pathogenesis of IBD. Given the location of IBD, this relationship between components of the diet and disease has been long considered, and immunologic mechanisms have been postulated to link food antigens and the development of intestinal inflammation. However, this logical and appealing explanation is far from proven. In addition, only a few unpersuasive studies provide only indirect evidence of a possible cause-and-effect relationship between specific dietary factors and IBD. Most of these case control studies are limited by methodological problems including diet recall, role of pre-illness diet versus diet selection post diagnosis. Contrary to
54
Shehzad Saeed and Subra Kugathasan
these case control studies, a population based study by Baron et al. [49] failed to identify any specific dietary factors as potential risk factors for development of IBD. However, a questionnaire based, population case control study [50] from Manitoba, Canada reported reduced ingestion of pork, and un- pasteurized milk as significantly associated with IBD compared to controls, while no difference was seen with beef or chicken meat ingestion, although the frequency of chicken intake was noted to be higher in patients with CD as compared to patients with UC. Ingestion of refined sugars has also been reported to be associated with CD [51, 52]. Gilat, et al. showed higher consumption of whole wheat bread and lower consumption of oat meal cereals in CD patients [53]. Lastly, there is some evidence supporting the benefits of elemental and polymeric liquid diets as primary or adjuvant therapy for CD, although in some studies this nutritional approach was less effective than conventional therapies, such as corticosteroids [54].
Drugs Oral contraceptives (OCP) and non-steroidal anti-inflammatory drugs (NSAIDs) are the two main classes of drugs that have been intensively studied for a possible epidemiological or causal relationship with IBD. Although there is no direct evidence for a causative relationship, the relative risk of CD in women taking oral contraceptives is about twice that of controls [55], In contrast, prevalence of usage of OCP in females in a case control study from Canada [50] did not differ in patients with IBD compared with controls; however, CD patients were more likely to use OCP than controls and patients with IBD tended to start OCPs at an earlier age than the controls. Inverse causality has also been implicated in OCP use in patients with abdominal symptoms since they are routinely used to treat menstrual associated complaints. The situation is less ambiguous in the case of NSAIDs, because their use is clearly associated with a higher risk of IBD. Primarily, IBD patients in clinical remission can relapse upon NSAIDs administration. In fact, interleukin-10 knockout mice spontaneously develop colitis when given NSAIDs and exhibit a far more rapid and severe form of colonic inflammation associated with blockade of protective prostaglandins and altered mucosal immune reactivity [56], suggesting a potential mechanisms by which NSAIDs may worsen IBD. However, NSAIDs and OCPs are less likely to be an important contributing factor in childhood onset IBD.
Socio-Economical, Educational and Occupational Status This group of interrelated factors is large and difficult to analyze, but is postulated to reflect the “westernization” process that is so intimately linked to the emergence of IBD in the last one-half century. Role of hygiene in pathogenesis of allergies, asthma and other chronic conditions has been well studied in both adults and children [57, 58]. Although much of the data comes from adult studies, emerging data from pediatrics also supports the role of “cleaner environment” as a risk factor for IBD, hypothesizing that the more sanitary environment prevents the host from developing tolerance to the microbial agents that may present later in life [59]. Both Baron, et al. [49] and Amre, et al. [60] reported increased risk of IBD with bedroom sharing and overcrowding. In a case control study, Gent, et al. [61] reported access to hot water, separate bathrooms and main drainage as increased risk factors for CD but not UC. Bernstein, et al. however, noted having larger families as a protective factor against CD [50]. Duggan, et al. [45] also reported no availability of hot water before 11 years of age as a protective factor. Traditionally, IBD has been more prevalent among higher socioeconomic groups, affecting more white-collar than blue-collar workers. Interestingly, outdoor workers have less risk of developing IBD, while individuals with indoor occupations are more susceptible. In addition, sedentary
Chapter 4 Epidemiology of Pediatric Inflammatory Bowel Disease
55
workers are at higher risk for IBD. A number of theories have been advanced to explain these intriguing disparities. One of them points to the delay in abdominal transit associated with being sedentary and the more prolonged time of contact of food antigens with the gut wall, resulting in inappropriate stimulation and inflammatory reaction. It is obvious that theories such as these are pure speculations, and the reality is that the relationship of social, economical, educational and occupational status with IBD is currently obscure.
Stress Investigations performed with the cotton top tamarin, a non-human primate native to tropical South American jungle, has shown that these animals develop an UC-type colitis only when kept in captivity in colder climates, and that the colitis goes into remission if returned to their natural habitat [62]. This observation supports the belief that stress may trigger IBD. In reality stress is more likely to modulate disease manifestations rather than being an initiating factor. Evidence that stress can modulate the course of IBD is provided by clinical observations, and studies of neuroimmune interactions in laboratory animals. Stress also augments intestinal permeability, and therefore, the entry of excessive amounts of luminal antigens could activate pre-sensitized mucosal T cells resulting in inflammation.
New Epidemiology We refer to “new epidemiology” as extensions and growth of descriptive epidemiology that advances our knowledge toward the pathogenesis of IBD. This will include genetic epidemiology, clinical epidemiology (outcome studies), some of the as-yet-to-be-identified environmental risk factors, studies of complex gene-environmental interactions as well as new approaches to analyze disease risk such as geo-coding and small area geographical mapping of disease incidence.
Genetic Epidemiology & its Impact on the Pathogenesis of IBD Great advances have been made over the last decade to identify some of the candidate genes associated with IBD and this topic will be discussed in greater depth in another chapter of this book. Although, significant strides have occurred and candidate genes with biological significance have been discovered, it is very clear from twin studies that genetic determinants account for at most 50% of IBD susceptibility in CD, and even significantly lower contributions in UC, stresses the importance of environmental factors in the etiology of IBD. However, the best use of genetic knowledge in the context of epidemiology will likely yield more useful information and breakthroughs in the pathogenesis of IBD [63].
Challenges in the Way Forward; Genes and Environmental Interactions There is little argument that a complex disease like IBD is the result of life-long interactions between genetic and environmental susceptibilities. However, there is a paucity of research incorporating genotype-by-environment interaction into human genetic studies. Despite the importance of gene-environmental interactions, most genetic studies make an early and prominent assumption that no genotype-by-environment interactions exist. In fact, one explanation for the research falling short of earlier expectations in IBD is the inability to incorporate gene-environmental interactions in study designs and statistical analysis. There are many underlying reasons for the
56
Shehzad Saeed and Subra Kugathasan
shortage of gene-environmental interaction studies. The greatest difficulty is the ability to measure an individual’s exposure to their environment. Although we have seen revolutionary advances in measuring genetic variation over the last decade, measurement of environmental factors are still largely based on questionnaires and indirect measurements. The second reason is the fear of further exponential explosions in the number of variables with which we have to contend with. There is clearly a lack of appreciation for good study design for estimating gene-environmental interactions. Arguably, however, the best study designs are those based on environmental modifications, such as cigarette smoking. The challenge is that such studies are expensive and difficult to execute in larger cohorts. Lastly, our inability to directly incorporate environmental factors into genetic studies is cultural. Most investigators who have the capability to perform state of the art genotyping technologies are likely to consider the results of diet habits and recall questionnaires to be soft and uninformative, and therefore, not worthy of serious considerations.
IBD Among New Populations The most exciting and intriguing aspect of IBD is the apparent exponential increase in the incidence of IBD. IBD continues to become more common in formerly low-incidence areas such as Southern Europe, the middle-East, East Asia, Indian subcontinent, Latin America and Eastern Europe. Although one can argue that improved methods of diagnosis and increased awareness among medical professionals is cause of this increase, the impact of IBD on same “low – incidence” immigrant population living in the Western world is undisputable. It has been suggested, therefore, that studies of these “new populations” will likely yield more clues about the etiology of IBD than studying the stable IBD populations.
New Approaches Geographical disease pattern analysis would be useful in epidemiological research of IBD to potentially identify locations of elevated disease incidence or “clusters”. These areas could be later examined for associations with specific geographic variables, such as the type of water supply. It is essential to perform this type of analysis with close collaboration between IBD epidemiologists and geographic information systems experts. To date however, studies of IBD clusters have remained outside the domain of medical geographers. Traditional disease mapping strategies have used geo-political boundaries such as countries, states or provinces, counties, or Zip-code areas to define incidence rates, but these arbitrary boundaries are unlikely to represent true distributions of disease. IBD cluster studies have been mostly limited to anecdotes of a few close individuals who develop IBD, but these have been without demographic or geo-spatial context. A few reports of IBD clusters have been reported in small towns or villages [64], but these too have used political boundaries. Furthermore, these clusters were often identified prior to specific geographic boundary definition, having the effect of erroneously minimizing the at-risk denominator populations, and thus increasing the apparent sizes of disease clusters. In many instances of cluster reporting, the terminology of cluster analysis has been applied loosely, with poor definitions of spatial boundaries. Modern Geographic Information Systems (GIS) spatial analytic technology, offers a new, high technology approach to disease cluster analysis [65] which could be applied to determining the pediatric IBD distribution within a defined location. Recently, Green et al. [66] reported another new approach to IBD epidemiology such as small area geographical mapping of disease incidence in the province of Manitoba, Canada to look for etiological clues.
Chapter 4 Epidemiology of Pediatric Inflammatory Bowel Disease
57
Summary Inflammatory bowel disease is a complex disease with an unknown etiology. Strong environmental influences have been implicated as the reason for the observed exponential increased incidence of IBD over the last five decades since the genetic determinants do not change within this short period of time. However, most of the environmental risks and associations are reported from retrospective data collection or questionnaire-based adult studies, and have not been systematically studied in a prospective and longitudinal format in a large population based cohort. With the association and identification of potential genetic loci for IBD, complex interaction between the environmental and genetic influences may well be within our reach. Continued assessment of pediatric epidemiology is necessary as the clinical presentation, progression of disease, risk factors for surgery and malignancy may drastically be altered in the next decade. It should be obvious to most people that if new discoveries are to be attained concerning the cause of IBD, the barriers to relaxing the assumptions of gene-environment interactions need immediate attention. The first design issue in studying a complex disorder like IBD is to identify and characterize the right population. Investigators should recognize this problem rather than simply work with convenient samples. For a variety of reasons, children with newly diagnosed IBD (incident cases) are ideally suited to carry out such investigations. It is imperative that pediatric focused, multicenter consortia efforts be established and tasked to develop well designed benchmarks for studying influences of environmental factors along with genetic determinants on early onset IBD. References 1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and enviromental influences. Gastroenterology 2004;126:1504–1517. 2. Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, Weisdorf-Schindele S, San Pablo W, Jr, Perrault J, Park R, Yaffe M, Brown C, Rivera-Bennett MT, Halabi I, Martinez A, Blank E, Werlin SL, Rudolph CD, Binion DG. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: A statewide population-based study. J Pediatr 2003;143:525–31. 3. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999;28:445–58. 4. Markowitz JE, Mamula P, delRosario JF, Baldassano RN, Lewis JD, Jawad AF, Culton K, Strom BL. Patterns of complementary and alternative medicine use in a population of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:599–605. 5. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three-fold rise in Crohn disease. Gut 1989;30:618–22. 6. Armitage E, Drummond HE, Wilson DC, Ghosh S. Increasing incidence of both juvenile-onset Crohn disease and ulcerative colitis in Scotland. Eur J Gastroenterol Hepatol 2001;13:1439–47. 7. Askling J, Grahnquist L, Ekbom A, Finkel Y. Incidence of paediatric Crohn disease in Stockholm, Sweden. Lancet 1999;354:1179. 8. Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987–2003. Inflamm Bowel Dis 2006;12:677–83. 9. Pozler O, Maly J, Bonova O, Dedek P, Fruhauf P, Havlickova A, Janatova T, Jimramovsky F, Klimova L, Klusacek D, Kocourkova D, Kolek A, Kotalova R, Marx D, Nevoral J, Petro R, Petru O, Plasilova I, Seidl Z, Sekyrova I, Semendak N, Schreierova I, Stanek J, Sykora J, Sulakova A, Toukalkova L, Travnickova R, Volf V, Zahradnicek L, Zeniskova I. Incidence of Crohn disease in the Czech Republic in the years 1990 to 2001 and assessment of pediatric population with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;42:186–9. 10. Auvin S, Molinie F, Gower-Rousseau C, Brazier F, Merle V, Grandbastien B, Marti R, Lerebours E, Dupas JL, Colombel JF, Salomez JL, Cortot A, Turck D. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988–1999). J Pediatr Gastroenterol Nutr 2005;41:49–55.
58
Shehzad Saeed and Subra Kugathasan
11. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 1991;100:143–9. 12. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690–7. 13. Armitage EL, Aldhous MC, Anderson N, Drummond HE, Riemersma RA, Ghosh S, Satsangi J. Incidence of juvenile-onset Crohn disease in Scotland: association with northern latitude and affluence. Gastroenterology 2004;127:1051–7. 14. Reddy SI, Burakoff R. Inflammatory bowel disease in African Americans. Inflamm Bowel Dis 2003;9:380–5. 15. Straus WL, Eisen GM, Sandler RS, Murray SC, Sessions JT. Crohn disease: does race matter? The Mid-Atlantic Crohn Disease Study Group. Am J Gastroenterol 2000;95:479–83. 16. Ogunbi SO, Ransom JA, Sullivan K, Schoen BT, Gold BD. Inflammatory bowel disease in AfricanAmerican children living in Georgia. J Pediatr 1998;133:103–7. 17. Fielding JF. The relative risk of inflammatory bowel disease among parents and siblings of Crohn disease patients. J Clin Gastroenterol 1986;8:655–7. 18. Logan RF. Inflammatory bowel disease incidence: up, down or unchanged? Gut 1998;42:309–11. 19. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999;149:916–24. 20. Sawczenko A, Sandhu BK, Logan RF, Jenkins H, Taylor CJ, Mian S, Lynn R. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001;357:1093–4. 21. Cohen ML. Changing patterns of infectious disease. Nature 2000;406:762–7. 22. Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 2005;21:408–13. 23. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911–20. 24. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006;12: 4807–12. 25. Borchers AT, Keen CL, Gershwin ME. Hope for the hygiene hypothesis: When the dirt hits the fan. J Asthma 2005;42:225–47. 26. Thomas GA, Rhodes J, Green JT. Inflammatory bowel disease and smoking–a review. Am J Gastroenterol 1998;93:144–9. 27. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12: 855–62. 28. Sopori ML, Kozak W, Savage SM, Geng Y, Kluger MJ. Nicotine-induced modulation of T Cell function. Implications for inflammation and infection. Adv Exp Med Biol 1998;437:279–89. 29. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: The role of environmental factors. Autoimmun Rev 2004;3:394–400. 30. Chiodini RJ, Van Kruiningen HJ, Thayer WR, Merkal RS, Coutu JA. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn disease. Dig Dis Sci 1984;29:1073–9. 31. Thomas GA, Swift GL, Green JT, Newcombe RG, Braniff-Mathews C, Rhodes J, Wilkinson S, Strohmeyer G, Kreuzpainter G. Controlled trial of antituberculous chemotherapy in Crohn disease: A five year follow up study. Gut 1998;42:497–500. 32. Ellingson JL, Anderson JL, Koziczkowski JJ, Radcliff RP, Sloan SJ, Allen SE, Sullivan NM. Detection of viable Mycobacterium avium subsp. paratuberculosis in retail pasteurized whole milk by two culture methods and PCR. J Food Prot 2005;68:966–72. 33. Wakefield AJ, Pittilo RM, Sim R, Cosby SL, Stephenson JR, Dhillon AP, Pounder RE. Evidence of persistent measles virus infection in Crohn disease. J Med Virol 1993;39:345–53. 34. Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn disease after in-utero measles virus exposure. Lancet 1996;348:515–7. 35. Fisher NC, Yee L, Nightingale P, McEwan R, Gibson JA. Measles virus serology in Crohn disease. Gut 1997;41:66–9. 36. Ghosh S, Armitage E, Wilson D, Minor PD, Afzal MA. Detection of persistent measles virus infection in Crohn disease: current status of experimental work. Gut 2001;48:748–52.
Chapter 4 Epidemiology of Pediatric Inflammatory Bowel Disease
59
37. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512–9. 38. Katz JA. Prevention is the best defense: Probiotic prophylaxis of pouchitis. Gastroenterology 2003;124: 1535–8. 39. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44–54. 40. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448–55. 41. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLAB27 transgenic rats. J Exp Med 1994;180:2359–64. 42. Girardin SE, Hugot JP, Sansonetti PJ. Lessons from Nod2 studies: Towards a link between Crohn disease and bacterial sensing. Trends Immunol 2003;24:652–8. 43. Koutroubakis IE, Vlachonikolis IG, Kouroumalis EA. Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm Bowel Dis 2002;8:277–86. 44. Koutroubakis IE, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. Am J Gastroenterol 2000;95:171–6. 45. Duggan AE, Usmani I, Neal KR, Logan RF. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. Gut 1998;43:494–8. 46. Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy is followed by increased risk of Crohn disease. Gastroenterology 2003;124:40–6. 47. Schack-Nielsen L, Michaelsen KF. Breast feeding and future health. Curr Opin Clin Nutr Metab Care 2006;9:289–96. 48. Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004;80:1342–52. 49. Baron S, Turck D, Leplat C, Merle V, Gower-Rousseau C, Marti R, Yzet T, Lerebours E, Dupas JL, Debeugny S, Salomez JL, Cortot A, Colombel JF. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005;54:357–63. 50. Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol 2006;101:993–1002. 51. Martini GA, Brandes JW. Increased consumption of refined carbohydrates in patients with Crohn disease. Klin Wochenschr 1976;54:367–71. 52. Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease? Eur J Gastroenterol Hepatol 2003;15:607–13. 53. Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn disease. An international cooperative study. Scand J Gastroenterol 1987;22:1009–24. 54. Griffiths AM. Enteral nutrition in the management of Crohn disease. JPEN J Parenter Enteral Nutr 2005;29:S108–12; discussion S112–7, S184–8. 55. Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995;37:668–73. 56. Berg DJ, Zhang J, Weinstock JV, Ismail HF, Earle KA, Alila H, Pamukcu R, Moore S, Lynch RG. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 2002;123:1527–42. 57. Wiedermann U. Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs. Curr Drug Targets Inflamm Allergy 2005;4:577–83. 58. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002;3:715–20. 59. Ekbom A, Montgomery SM. Environmental risk factors (excluding tobacco and microorganisms): critical analysis of old and new hypotheses. Best Pract Res Clin Gastroenterol 2004;18:497–508. 60. Amre DK, Lambrette P, Law L, Krupoves A, Chotard V, Costea F, Grimard G, Israel D, Mack D, Seidman EG. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn disease: a case-control study. Am J Gastroenterol 2006;101:1005–11. 61. Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994;343:766–7.
60
Shehzad Saeed and Subra Kugathasan
62. Stadnicki A, Colman RW. Experimental models of inflammatory bowel disease. Arch Immunol Ther Exp (Warsz) 2003;51:149–55. 63. Kugathasan S, Amre D. Inflammatory bowel disease–environmental modification and genetic determinants. Pediatr Clin North Am 2006;53:727–49. 64. Van Kruiningen HJ, Freda BJ. A clustering of Crohn disease in Mankato, Minnesota. Inflamm Bowel Dis 2001;7:27–33. 65. Rushton G. Public health, GIS, and spatial analytic tools. Annu Rev Public Health 2003;24:43–56. 66. Green C, Elliott L, Beaudoin C, Bernstein CN. A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol 2006;164:615–23; discussion 624–8. 67. Cosgrove M, Al-Atia RF, Jenkins HR. The epidemiology of paediatric inflammatory bowel disease. Arch Dis Child 1996;74:460–1. 68. Bjornsson S, Johannsson JH. Inflammatory bowel disease in Iceland, 1990–1994: a prospective, nationwide, epidemiological study. Eur J Gastroenterol Hepatol 2000;12:31–8. 69. Gottrand F, Colombel JF, Moreno L, Salomez JL, Farriaux JP, Cortot A. Incidence of inflammatory bowel diseases in children in the Nord-Pas-de-Calais region. Arch Fr Pediatr 1991;48:25–8. 70. Stordal K, Jahnsen J, Bentsen BS, Moum B. Pediatric inflammatory bowel disease in southeastern Norway: a five-year follow-up study. Digestion 2004;70:226–30. 71. Olafsdottir EJ, Fluge G, Haug K. Chronic inflammatory bowel disease in children in western Norway. J Pediatr Gastroenterol Nutr 1989;8:454–8. 72. Lindberg E, Lindquist B, Holmquist L, Hildebrand H. Inflammatory bowel disease in children and adolescents in Sweden, 1984–1995. J Pediatr Gastroenterol Nutr 2000;30:259–64. 73. Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990–2001. Gut 2003;52:1432–4. 74. Hassan K, Cowan FJ, Jenkins HR. The incidence of childhood inflammatory bowel disease in Wales. Eur J Pediatr 2000;159:261–3. 75. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003;52:1587–90. 76. Phavichitr N, Cameron DJ, Catto-Smith AG. Increasing incidence of Crohn disease in Victorian children. J Gastroenterol Hepatol 2003;18:329–32.
5 Early Onset Inflammatory Bowel Disease- Epidemiology and Clinical Features Melvin B. Heyman* and Neera Gupta
Introduction About 20–30% of individuals with inflammatory bowel disease (IBD) have symptom onset before 20 years of age. Ten to 15% of all IBD patients have an established diagnosis under the age of 18 years. Young children (i.e., under 6 years of age) with IBD represent a unique cohort of patients that is recognized as a valuable group to investigate due to their relative lack of environmental exposures compared with older patients. However, information is sparse regarding the presentation and course of disease in this subset of patients. We therefore present information on both early onset (0–5 years) and later onset (6–18 years) pediatric IBD.
Epidemiology of Pediatric Inflammatory Bowel Disease Incidence of Disease and Family History The epidemiology of pediatric IBD has been described in population-based studies from European centers. In an earlier report from Denmark, data collected between 1962 and 1987 revealed that the mean incidence of IBD among children below 15 years was 2.2/100,000, 2.0 for UC and 0.2 for CD. At diagnosis, children with UC had more extensive disease than adults (P < 0.05) [1]. A similar study on the incidence of Crohn disease (CD), ulcerative colitis (UC), and indeterminate colitis (IC) in children was conducted in western Norway in 1984–85 [2]. During this two-year study period, 27 new cases of IBD were diagnosed in children aged 15 years or less, 10 new cases of CD, and 17 of UC. The mean annual incidence of CD in the child population was 2.5/100,000/year, whereas the incidence of UC in the child population was 4.3/100,000/year [2]. In a similar study Sawczenko, et al., reported on a 13-month prospective survey to determine the incidence of childhood IBD in the United Kingdom and the Republic of Ireland, finding an incidence of 5.2/100,000 per year in children younger than 16 years of age from 1998–1999. Of the 739 evaluable pediatric subjects reported, 4% were under 5 and 17% were 5-10 years ∗ Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, University of California, San Francisco, San Francisco, CA 94143-0136, Phone: 415-476-5892, Fax: 415-476-1343, Email:
[email protected] Supported in part by NIH Grants K24-DK060617 (mbh) and T32-DK007762 (ng).
61
62
Melvin B. Heyman and Neera Gupta
of age [3]. Data from a 12-year period in Sweden showed an annual incidence of 5.8/100,000 in children 15 years of age or less [4]. The data suggested increasing incidence of IBD from 4.6/100,000 in 1984–86 to 7.0/100,000 in 1993–5 [4]. Most of the increase was among those with UC, with an increase in incidence from 1.4 to 3.2 per 100,000 per year [4]. In contrast, in North America, most available information originates primarily from singlecenter studies that are inadequate to generate incidence or prevalence data. However, Kugathasan, et al., studied a population-based cohort and found an overall incidence of IBD of 7.05/100,000, noting that the incidence of Crohn disease (4.56/100,000) was more than double that of ulcerative colitis (2.14/100,000) [5]. Furthermore, the overall incidence of IBD was less than 5 per 100,000 until age 8 years, increasing to an incidence of 13 per 100,000 by 10 years of age. The 15-year old age group had the highest age-related occurrence of new-onset pediatric IBD, likely because older children are often referred to adult gastroenterologists. Most (89%) of the new IBD diagnoses had no family history of IBD [5]. Paul et al. analyzed data from 413 consecutive pediatric IBD outpatients attending their center between 1995–2000. 50 patients were diagnosed before the age of 5 years. First-degree family history was highest in early-onset (diagnosis before age 5 years) UC (26%) compared with the older (5–15 years) UC group (11%) [6]. Similarly, Heyman et al. found the subgroup of children younger than 3 years of age with UC had the highest prevalence of first-degree relatives with IBD (44%) compared with the other age groups [7]. However, Paul et al. found that familial aggregation overall was more frequent in CD than in UC [6].
Age of Diagnosis The most common age of diagnosis among pediatric populations tends to favor young teens, possibly because older teens are lost to pediatric practices as they are referred to adult gastroenterologists. However, young children and infants are not infrequently diagnosed with IBD. Heyman et al. reported on 1739 IBD patients from a large mutlicenter registry, finding that 6.1% of the patients were diagnosed with IBD at age less than 3 years [7]. Similarly, diagnosis was established in 211 (15.4%) prior to 6 years of age, 654 (47.7%) between 6 and 12 years, and 505 (36.9%) 13 to 17 years of age [7]. Lindberg, et al., found that of 639 children diagnosed with IBD in Sweden between 1984 and 1995, 7.5% were under 6 years of age, 30.2% were 6–10 years of age, and 62.3% were 11 years or older at diagnosis [4]. Kugathasan et al. reported that 20% of all pediatric cases were diagnosed before 10 years of age [5].
Disease Distribution and IBD Classification The intestinal distribution of disease varies by age. Younger children appear to have more colonic disease and specifically UC, IC or Crohn colitis. In contrast, older children appear to have more diffuse disease, with Crohn colitis being more prevalent. Paul, et al. compared disease distribution in children with early onset IBD (0–5 yrs) to children with later-onset IBD (5–15 yrs). They reported 66% of children with early onset IBD had a diagnosis of UC, while 67% of cases in the later-onset group had a diagnosis of CD. Furthermore, they reported isolated colonic disease was most common in the younger CD age group (76.5%), compared with ileocolic disease (45.5%) in the older CD age group [6]. Gryboski, et al., in early reports noted more UC in younger children and CD predominating in older children among pediatric patients with IBD [8]. In the largest pediatric report to date, Heyman et al. noted that 63% of children with IBD who were under 8 years of age had isolated colonic disease (UC, IC or Crohn colitis) at the time of diagnosis compared with 35% of children 8 years of age and older (p<0.0001) [7] Overall, 58% of the patients were ultimately diagnosed with CD, 29% with UC and 13% with IC [7]. Sawczenko et al. found an equivalent distribution: 58% were CD, 29% UC, and 12% IC [3].
Chapter 5 Early Onset Inflammatory Bowel Disease
63
Clinical Features of Pediatric Inflammatory Bowel Disease Presentation Inflammatory bowel disease can present at any age, including infancy. In children a delay in diagnosis of 5 months is typical, and diagnostic delays may even extend beyond two years [9]. Sawczenko and Sandhu found a negative correlation (p<.001) between the length of delay in diagnosis and the age of onset of symptoms (determined by recall), suggesting it was more difficult to recognize IBD in younger children [9]. Heyman, et al., reported that 37 (2.7%) of 1370 pediatric patients in a large registry had IBD-specific symptoms before 1 year of age [7]. The most common symptoms at presentation are abdominal pain, diarrhea, weight loss, fever, and in ulcerative colitis bloody stool. Children and adolescents, but not adults, are at risk for significant growth retardation and growth failure. In a cohort of children 5 years of age and younger, Mamula et al. reported that failure to thrive (poor weight gain) at initial presentation was more frequent in those with CD or IC than with UC (p = 0.004) [10]. In this cohort, patients initially diagnosed with UC who had failure to thrive as a presenting symptom typically had their diagnosis changed to IC or CD [10]. Delayed growth is much more common in patients with CD compared with UC [9]. Chronic fever was associated with CD but not with UC or IC, and vomiting was associated with CD or IC but not UC (p = 0.01) in patients 5 years of age and younger [10]. The utility of laboratory tests in early onset IBD requires further investigation. Erythrocyte sedimentation rate (ESR) and C-reactive protein may be normal. Albumin levels may be normal or low. However, Paul et al. reported no significant differences in hemoglobin, albumin, or ESR between age groups or disease groups [6]. Antibody testing for IBD in younger children appears to be a poor marker for either UC or CD compared with older patients, although a recent report by Amre, et al., suggests that Anti-Saccharomices cerevisiae antibody (ASCA) may predict more severe disease with rapid progression in pediatric patients [11]. Growth Children and adolescents with IBD, particularly those with CD, are prone to poor linear growth, delayed puberty, and loss of bone mass, all of which can have deleterious physiological and psychosocial effects on the patients [12–14]. Pediatric gastroenterologists are and must be acutely aware of these aspects of pediatric IBD and apply treatment regimens that appropriately help to reverse and prevent these effects from occurring. Delayed diagnosis has been correlated with lower height z scores at diagnosis [15]. The mean adult height of patients with onset of symptoms before the age of 16 has been reported to be reduced [16]. While the etiology of growth failure in IBD is multifactorial, the most likely reasons are anorexia resulting in decreased nutrient intake, the inflammatory process resulting in excessive energy and protein expenditure, intestinal nutrient losses, secondary hypopituitarism and medications, mainly use of corticosteroids. Most children with UC will improve growth with treatment of the colitis. Treatment of CD including topical steroids, immunosuppressant medications, anti-TNF antibody, enteral nutrition, surgical resection, and growth hormone have some role but variable efficacy in inducing remission, restoring nutritional status and promoting linear growth [17–19]. While outcome studies remain to be performed, investigators have suggested that earlier intervention especially in children with CD may help to reverse some of the growth faltering that has been reported in IBD [20]. Medical Management Response to treatments is variable, as in adults. It is important that providers caring for pediatric patients with IBD remain vigilant in evaluating patients for disease activity, growth, nutrition
64
Melvin B. Heyman and Neera Gupta
status, and social issues (that may, particularly in teenagers, lead to non-compliance) in order to optimize therapy. Adverse reactions to medications may manifest in adolescents, even after many years on the same medications, as they progress through puberty and their metabolism changes. Age-specific treatment regimens will likely evolve over the next few years as we learn more about the course and response of early onset IBD. Surgery in Pediatric Patients with IBD Crohn Disease: Gryboski reported that 42% of the CD patients required surgical procedures, although a time frame was not specified in this retrospective study [15]. Gupta et al. reported that in a cohort of 989 pediatric patients with CD, the cumulative incidence of surgery was 17% at 5 years and 28% at 10 years [21]. Younger age at the time of diagnosis was associated with a decreased risk for surgery [21]. The relationship of genetic markers such as CARD15(NOD2) gene mutations and risk for surgery due to stricturing or fistulizing disease in pediatric patients requires further study. The role of newer agents, particularly the biologic therapies, in preventing the need for surgery in CD remains to be determined. Ulcerative Colitis: Only 5% (2/40) of patients with UC required surgery in Gryboski’s report [8]. In contrast, pediatric patients with UC are also reported to be more likely to have severe disease, including pancolitis, compared with adults, with surgery required in up to 20% in the first few years of disease [22, 23]. At one center, a retrospective review of children and adolescents with UC revealed a decrease in the frequency of colectomy from 48.9% from 1955 through 1964 to 26.2% from 1965 through 1974 [24]. Hyams and colleagues, in a retrospective review, reported that the 5-year colectomy rate in patients with mild disease at presentation was 8% compared with 26% in patients with moderate to severe disease at presentation [25]. A more recent but retrospective review of 73 children with UC between the ages of 1 and 18 years revealed that the combination of steroid dependency and pancolitis was associated with an increased need for colectomy [26]. Risk of Cancer The risk of colon cancer in UC or small intestinal and colon cancer in CD is increased in patients with disease of long duration. Thus, children with early onset IBD may have greater lifetime risk for development of cancer due to the length of time they have disease compared with later onset IBD. Few cases of colon cancer are described in the pediatric literature. However, ongoing surveillance colonoscopy is recommended for all children with disease of 8–10 years duration. Prospective, longitudinal studies of very young children with IBD including surveillance for potential surrogate markers for cancer and the cumulative effects of immunomodulatory and newer biologic agents are needed. References 1. Olafsdottir EJ, Fluge G, Haug K. Chronic inflammatory bowel disease in children in western Norway. J Pediatr Gastroenterol Nutr 1989;8(4):454–8. 2. Langholz E, Munkholm P, Krasilnikoff PA, Binder V. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997;32(2):139–47. 3. Sawczenko A, Sandhu BK, Logan RF, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001;357(9262):1093–4. 4. Lindberg E, Lindquist B, Holmquist L, Hildebrand H. Inflammatory bowel disease in children and adolescents in Sweden, 1984–1995. J Pediatr Gastroenterol Nutr 2000;30(3):259–64. 5. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003;143(4):525–31.
Chapter 5 Early Onset Inflammatory Bowel Disease
65
6. Paul T, Birnbaum A, Pal D, Pittman N, Ceballos C, LeLeiko N, Benkov K. Distinct Phenotype of Early Childhood Inflammatory Bowel Disease. J Clin Gastroenterol 2006; 40:583–586. 7. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146(1):35–40. 8. Gryboski JD. Crohn disease in children 10 years old and younger: comparison with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994;18(2):174–82. 9. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88(11):995–1000. 10. Mamula P, Telega GW, Markowitz JE, et al. Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol 2002;97(8):2005–10. 11. Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn disease patients. Am J Gastroenterol 2006;101(3):645–52. 12. Bland RM, Evans TJ, Raine P, Weaver LT. Inflammatory bowel disease in Scottish children. Health Bull (Edinb) 1999;57(6):365–73. 13. Stephens M, Batres LA, Ng D, Baldassano R. Growth failure in the child with inflammatory bowel disease. Semin Gastrointest Dis 2001;12(4):253–62. 14. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004;18(3):509–23. 15. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn disease. Pediatrics 2006;118(1):124–9. 16. Sawczenko A, Ballinger AB, Croft NM, Sanderson IR, Savage MO. Adult height in patients with early onset of Crohn disease. Gut 2003;52(3):454–5; author reply 5. 17. Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn disease and short stature: a pilot study. Inflamm Bowel Dis 2005;11(5):435–41. 18. Cezard JP, Touati G, Alberti C, Hugot JP, Brinon C, Czernichow P. Growth in paediatric Crohndisease. Horm Res 2002;58 Suppl 1:11–5. 19. Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn disease. Cochrane Database Syst Rev 2005(3):CD003873. 20. Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994;8(1):83–100. 21. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn disease. Gastroenterology 2006;130(4):1069–77. 22. Fonkalsrud EW. Long-term results after colectomy and ileoanal pull-through procedure in children. Arch Surg 1996;131(8):881–5; discussion 5–6. 23. Stordal K, Jahnsen J, Bentsen BS, Moum B. Pediatric inflammatory bowel disease in southeastern Norway: a five-year follow-up study. Digestion 2004;70(4):226–30. 24. Michener WM, Farmer RG, Mortimer EA. Long-term prognosis of ulcerative colitis with onset in childhood or adolescence. J Clin Gastroenterol 1979;1(4):301–5. 25. Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr 1996;129(1):81–8. 26. Falcone RA, Jr., Lewis LG, Warner BW. Predicting the need for colectomy in pediatric patients with ulcerative colitis. J Gastrointest Surg 2000;4(2):201–6.
6 The Natural History of Pediatric Crohn Disease James Markowitz∗
Introduction Determining the natural history of Crohn disease involves the consideration of a number of different factors: disease activity over time, frequency of complications, the need for surgery and the risk of disease recurrence following both medically induced and surgically induced remission. In children, evaluation of the natural history also must include the effects of Crohn disease on growth and development and on quality of life. The true natural history of Crohn disease remains largely unknown, however, primarily because there are virtually no data describing the long-term course of untreated children or adults with this illness. The data that do exist arise from early clinical experience treating patients with corticosteroids and 5-aminosalicylate medications, and from a small number of placebo-controlled treatment trials.
Disease Activity Spontaneous remission in the absence of specific treatment can occur in Crohn disease. Two early adult trials, the National Cooperative Crohn’s Disease Study (NCCDS) [1] and the European Cooperative Crohn’s Disease Study (ECCDS) [2], included placebo treatment arms enrolling a total of less than 300 adult subjects. Among the 135 subjects with active disease at entry into the 2 trials, 26–42% achieved clinical remission after 3–4 months of placebo treatment, and 18% in both studies remained in clinical remission at 1 year [1, 2]. Prolonged spontaneous remission therefore appears to occur in only a small number of adults with Crohn disease. However, in the NCCDS, among the subgroup of 20 subjects with active disease who achieved clinical remission by 17 weeks, 75% remained in remission at 1 year, and 63% at 2 years [1]. Similarly, among the 153 subjects in the NCCDS and ECCDS who had inactive disease when randomized into the placebo arms of a maintenance study, 52–64% remained in remission at about 1 year and 35–40% at about 2 years [1, 2]. No comparable data from untreated or exclusively placebo treated children exist. However, in children with moderate-severe disease activity who achieve remission after a course of prednisone, ∗
Professor of Pediatrics, NYU School of Medicine, Attending Pediatrician, North Shore – LIJ Health System, Division of Pediatric Gastroenterology, Schneider Children’s Hospital, New Hyde Park, New York, E-mail:
[email protected]
67
68
James Markowitz
Figure 6.1. Yearly Crohn disease activity over the first 10 years after diagnosis in a Danish population of children diagnosed prior to 15 years of age. Data from Langholz et al. [5] [figure redrawn]. Reprinted from Inflammatory Bowel Diseases with Onset in Childhood Clinical features, morbidity and mortality in a regional cohort by Langholz E, Munholm P, Krasilnikoff PA, Binder V from Scan J Gastroenterology, www.tandf.no/gastro, 1997; 32, 139–147 by permission of Taylor & Francis
the likelihood of prolonged remission without ongoing therapy appears lower than in adults. Newly diagnosed children randomized to the control arm of a multicenter trial received prednisone for induction of remission and were then maintained only on placebo [3]. One year following the course of corticosteroids, only 43% remained in remission. Similarly, 95% of a cohort of Italian children maintained on mesalamine following an 8-week course of corticosteroids relapsed by 1 year [4]. Periods of active Crohn disease continue to be a problem beyond the first year after diagnosis. Disease activity over time has been described in a report derived from a large population based inception cohort of patients with inflammatory bowel disease diagnosed and treated in Copenhagen County, Denmark between 1962 and 1987 [5]. While useful, the data describing the course of pediatric Crohn disease in this study are based on observations of only 23 children. At diagnosis, 82.6% had disease activity characterized as moderate to severe. In each of the succeeding 9 years, only about 50% of the cohort were characterized as inactive during any given year, while roughly 20–35% had periods of high disease activity despite treatment (Figure 6.1). Observations in the larger, primarily adult onset cohort from the same geographic area revealed that individual patients had different patterns of clinical activity over time: some experienced frequent relapses, some only occasional relapses, and others had prolonged periods of disease quiescence [6]. In this cohort, relapse in any given year after diagnosis increased the risk of relapse in the following year. Relapse rate in the first year after diagnosis also correlated with relapse rate in the next 5–7 years. A review of North American experience revealed similar patterns of disease, with most patients having a chronic intermittent disease course, but 13% of patients having an unremitting disease course and only 10% experiencing a prolonged remission [7].
Evolution of Disease Phenotype At the time of initial diagnosis, the vast majority of children have an inflammatory disease phenotype. However, as time goes on, an increasing proportion expresses a changing phenotype, characterized as either stricturing or penetrating. This phenotypic change may be associated with the presence of specific genetic allelic variants. For instance, patients with NOD2/CARD15 variants appear to be at increased risk for fibro-stenosing complications [8, 9], while those with
Chapter 6 The Natural History of Pediatric Crohn Disease
69
abnormalities in the IBD5 gene may be more likely to develop perianal fistulae [10]. Children at risk for stricturing or internal penetrating complications have also been shown to be more likely to have increased immune responses to microbial antigens, characterized by the presence of high titer antibodies such as anti-ompC and anti-I2 [11].
Growth For a significant subgroup of children with Crohn disease, growth impairment is an important characteristic of the disease’s natural history. While acute weight loss commonly is present in children with both ulcerative colitis and Crohn disease, impairment in linear growth is primarily a problem in the latter condition. At the time of initial diagnosis, about a third of children with Crohn disease has already dropped two or more major growth channels from their pre-illness growth percentiles [12, 13]. More dramatically, 88% have delayed height velocity at diagnosis [14]. Over time, periods of significantly impaired growth can be seen in about 60% of children and adolescents [15]. While catch-up growth is often possible, 7–35% of young adults diagnosed with Crohn disease during childhood have final heights that are significantly shorter than expected [13]. As a group, young adults who develop Crohn disease as children have adult heights skewed towards the lowest percentiles. In reports from both Chicago and New York, ∼ 50% of young adults with childhood onset Crohn disease have final adult heights less than the 10% for the general population, and ∼ 25% have adult heights less than the 5% [12, 13].
Corticosteroid Dependence An important characteristic of Crohn disease in children as well as adults is the tendency to develop corticosteroid dependence. Population based studies in adults from both Olmstead County, Minnesota [15] and Copenhagen County, Denmark [16] demonstrate similar findings. These studies document that acute response to corticosteroid therapy in adults with Crohn disease is reasonably good (complete remission in 48–58%, partial remission in 26–32% and no response in 12–20%). However, long term response is less optimal, with rates of corticosteroid dependence of 28–36% at 1 year [15, 16]. A similar risk for corticosteroid dependence is evident in children. As in adults, acute response to a course of corticosteroids is good. In data derived from a multicenter North American observational registry, among newly diagnosed children with moderate-severe Crohn disease activity treated with corticosteroids, 60% have a complete and 24% a partial clinical response by 3 months after initiation of treatment [17]. However, despite concomitant use of immunomodulators in many of these children, 31% are corticosteroid dependent at 1 year. In fact, without infliximab, only 46% of the children in this study maintained a corticosteroid free remission 1 year following an initial course of corticosteroids [17].
Surgery The need for surgery represents another important aspect of the natural history of Crohn disease in children. Table 6.1 summarizes published rates for surgery in children from a variety of different countries. Data from Denmark estimate a mean yearly operation rate of approximately 13%. The cumulative probability of surgery in this Danish cohort at 20 years was estimated to be 47% [5]. A more recent multicenter experience from the US estimates the cumulative incidence of surgery to be 6% at 1 year, 17% at 5 years and 28% at 10 years after diagnosis [18]. The presence of variant NOD2/CARD15 alleles appear to increase the risk for surgery, presumably due to the known
70
James Markowitz
Table 6.1. Surgical frequency in Crohn disease. Author
# Children Observed (Period studied) % Operated % Permanent Stomas
Farmer [40] (US) Ferguson [41] (UK) Griffiths [26] (Canada) Besnard [42] (France) Langholz [5] (Denmark) Gupta [18] (US)
522 50 275 119 23 989
(1955–1974) (1968–1983) (1970–1987) (1975–1994) (1962–1987) (1987–2003)
67% 78% 32% 30% 43% 13%
Not reported 30% 2% 2% Not reported 10%
association of these genetic polymorphisms with the development of fibrostenotic ileal disease [8, 9]. The presence of anti-Saccharomyces cerevisiae antibodies also appear to be associated with increased risk for surgery [11, 18].
Postoperative Recurrence Although there is little hard data published to document clinical experience, following surgery, the natural history of Crohn disease is to recur both endoscopically and symptomatically. In retrospective adult studies, symptomatic recurrence of Crohn disease following so-called “curative resection” (complete resection of all visibly evident disease) is reported to be 20–30% within the first year after surgery, with increasing likelihood in each subsequent year [19]. One or more additional surgeries are required in 15–45% of adults within 3 years, 26–65% in 10 years, and 33–82% in 15 years [20]. Controlled trials document severe endoscopic recurrence after placebo treatment in 43–79% of adult subjects by 1 year after surgery and in 42–85% of subjects after 2 years [21–25]. In children, the overall rate of clinical recurrence is estimated to be 50% at 5 years after initial resection [26]. However, the site and extent of preoperative Crohn disease can affect the recurrence free interval, such that it is estimated that 50% of children with extensive ileocolitis recur within 1 year, compared to a 50% recurrence rate after 5 years in children with ileocecal disease, and a 50% recurrence rate after 6 years if preoperative disease is confined to the small bowel [26]. Additional risk factors for postoperative recurrence in children are summarized in Table 6.2.
Cancer Risk Whether children with Crohn disease are at increased risk for malignancy over their lifetime is unknown. No data derived from a population with childhood onset Crohn disease have been reported. Studies in adults, however, suggest that Crohn disease patients do have an excess of malignancies compared to the general population. In a population-based cohort from the Upsala region of Sweden, there was an increased relative risk of colorectal cancer of 2.5 (95% confidence interval 1.3–4.3) in patients with Crohn disease [27]. Duration of illness and gender did not affect risk, but those subjects with colonic disease had a greater risk of colorectal cancer than those with only small bowel involvement. Of note, however, among those subjects with any colonic involvement diagnosed with Crohn disease before the age of 30 years, the relative risk of colorectal cancer increased to 20.9 (95% Confidence interval 6.8–48.7) [27]. By contrast, a similar population-based study from Denmark identified a relative risk of colorectal cancer of only 1.1 (95% confidence interval 0.6–1.9), and no risk differences were noted in different subgroups of patients [28]. A similar modest increase in colorectal cancer risk (1.9; 95% confidence interval 0.7–4.1) was found in a population-based study from Olmstead County, Minnesota [29].
Chapter 6 The Natural History of Pediatric Crohn Disease
71
Table 6.2. Risk factors for postoperative recurrence in children. Author
N
Ages (yrs)
Risk Factors for Recurrent Crohn Disease
Griffiths [26] (Canada)
89
5.9–19
Besnard [42] (France)
30
7.5–16.5
Baldassano [43](US)
79
0.3–21
Effect of initial disease location on RFI*: extensive ileocolonic = 1 yr ileo/ileocecal = 5 yrs small bowel = 6 years Effect of surgical indication on RFI: Specific intestinal indication (e.g. stricture, fistula) = 6 years Failed medical therapy = 1.7 years Effect of preoperative duration of disease on RFI: <1 year = 8+ years >1 year = 3 to 4 years No difference on RFI found for: Age, Pathologic features, Pre-op bowel rest Multifocal disease pre-operatively: 12/12 recurrences with upper GI or perianal disease No difference found for: Age, Pre-operative disease duration, Disease Activity, Extension, Pre-operative nutritional support, Pre-operative mesalamine or azathioprine Effect of pre-operative 6-MP on RFI: No pre-operative 6-MP = 4.45 yrs Pre-operative 6-MP = 1 yr If 6-MP discontinued post-operatively, 5/6 relapse in 8 months If 6-MP continued post-operatively, 1/3 relapse at 2.5 yrs Effect of initial disease location on RFI: Colonic = 1.16 yr Ileocecal = 4.36 yr Colon/small bowel = 2.95 yr No difference found for: Age, Race, Gender, Appendecto my, Pre-operative disease duration, Indication for surgery, pathology
* RFI = recurrence free interval Reprinted from Workshop report: prevention of postoperative recurrence in Crohn’s Disease by Markowitz, J. et al. from Journal of Pediatric Gastroenterology and Nutrition, 2005, Aug; 41[2]: 145–151 by permission of Lippincott Williams & Wilkins [44]
By contrast, the risk of small bowel cancer consistently appears increased in patients with Crohn disease. In part because the rate of small bowel cancer in the general population is very low (estimated to be 0.005% at 5 years and 0.03% at 25 years according to data cited in reference 29), the relative increased risk for small bowel cancers in Crohn disease patients are significantly elevated. In the Danish study cited above, the relative increased risk for small bowel cancer was 17.9 (95% CI 4.8–42) [28]. In Olmstead County, the relative risk was found to be 40.6 (95% CI 4.4–118) [29]. Duration of Crohn disease did not appear to influence risk of developing a small bowel cancer. Adenocarcinoma, carcinoid, leiomyosarcoma and primary intestinal lymphoma have all been reported. The effect of age at Crohn disease onset on the risk of developing small bowel cancer has not been reported. There may also be a slight increase in risk of developing lymphoma. Among 454 adults living in Olmstead County who developed Crohn disease between 1950 and 1993, 1 developed a nonHodgkin’s lymphoma, resulting in a slight increase in relative risk (2.4; 95% CI 0.1–13) compared
72
James Markowitz
to the general population [30]. In this report, however, the referral practice of the same group of investigators revealed that development of lymphoma was associated with treatment with immune modifiers in about 5% of cases [30]. A recent meta-analysis utilizing data from 6 studies estimates the risk of lymphoma in IBD patients treated with azathioprine or 6-mercaptopurine to be increased about fourfold (4.18; 95% CI 2.07–7.51) [31]. Infliximab may add an additional element of risk, especially for children and young adults, in whom the development of a hepatosplenic T-cell lymphoma has been described [32]. Whether these risks to children with Crohn disease are due to the nature of the illness in children, their frequent need for potent immune modifier and biologic therapy, or both is not known.
Quality of Life In addition to imposing significant physical morbidity, the natural history of Crohn disease in childhood imposes potentially dramatic psychosocial burdens as well. Health related quality of life (HRQOL) scores, as measured by the IMPACT questionnaire (a validated, pediatric IBD health related quality of life questionnaire) [33] correlate with physician’s global assessment of disease severity, such that children with moderate-severe activity have the poorest HRQOL scores [34]. Over the first year after diagnosis, age also appears to be an independent factor affecting HRQOL scores, with older children reporting poorer IMPACT scores [34]. While treatment results in significant improvement in IMPACT scores in the first year after diagnosis, it is unknown whether further improvements in HRQOL occur over time. Children frequently report being bothered by having a chronic illness, by having to undergo tests, and by feeling tired. Over time, they also report feeling that it is unfair that they have their illness, and that they experience problems revolving around having to keep their illness a secret from others [34]. Other studies have noted that children with Crohn disease experience frequent absences from school, that they frequently require home tutoring, and that they commonly cannot participate fully or at all in physical education classes [35, 36]. Children express fears concerning everyday childhood activities, schooling and ability to get a job [37]. Fifty seven percent of a cohort was reported to have had an absence from school of at least 2 months duration, and in this same cohort, 8% were involuntarily unemployed as young adults [38]. Similar impairments are described in adult Crohn disease populations, with 15% of a Danish population on disability by 15 years after diagnosis, 25% reporting some inability to work in any given year of follow-up, and 50% reporting 1 or more years during first decade of disease with at least some inability to work [39]. References 1. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterol 1979;77(4 Pt 2):847–869. 2. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterol 1984;86(2):249–266. 3. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterol 2000;119:895–902. 4. Romano C, Cucchiara S, Barabino A, et al. Usefulness of -3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn’s disease: A double-blind, randomized, placebo-controlled study. World J Gastroenterol 2005;11(45): 7118–7121. 5. Langholz E, Munkholm P, Krasilnikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997;32:139–147. 6. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995l;30(7):699–706. 7. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002;16(1):51–60.
Chapter 6 The Natural History of Pediatric Crohn Disease
73
8. Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and the risk for early surgery in pediatric-onset Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:1003–1009. 9. Russell RK, Drummond HE, Nimmo EE, et al. Genotype-phenotype analysis in childhood-onset Crohn’s disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005;11(11):955–964. 10. Vermeire S, Pierik M, Hlavaty T, et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn’s disease but not with susceptibility to IBD. Gastroenterol 2005;129(6): 1845–1853. 11. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol 2006;101(2):360–367. 12. Kirschner BS. Growth and development in chronic inflammatory bowel disease. Acta Paediatr Scand Suppl 1990;366:98–104. 13. Markowitz J, Grancher K, Rosa J, et al. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16(4):373–380. 14. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988;95(6):1523–1527. 15. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121(2):255–260. 16. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35(3):360–362. 17. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1 year outcomes in newly diagnosed children with Crohn disease. Clin Gastroenterol Hepatol 2006;4(9): 1124–1129. 18. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology. 2006;130(4):1069–1077. 19. Becker JM. Surgical therapy for ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am 1999;28(2):371–390, viii–ix. 20. Chardavoyne R, Flint GW, Pollack S, et al. Factors affecting recurrence following resection for Crohn’s disease. Dis Colon Rectum 1986;29(8):495–502. 21. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn’s disease. Italian Cooperative Study Group. Gastroenterology 1995;108:345–349. 22. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of post-operative recurrence of Crohn disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994;8:35–43. 23. Rutgeerts P, Heile M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995;108:1617–1621. 24. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128(4):856–861. 25. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remissions with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterol 2004;127:723–729. 26. Griffiths AM. Factors that influence the postoperative recurrence of Crohn’s disease in childhood. In Inflammatory Bowel Disease and Coeliac Disease in Children. Hadziselimovic F, Herzog B, BurginWolff A (eds). Boston: Kluwer Academic Publishers, 1990, pp. 131–136. 27. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990;336:357–359. 28. Mellemkjaer L, Johansen C, Gridley G, et al. Crohn’s disease and cancer risk (Denmark). Cancer Causes and Control 2000;11:145–150. 29. Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterol 2006;130:1039–46. 30. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308–2312.
74
James Markowitz
31. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54(8):1121–1125. 32. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40:220–222. 33. Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;35:557–563. 34. Otley A, Griffiths AM, Hyams J, et al. Health-related quality of life in the first year following a diagnosis of pediatric inflammatory bowel disease. Inflamm Bowel Dis;12(8):684–691. 35. Rabbett H, Elbadri A, Thwaites R, et al. Quality of life in children with Crohn disease J Pediatr Gastroenterol Nutr 1996;23:528–533. 36. Akobeng AK, Suresh-Babu MV, Firth D, et al. Quality of life in children with Crohn’s disease: a pilot study. J Pediatr Gastroenterol Nutr 1999;28:S37–S39. 37. Moody G, Eaden JA, Mayberry JF. Social implications of childhood Crohn’s disease. J Pediatr Gastroenterol Nutr 1999;28:S43–S45. 38. Ferguson A, Sedgwick DM, Drummond J, et al. Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life. Gut 1994;35:665–8. 39. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995;30:699–706. 40. Farmer RG, Michener WM. Prognosis of Crohn’s disease with onset in childhood or adolescence. Dig Dis Sci 1979;24(10):752–757. 41. Ferguson A, Sedgwick DM. Juvenile-onset inflammatory bowel disease: predictors of morbidity and health status in early adult life. J R Coll Physicians Lond 1994;28(3):220–227. 42. Besnard M, Jaby O, Mougenot JF, et al. Postoperative outcome of Crohn’s disease in 30 children. Gut 1998;43(5):634–638. 43. Baldassano RN, Han PD, Jeshion WC, et al. Pediatric Crohn’s disease: risk factors for postoperative recurrence. Am J Gastroenterol. 2001;96(7):2169–2176. 44. Markowitz J, Markowitz JE, Bousvaros A, et al. Workshop report: prevention of postoperative recurrence in Crohn’s disease. J Pediatr Gastroenterol Nutr 2005;41(2):145–151.
7 Natural History of Pediatric Ulcerative Colitis Jeffrey S. Hyams∗
Introduction Defining the natural history of a chronic disease is made difficult by the continuously changing landscape of available therapies, earlier recognition of disease by more sensitive diagnostic techniques, and changes in intrinsic biological behavior. The natural history of ulcerative colitis following therapy with aminosalicylates and corticosteroids as were used in the 1960s and 1970s would be expected to differ from that following the current widespread use of immunomodulators and biological therapy. The data presented in this chapter reflect what we know of natural history now, and will likely be different than what we might describe in 10 years. Discussion of drugs will mostly focus on maintenance of remission. Whether course of disease in children is different than in adults is not clear, but will also be examined in this discussion. Lastly, possible methodology to predict response to therapy and alter natural history will be addressed.
Historical Perspective – Children In 1973 a report from Scotland described 25 children who had ulcerative colitis severe enough to be hospitalized [1]. Four had a single attack and 19 had chronic intermittent disease. During the follow-up period, averaging 24 years, 5 (20%) had died, usually in the post-operative period following colectomy. In 1979 a report from the Cleveland Clinic was published [2] describing the course of 336 patients diagnosed with ulcerative colitis before age 21 years between 1955 and 1974. Eleven per cent were deemed to have had a single episode of disease, 20% intermittent episodes returning to normal between bouts, 51% chronic but not incapacitating disease, and 18% chronic and incapacitating disease. Thirty five per cent underwent surgery. Five per cent of the patients died during the study period, most commonly from carcinoma of the colon (50%), lymphoma (6%), or chronic disease (27%). A report in 1996 of 171 subjects seen at two large pediatric inflammatory bowel disease centers in the Northeastern United States presented a somewhat more encouraging picture [3]. In this cohort, 43% had mild disease and 57% moderate or severe disease at presentation. Forty three percent had pancolitis. Over 80% had resolution of
*Professor of Pediatrics, University of Connecticut School of Medicine, Head, Division of Digestive Diseases and Nutrition, Connecticut Children’s Medical Center, 282 Washington Street, Hartford, Connecticut 06106, Tel.: (860) 545 9532, Fax.: (860) 545 9561, Email:
[email protected]
75
76
Jeffrey S. Hyams
Figure 7.1. Cumulative probability of colectomy at yearly intervals following diagnosis as a function of disease activity at diagnosis. Original population: mild disease, n = 73, moderate disease, n = 98. Confidence intervals: mild disease: 1 year (0 to 4%), 5 years (2% to 16%); moderate/severe disease: 1 year (3% to 13%), 5 years (16% to 36%). Mild disease vs. moderate/severe disease, p < 0.03. From Hyams JS et al. [3], with permission.
symptoms within 6 months of diagnosis and during subsequent yearly follow-up intervals 55% were symptom free, 38% had chronic intermittent symptoms, and 7% had continuous symptoms. Corticosteroid therapy was used in 27% of those with initially mild disease and 70% of those with moderate/severe disease by 1 year. Eleven per cent of those with moderate/severe disease received additional immunomodulatory therapy (azathioprine/6-mercaptopurine or cyclosporine) during the first year. By 1 year following diagnosis, 1% of those with initial mild disease and 8% of those with moderate/severe disease had required colectomy; at 5 years the risk of colectomy was 9% and 26% in the two groups, respectively (Figure 7.1). A report from Denmark in 1997 describing 80 children with ulcerative colitis demonstrated a cumulative colectomy rate of 6% and 23% at 1 and 5 years, respectively [4].
Historical Perspective – Adults The first report of the use of corticosteroids in the treatment of ulcerative colitis in adults appeared in the mid 1950s [5]. Truelove and Witts reported their experience using cortisone (100 mg per day) and demonstrated improvement or remission in 69% of treated subjects compared to 40% of controls. However, 6% of the cortisone treated patients and 15% of the control patients died during the 9 month study period. The largest report of the natural history of ulcerative colitis in adults appeared in 1994 and documented the course of 1161 patients diagnosed in Denmark between 1962 and 1987 [6]. Slightly less than half had distal disease at diagnosis, defined by rigid proctosigmoidoscopy and double contrast barium enema. Only 18% had pancolitis. During each year of follow-up beyond the first year, approximately 50% of patients were in clinical remission, 30–40% with intermittent symptoms, and 10% with continuous symptoms. Very few patients had a single episode of disease. The colectomy rate was 9% in the year of diagnosis, 3% per year in the following 4 years, and 1% per year subsequently. At 10 and 15 years from diagnosis, the cumulative colectomy rate was 24% and 30%, respectively.
Chapter 7 Natural History of Pediatric Ulcerative Colitis
77
Clinical Characteristics Influencing Course Extent of Disease There are limited data on proctitis in children. In one report of 34 children with limited disease approximately 55% of patients were in remission in any one year following initial therapy, 40% had chronic intermittent symptoms, and 5% had continuous symptoms [7]. Proximal extension of disease was noted in 30% of patients over a 5-year period. Severity of Disease at Presentation Moderate to severe disease activity at presentation is common in children with ulcerative colitis. There is evidence to suggest that more severe disease at diagnosis is associated with a higher colectomy rate (9%) at one year than is mild disease at presentation (1%) [3].
Drug Modification of Natural History Aminosalicylates Maintenance therapy with sulfasalazine has been used for many years and is effective in up to 65 to 80% of adult patients [8]. Higher doses are more effective but may also be associated with greater side-effects. Clinical experience suggests mesalamine is also an effective maintenance therapy for mild to moderate ulcerative colitis [9]. There are no prospective, controlled trials examining the efficacy of mesalamine in maintaining remission of ulcerative colitis in children, though this therapy is commonly used. Corticosteroids Corticosteroids remain the mainstay of therapy for moderate to severe ulcerative colitis and therefore understanding the course of disease following these medications is critical to understanding natural history. The outcome of corticosteroid therapy for adults with UC in a populationbased study in Olmsted County, Minnesota was published in 2001 [10]. In this study of 185 patients diagnosed with UC over a 23-year period, only 63 (34%) received corticosteroids. Fiftyfour per cent of subjects receiving corticosteroids had a complete clinical response by 30 days, 30% a partial response, and 16% no response. By one year 49% had a prolonged response, 22% were termed corticosteroid-dependent, and 29% had undergone colectomy. Immunomodulators were used in very few of these patients. In children with ulcerative colitis treated with corticosteroids within 30 days of diagnosis, disease activity at 3 months was inactive in 60%, mild in 27%, and moderate/severe in 11% of patients in one study [11]. At one year, 31/62 (50%) of the corticosteroid treated patients were considered corticosteroid-responsive and 28 (45%) corticosteroid-dependent. A total of 4 patients receiving corticosteroids (5%) required colectomy in the first year. Immunomodulators were used in 61% of all corticosteroid treated patients. Thus, it is clear that response to corticosteroids plays a large role in defining natural history. It has recently been proposed that the multi-drug resistance (MDR) gene (MDR-1) may play an important role in determining response to corticosteroids [12, 13]. The MDR-1 gene codes for a 170-kilodalton cell membrane drug efflux pump P-glycoprotein 170 that transports MDR substrates out of cells, lowering their intracellular concentration. This glycoprotein is expressed in the apical surface of intestinal epithelium as well as in peripheral blood lymphocytes. Corticosteroids, cyclosporine, and methotrexate are all MDR substrates. Patients with ulcerative colitis refractory to corticosteroids have been shown to have higher MDR expression compared to controls [12].
78
Jeffrey S. Hyams
Immunomodulators The past 15 years has seen a great increase in the use of immunomodulators to treat ulcerative colitis, largely based on the previous positive experience in Crohn disease. A recently published review of 7 blinded, controlled trials of azathioprine in ulcerative colitis highlighted the methodological issues with many of the early studies which left unanswered the question of whether this drug was useful in maintaining remission [14]. A review of the 30 year experience with azathioprine in a large cohort of patients in Oxford, England suggested significant utility of azathioprine in maintaining remission [15]. Almost two-thirds of patients maintained remission for up to 5 years, and median time to relapse upon stopping the drug with 18 months. The addition of the 5-aminosalicylate olsalazine to azathioprine does not improve the maintenance of remission rate compared to azathioprine alone in steroid dependent adults with ulcerative colitis [16]. No controlled data are available in children. Two small retrospective series support the use of azathioprine in steroid dependent disease in children [17, 18]. Though cyclosporine is widely accepted as effective therapy for inducing remission in severe ulcerative colitis, controlled data supporting this assumption are limited [19, 20]. In children the experience is limited to retrospective chart review [21]. However, nephrotoxicity, increased susceptibility to infection, and other side-effects generally preclude its use as maintenance therapy. Therefore, monotherapy with cyclosporine to maintain remission is not indicated, and patients with cyclosporine induced remission are often transitioned to azathioprine for maintenance [22, 23]. Nonetheless, it is not clear whether long-term outlook is improved as many patients requiring cyclosporine therapy require colectomy within 2–3 years [21, 24]. Biologic Therapy While initial studies of infliximab for the treatment of ulcerative colitis were conflicting [25–27], more recent data have suggested efficacy. In 2005, two randomized, double-blind, placebo controlled studies, ACT 1 and ACT 2, were published in a single paper evaluating the efficacy of infliximab for induction and maintenance in 728 adults with active ulcerative colitis (Mayo score 6–12) [28]. Clinical response at 8 weeks (decrease in Mayo score by 3 points) was observed in approximately 65% of subjects receiving a 3-dose induction of infliximab (either 5 mg/kg/dose or 10 mg/kg/dose) compared to approximately 33% of placebo patients. Clinical remission at week 8 (Mayo score of 2 or lower, no item more than 1) was observed in approximately 33% of infliximab treated patients versus 10% in the placebo group. Mucosal healing at week 8 was seen in approximately 60% of infliximab treated patients versus 30% of placebo treated patients. Week 54 data were available for 364 ACT 1 patients; 42% of infliximab treated patients were in remission compared to 20% of those treated with placebo. Clinical remission without corticosteroids was seen in 9% of placebo treated patients, 26% of those receiving 5 mg/kg maintenance doses of infliximab every 8 weeks and 16% of those receiving 10 mg/kg doses. At the start of ACT 1 and ACT 2 approximately 30% of patients were felt to have corticosteroid refractory disease, 50-60% were taking corticosteroids at the time infliximab was initiated, and 70% were receiving 5-aminosalicylate preparations and 40–50% immunomodulators. Average disease duration was approximately 6 years. Longer term follow-up will be required to determine if this degree of disease suppression remains. In one study of hospitalized adults with severe ulcerative colitis refractory to corticosteroid therapy, the addition of infliximab was superior to placebo in preventing colectomy (Odds ratio 4.9, range 1.4–17) [29]. There are no comparable data for pediatric patients. No placebo controlled data are currently available for pediatric ulcerative colitis. Reported data from open-label experience demonstrate short-term improvement in 75–80% of subjects and longer term improvement in 60% [30–33]. It has been suggested that patients with chronic corticosteroid dependent disease are less likely to respond to infliximab than those with short-term disease [30].
Chapter 7 Natural History of Pediatric Ulcerative Colitis
79
However, these observations were based on very small patient numbers and will require further study. Long-term data will be required to see whether the frequency of corticosteroid dependency or need for colectomy will decrease compared to the pre-biological therapy era, and whether long-term safety can be demonstrated. Additional biological agents have also been evaluated in limited clinical trials. MLN02 is a humanized monoclonal antibody that specifically recognizes the 4 7 heterodimer and selectively blockades the interaction between leukocytes and vascular endothelium in inflamed gut. One hundred eighty one adult patients with active ulcerative colitis, not receiving corticosteroids or immunomodulators, received either placebo or one of two doses of MLN02 (Day 1, 29). Clinical remission at week 6 was 14% in the placebo group and 32% in the treated groups [34]. Visilizumab is a humanized anti-CD3 antibody that selectively induces apoptosis in activated T cells. Phase I/II studies showed efficacy in corticosteroid resistant UC. Cytokine release syndrome and elevations in EBV DNA levels were observed [35].
Can We Predict the Course of Disease? Being able to predict the course of those patients who present with severe disease might be helpful in designing treatment strategies. Both clinical paradigms and laboratory evaluation have been examined in this regard. In 1977, Werlin and Grand reported 19 children with severe colitis (14 ulcerative colitis, 5 Crohn disease) defined as having 4 out of the following 5 features: ≥5 bloody stools per day, oral temperature >100°F, pulse ≥90, hematocrit ≤30%, albumin ≤3.0 g/dl [36]. One-third of their patients responded to therapy (bowel rest, parenteral nutrition, corticosteroids) and the remainder underwent colectomy within 2 years. In adults a duration of acute symptoms for more than 6 weeks, deep rectocolonic ulcers, or the presence of Truelove and Witts criteria [5] for severe disease had an 85% chance of medical failure with conventional therapy [37]. In another study of adults the presence of pedal edema, transverse colon dilatation (>5 cm), high C-reactive protein, low serum fibrinogen, prolonged prothrombin time, and Truelove and Witts criteria for severe disease predicted failure of medical therapy [38]. Similar findings on day 3 after hospital admission all predict a higher likelihood of requiring colectomy [39, 40]. Attempts have also been made to try to correlate disease course with genetic profiles. An association between severe and extensive disease and the major histocompatability complex (MHC) genes DRB1*0103 and DRB1*15 has been identified [41–43]. A structural polymorphism in the IKBL (inhibitor of B-like) gene, located in the central region of the MHC locus, has also been associated with severe disease [44]. Refractory ulcerative colitis has been associated with a polymorphism in the hMLH1 gene, a mismatch repair gene [45]. To date, no specific data on genetic associations and course of pediatric ulcerative colitis have been identified.
Summary Short of a cure, the ideal therapy for ulcerative colitis quickly induces and then effectively maintains remission with healing of the colonic mucosa and presents minimal toxicity to the patient. No current therapy meets all these requirements. The natural history of ulcerative colitis will continue to change as newer therapies are introduced. At present, aminosalicylates should be used to maintain remission given their favorable side-effect profile. Immunomodulators also appear to be effective in those patients failing aminosalicylates, as is infliximab. Long term safety data will be required to better understand the risk-benefit ratio of these therapies. In the future clinicians may be able to obtain a genetic profile of their patients that will help predict response to various therapies and thereby decrease the likelihood of treatment failure and complications of ineffective treatments. As was recently noted in a review article on severe colitis in children,
80
Jeffrey S. Hyams
“only scientifically proven data developed in children will allow us to safely and convincingly move from experience derived from adult studies to the pediatric population” [46]. References 1. Goel KM, Shanks RA. Long-term prognosis of children with ulcerative colitis. Arch Dis Child 1973;48:337–42. 2. Michener WM, Farmer RG, Mortimer EA. Long-term prognosis of ulcerative colitis with onset in childhood or adolescence. J Clin Gastroenterol 1979;1:301–5. 3. Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr 1996;129:81–8. 4. Langholz E, Munkholm P, Krasilnikoff PA, Binder V. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997;32:139–47. 5. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;1041–8. 6. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3–11. 7. Hyams J, Davis P, Lerer T, et al. Clinical outcome of ulcerative proctitis in children. J Pediatr Gastroenterol Nutr 1997;25:149–52. 8. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002;CD000544. 9. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:204–11. 10. Faubion WA, Jr., Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255–60. 11. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006;4:1118–23. 12. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279–88. 13. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178:339–46. 14. Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006;55:437–41. 15. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485–9. 16. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004;99:1122–8. 17. Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999;28:54–8. 18. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117:809–14. 19. D’Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323–9. 20. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841–5. 21. Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995;38:474–9. 22. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining longterm remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498–9.
Chapter 7 Natural History of Pediatric Ulcerative Colitis
81
23. Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73–8. 24. Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998;12:973–8. 25. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7 Suppl 1:S30–3. 26. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577–84. 27. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998–1002. 28. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76. 29. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11. 30. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004;39:166–70. 31. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004;38:298–301. 32. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN, Jr., Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823–8. 33. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005;11:213–8. 34. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499–507. 35. Sandborn WJ, Baumgart DC, Targan SR, et al. Long-term outcome following visilizumab for the treatment of intravenous steroid-refractory ulcerative colitis (IVSRUC). Gastroenterology 2007;132:A506. 36. Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology 1977;73:828–32. 37. Carbonnel F, Lavergne A, Lemann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39:1550–7. 38. Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004;19:1247–52. 39. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905–10. 40. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19:1079–87. 41. Bouma G, Crusius JB, Garcia-Gonzalez MA, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999;115:294–300. 42. Trachtenberg EA, Yang H, Hayes E, et al. HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. Hum Immunol 2000;61:326–33. 43. Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 2003;62:527–35. 44. de la Concha EG, Fernandez-Arquero M, Lopez-Nava G, et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology 2000;119:1491–5. 45. Bagnoli S, Putignano AL, Melean G, et al. Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. Inflamm Bowel Dis 2004;10:705–8. 46. Kugathasan S, Dubinsky M, Keljo D, et al. Severe colitis in children. J Pediatr Gastroenterol Nutr 2005;41:375–85.
8 Natural History of Pediatric Indeterminate Colitis Michael D. Kappelman∗ and Richard J. Grand
Introduction The term “Indeterminate Colitis” (IC) refers to a heterogeneous subset of patients with inflammatory bowel disease (IBD) who, for a number of different reasons, cannot be classified as either Crohn disease or ulcerative colitis. These patients have primarily colonic disease involvement, but several clinical, anatomic, endoscopic, or histologic features such as nonspecific gastritis, ileal inflammation or minor ulceration, rectal sparing, or growth failure make the diagnosis of ulcerative colitis uncertain. Not only are these patients a heterogeneous group; so too are their physicians. Because there are no established criteria for diagnosing IC, individual clinicians may vary on how, when, and how frequently they use this term. [1] As an example of this subjectivity, consider the child with pancolitis and mild histologic inflammation of the terminal ileum. One clinician may diagnose “ulcerative colitis with backwash ileitis”, another may diagnose indeterminate colitis, and a third may consider this a case of Crohn disease. [1] The heterogeneity of clinical presentations that have been described as IC, as well as the diagnostic subjectivity, limit the ability to describe the natural history of this condition. For example, are these patients at increased risk of disease recurrence and/or pouchitis following surgery? How will they respond to biologics and other therapies that have only been studied in patients with classical CD or UC? As a result, patients with IC and their physicians are often frustrated, especially when trying to understand disease prognosis, plan for the future, and weigh the risks/benefits of certain medical and surgical therapies. An additional concern is that these patients are often excluded from clinical trials, limiting their access to emerging therapeutics. In this chapter, we will explore the factors which lead to the diagnosis of indeterminate colitis, review the definitions of IC that have been used in the literature, describe the epidemiology of this condition relative to that of CD and UC, discuss the natural history of IC (subject to the limitations described above), and summarize the recommendations of the combined CCFA/NASPGHAN
∗
Assistant Professor of Pediatrics, University of North Carolina Chapel Hill, 5143 Bioinformatics Bldg; CB#7229, Chapel Hill, NC 27599, E-mail:
[email protected] Supported in part by AHRQ Grant No. T32 HS000063-12 to the Harvard Pediatric Health Services Research Fellowship Program, General Clinical Research Center Grant M01 RR002172, and the Wolpow Family Fund.
83
84
Michael D. Kappelman and Richard J. Grand
Table 8.1. Summary of studies describing reclassification of patients initially diagnosed with IC. Author
Population
Moum (15) Joosens (17) Meucci (16) Total adult Lindberg (19) Carvalho (13) Mamula (18)
Adult Adult Adult
Total children
Pediatric Pediatric Pediatric (≤5 years)
Initial dx IC
Follow-up dx UC
Follow-up dx CD
Other follow-up dx (IC, not IBD, probable IBD)
35 97 48 180 171 74 19
12 14 17 43 (24%) 23 9 1
6 17 20 43 (24%) 6 16 4
17 66 11 94 (52%) 142 49 14
264
33(12.5%)
26 (10%)
205 (77.5%)
working group on the differentiation between ulcerative colitis, Crohn disease, and indeterminate colitis in children and young adults.
Factors Leading to a Diagnosis of Indeterminate Colitis Several endoscopic and histologic factors contribute to difficulty in distinguishing between CD and UC and lead to the diagnosis of IC, particularly in the pediatric and adolescent age range. Other factors, however, are the subject of considerable confusion among clinicians and pathologists, and may result in the inappropriate diagnosis of IC. First, there is increasing debate over the necessary findings of UC, which have traditionally included rectal involvement and continuous, distal to proximal distribution. This may be especially true for pediatric patients, as in one study up to 21% of newly diagnosed children with patchy colonic disease carried the diagnosis of UC. In this same study, the authors allowed for relative rectal sparing in 23% and absolute rectal sparing in 3%. [2] Non-classical findings such as these may cast doubt on a diagnosis of UC or raise the suspicion for Crohn disease, resulting in a provisional diagnosis of IC. Secondly, the relative infrequency of granulomas in colonic biopsy specimens in patients with colitis may lead to an overdiagnosis of IC in cases that would have ordinarily been diagnosed as Crohn colitis. Two recent reports demonstrated that the frequency of granulomas detected in colonic biopsies of patients with CD was between 21.7 and 30.2%. [3, 4] Of note, the addition of upper gastrointestinal and ileal biopsies increased the likelihood of granuloma detection to 43.8% in one of these studies. [3] Although these authors recommend Esophagogastroduodenoscopy (EGD) with biopsy and Terminal ileum (TI) intubation with biopsy for all patients with possible IBD, this practice is not yet universally accepted. [3, 4] Another reason for the diagnosis of IC is that the classical pathologic features of ulcerative colitis are often obscured in surgical resection specimens in patients with fulminant UC due to early superficial ulceration, transmural inflammation, and even rectal sparing. [5] Other, less appropriate reasons for the diagnosis of indeterminate colitis include the misinterpretation of pathologic features that are accepted variants of ulcerative colitis such as “backwash ileitis”, “gastritis”, and periappendiceal inflammation (commonly referred to as the “cecal patch”), and failure to use “hard” criteria such as transmural inflammation, granulomas, deep fissuring ulceration, ileal involvement, or segmental disease as representative of CD. [1, 5]
Chapter 8 Natural History of Pediatric Indeterminate Colitis
85
Children with initial diagnosis of IC 264 patients
Follow up diagnosis of UC 33 patients (12.5%)
Follow up diagnosis of CD 26 patients (10%)
Other follow up diagnosis 205 patients (77.5%)
Definitions Because no standard definition for indeterminate colitis exists, our understanding of the epidemiology and natural history of this condition is limited. Originally, IC was purely a “histopathologic” diagnosis, established only after the examination of surgical specimens. Since the majority of these patients were operated because of fulminant colitis, the disease spectrum was limited to patients with severe colitis. Although many authors still support this original definition, other investigators are now using the term IC more broadly, including all cases with endoscopic, radiographic, and histologic evidence of IBD confined to the colon but features that make the clinician uncertain as to whether the diagnosis is CD or UC. [6] For example, in a prospective, population-based study of newly diagnosed IBD patients in Norway, Moum et al. defined the diagnostic criteria for IC as “endoscopy and histopathology were either inconclusive or divergent with regard to the diagnosis of UC or CD”. [7] Similarly, Kugathasan et al, in a community based study of the epidemiology of pediatric IBD in Wisconsin, defined indeterminate colitis as “inflammatory colitis in the setting of histopathological changes indicative of chronic IBD colitis, containing both endoscopic and histologic findings that were consistent with both CD and UC”. [8] By allowing the inclusion of all patients, not just those who have undergone surgery, “clinicopathologic” definitions such as these have expanded the subgroup of patients (and the spectrum of disease) categorized as indeterminate colitis. Finally, it should be emphasized that some experts believe that IC is not a distinct disease entity with specific diagnostic criteria. Rather, they believe that IC is a provisional descriptive term used until the true nature of the patient’s underlying type of IBD becomes apparent, usually within a few years following diagnosis. [5]
Epidemiology As illustrated by the discussion above, disagreement concerning the definition(s) of IC has lead to varying estimates of the incidence and prevalence of this disorder, not to mention uncertainty regarding the natural history. For the remainder of this chapter, our discussion will concentrate on patients who meet the broader, “clinicopathologic” diagnostic criteria, as we believe this definition is more useful to clinicians concerned with diagnostic and therapeutic decisions. There are only a few studies examining the incidence of IC. Moum et al. prospectively registered all new cases of UC and IC in a population based study in southeastern Norway. The study population consisted of a total of 525 cases of UC and 93 cases of IC. The mean annual incidence of IC was 2.4 per 100,000, comprising 13% of all newly diagnosed cases of IBD. [7] It should be noted that the average age of onset was 35 years indicating that the study population was predominantly adults.
86
Michael D. Kappelman and Richard J. Grand
In the Wisconsin-based pediatric study, 10 out of 199 incident IBD cases (5%) were classified as IC, with an overall incidence of 0.35 per 100,000. [8] Another prospective study of pediatric IBD in Sweden reported a similar overall incidence of pediatric IBD; however, in this study approximately 25% of patients were classified as IC. [9] Additional reports from the pediatric literature estimate the proportion of newly diagnosed cases of IBD cases categorized as IC to be anywhere between 3.3% and 30%. [10–13] We believe that these widespread differences in the proportion of incident IBD cases categorized as IC, despite relatively similar overall IBD incidence rates, represents extremes in diagnosis and categorization rather than actual “biologic” differences. This variation underscores not only the heterogeneity of conditions labeled as IC, but also the inadequacy of the current classification system. The prevalence of IC is affected not only by the number of new cases, but also by the number of cases exiting the prevalent pool. Because of the chronic nature of this illness, patients leave the pediatric prevalence pool only under a limited number of circumstances: 1) becoming adults, 2) death (uncommon), and 3) having their diagnosis changed to CD or UC. Therefore, estimates of prevalence are limited not only by the diagnostic concerns addressed above, but also by the natural history and disease evolution which will be the subject of the next section.
Natural History Both for prognostic and therapeutic purposes, it is important to understand the natural history of indeterminate colitis. Are these patients more likely to follow a Crohn disease clinical course, or an ulcerative colitis-like course? Or, do these patients comprise a distinct subgroup and follow a unique clinical course? Many authors believe that patients with indeterminate colitis have a more severe clinical course than those with UC. For example, Stewenius et al. followed a cohort of 354 patients with IC, UC, and probable UC. After ten years of follow up, the relapse risk in patients with IC was twice as high as in patients with definite UC (relative risk, 1.9, 95% confidence interval, 1.6–2.4). [14] Other important questions regarding the natural history of indeterminate colitis include the following: How will these patients respond to medical therapy? What about surgical therapy? Are these patients at increased risk for post-operative complications such as pouch failure and postoperative fistulas? Our discussion of the natural history of IC will focus on three elements: 1) Diagnostic reclassification based on the development of features typical of UC or CD, 2) Response to medical management, and 3) Surgical outcomes.
Diagnostic Reclassification Several studies have attempted to determine what proportion of patients initially diagnosed with indeterminate colitis is ultimately re-classified as either CD or UC (Table 8.1). Of course, this depends on whether the diagnosis of IC was a pathologic one, based on colectomy specimens, or a clinicopathologic one, based on clinical, radiographic, endoscopic, and histologic data. In this section, we will discuss only the studies which classify patients according to clinicopathologic criteria. In 1997, Moum et al. offered clinical follow up one to two years following a diagnosis of IBD to a cohort of adult patients in south eastern Norway. Of the 36 cases of indeterminate colitis, 35 were available for clinical follow up. One third of these were reclassified as UC, 17% as CD, 29% as possible IBD, and 14% as non-IBD. Only 6% remained classified as IC. In contrast, less than 1% of patients with CD or UC were reclassified as IC during the follow up period. [15]
Chapter 8 Natural History of Pediatric Indeterminate Colitis
87
In a multi-center, retrospective study based in Northern Italy, Meucci et al. analyzed the frequency of re-classification within eight years of an initial diagnosis of IC. In this study, fifty out of 1113 adult IBD patients were initially diagnosed as having indeterminate colitis (4.6%). Of these, 72.5% had their diagnosis changed to either CD or UC during the follow up period. [16] More recently, Joossens et al. prospectively followed 97 adult patients with indeterminate colitis in three European centers. During a mean follow up period of 2.4 years, 31 patients (32%) received a definitive diagnosis. Of these, 55% were reclassified as CD and 45% were reclassified as UC. [17] In the largest pediatric study, Lindberg et al. prospectively followed children with IBD between the years 1984 and 1995. Of the 171 children initially diagnosed with IC, 23 (13%) had their diagnosis changed to UC, 6 (4%) had their diagnosis changed to CD, and 3 (2%) had their diagnosis changed to probably CD. [9] Recently, Carvalho published a retrospective database analysis of 250 children with IBD diagnosed between 1996 and 2001. Of these, 74 (29.6 %) had IC. After a median follow-up of 1.9 years, 33.7% of these were reclassified as CD (n = 16) or UC (n = 9). [13] Mamula et al. reported on the reclassification of children with early onset IBD (five years of age and younger). In this retrospective study of 82 patients, 19 (23%) were initially diagnosed with indeterminate colitis. Of these, 26% were ultimately reclassified over a median follow up period of 7.5 years (range 6 months to 23 yr); 80% of these had a final diagnosis of CD and 20% UC. The majority of patients in whom the diagnosis was changed had the initial diagnosis made before 1991. This finding may be explained either by the longer duration of follow-up in children diagnosed before 1991 or by recent improvements in the technical aspects of pediatric colonoscopy allowing a more precise initial diagnosis in patients diagnosed after 1991. [18] Taken together, these studies indicate that diagnostic re-classification is common for patients with indeterminate colitis, reinforcing the sentiment that IC is often a provisional diagnosis. However, the rate of re-classification and the proportion of cases ultimately diagnosed as either CD or UC varies with each study, precluding any definitive conclusions. Generally, it appears that at least half of adult patients and ¼ of pediatric patients will ultimately be reclassified as either CD or UC. One exception may be very young children, who appear more likely to receive a final diagnosis of CD; however, this finding is based on a limited population and should be confirmed. Response to Medical Management There are no randomized clinical trials of medical therapy for indeterminate colitis. In fact, patients with IC are generally excluded from clinical trials. Therefore, little is known about the response of these patients to conventional medical therapies. It is frequently assumed that because many patients with indeterminate colitis will eventually be diagnosed with either CD or UC, any therapy that is effective in both diseases may be useful for the treatment of IC as well. Burakoff advocates that the approach to medical treatment should be based on the anatomic distribution of disease and the severity of relapse. [19] Our anecdotal experience confirms that these patients often respond to steroids, salicylates (oral and topical), and immunosuppressives such as 6 mercaptopurine and azathioprine; however, no data exist on the response rate of patients with IC compared to that of patients with CD or UC. Recently, Black et al. reported the results of an open label trial of infliximab in the treatment of medically refractory indeterminate colitis. Of 20 patients treated with infliximab, 14 (70%) had a complete response, 2 (10%) had a partial response, and 4 (20%) had no response. Of note, half of the enrolled patients were ultimately diagnosed with CD, though the response rate was no different in these patients compared to those who retained a diagnosis of IC. [20] Therefore, although
88
Michael D. Kappelman and Richard J. Grand
limited studies and no controlled trials prove that patients with IC respond to conventional IBD therapies, we believe that a high percentage of these patients will respond to medical therapy and agree with Burakoff that therapy should be based on both anatomic location and disease severity. Surgical Outcomes Several studies have examined the surgical outcomes and complications of patients with indeterminate colitis following colectomy and ileal pouch-anal anastomosis (IPAA); however, there are no reports on the natural history of children with IC who underwent these operative procedures. Although these studies are all limited by their retrospective design, we will summarize and interpret their major findings in the remainder of this section. Yu et al. retrospectively studied 1437 adult patients with chronic UC and 82 patients with IC between 1981 and 1995. Median follow up time was 6.9 years. At ten years, patients with IC had significantly more episodes of pelvic sepsis (17% vs 7%; p < .01), pouch fistula (31% vs 9%; p < .01), and pouch failure (27 vs 11 %; p < .01). In this study, there were no significant differences in the rate of pouchitis between the two groups. Importantly, 15% of the IC patients had their diagnosis changed to CD during follow-up, compared to only 2% of those originally diagnosed with UC (p < .01). When the patients re-classified as CD were removed from analysis, patients with persistent IC did not have significantly different outcomes when compared to patients with chronic UC. Therefore, in this study it appears that the higher rate of surgical complications is limited to the subgroup of patients who were ultimately diagnosed with Crohn disease. [21] In another study, McIntyre et al. compared the outcomes of 71 adult IC patients and 1232 UC patients following IPAA. Mean follow up was 56 months for the IC group and 60 months for the UC group. The number of bowel movements and incontinence rates were similar in both groups; however, failure rate was higher in the IC group compared to the UC group (19% vs 8%). [22] A third study retrospectively compared complication rates in 140 adult patients with IC and 231 UC patients matched for age, sex, method of anastomosis, presence of defunctioning stoma, and length of follow up. The IC patients were more likely to develop minor perianal fistulae and pelvic abscess, but not anastomotic leak or major fistulae. There were no significant differences in the rate of pouch failure. As in previous studies, the proportion of patients who were diagnosed with CD following surgery was greater in IC patients than the UC controls. The same authors also compared 115 IC patients with 1399 UC controls in a prospective analysis, and found no significant differences in functional outcomes, quality of life, or satisfaction with IPAA surgery. [23] Taken together, these studies suggest that post-surgical complications such as pouch failure, fistula, and pelvic sepsis may be higher in adult IC patients undergoing colectomy and IPAA when compared to UC patients; however, these studies suggest that the higher complication rate may be limited to the subset of patients who ultimately receive a diagnosis of Crohn disease. This underscores the importance of complete pre-surgical evaluation, as proper classification prior to surgery may lead to improved risk assessment. Regardless of the complication rates, several of these studies have demonstrated that IC and UC patients have similar functional status, satisfaction, and quality of life following surgical treatment, and therefore, patients with IC should not be precluded from undergoing colectomy and restorative IPAA. Additional data concerning the natural history of children with IC following surgery are desperately needed before any generalizations can be made about pediatric patients with indeterminate colitis, particularly in very young children who may be at higher risk of Crohn disease when compared to older children and adults.
Chapter 8 Natural History of Pediatric Indeterminate Colitis
89
Recommendations To address the questions, inconsistencies, and controversies in the diagnosis and classification of pediatric inflammatory bowel disease, the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn and Colitis Foundation of America (NASPGHN) (CCFA) jointly organized a working group of 10 pediatric gastroenterologists, one adult gastroenterologist, one epidemiologist, and four GI pathologists which met in December of 2003. The goals of this working group were to establish an agreed upon set of definitions and phenotypes, and to develop an algorithm that would improve inter observer agreement in the diagnosis and classification of CD, UC, and IC. Although the working group was unable to determine evidence-based criteria for diagnosing IC, they put forth several general recommendations. First, the group suggested that clinicians try to avoid overuse of the diagnosis of IC, and specifically stated that the following criteria do not preclude a diagnosis of UC in children with colitis: backwash ileitis, rectal sparing, histologic patchiness, appendiceal inflammation, and gastritis. The committee also recommended that for patients diagnosed with IC based on symptoms highly atypical for UC such as ileal apthae, backwash ileitis in a patient with left sided colitis, profound growth failure, large oral apthae, or absolute rectal sparing, clinicians should precisely specify the reason(s) for this diagnosis rather than UC or CD. The committee further recommended patients given a provisional diagnosis of IC undergo additional endoscopic and radiographic evaluation after one year or during the next disease exacerbation to try to establish a definitive diagnosis, while acknowledging that partially treated disease may have a patchy distribution.
Summary Patients with indeterminate colitis are a heterogeneous group, and controversy exists regarding the diagnostic criteria for this condition. Marked variability in the usage of this term among physicians has resulted in widespread differences in the prevalence of this condition and has limited our understanding of the natural history. Additionally, patients with IC are often excluded from clinical trials, further limiting our understanding of both the clinical course and response to therapy, and this lack of evidence is particularly problematic in the pediatric population. We conclude that efforts should be made to standardize diagnostic criteria and to prospectively characterize the clinical course and response to therapy by a combination of observational and randomized studies. In the meantime, we believe that indeterminate colitis represents a mixture of patients with UC, patients with CD, and patients in whom, after several years of follow-up and re-evaluation, the diagnosis remains “indeterminate”. It appears that patients with IC are ultimately more likely to be diagnosed with UC rather than CD; however, the reverse may be true in very young children. We advocate medical treatment with agents that are effective in both CD and UC (i.e. steroids, salicylates, immunomodulators, and infliximab), with specific therapies chosen based on disease location, severity, and estimation of risk for recurrence. Although IC patients who undergo surgical therapy such as colectomy and IPAA may be at higher risk of post-operative complications, they appear to have similar functional outcomes. As such, surgical therapy should not be withheld from IC patients with refractory disease, once an attempt has been made to re-classify their disease status. References 1. Bousvaros A, Antonioli D, Colletti RB, et al. The differentiation between colitis, Crohn disease, and indeterminate colitis in childern and young adults. Report of a combined CCFA/NASPHGAN working group, and a proposed classification scheme and algorithm.
90
Michael D. Kappelman and Richard J. Grand
2. Glickman JN, Bousvaros A, Farraye FA, et al. Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. The American journal of surgical pathology, 2004;28(2):190–7. 3. De Matos V, Baldassano RN, Russo PA. Granuloma Prevalence and Distribution in Pediatric Crohn Diseaes: Importance of Upper Endoscopy and Terminal Ileal Biposies: 181. Journal of Pediatric Gastroenterolgy and Nutrition, 2005;41(4):549. 4. Shaoul R, Karban A, Weiss B, et al. NOD2/CARD15 mutations and presence of granulomas in pediatric and adult Crohn disease. Inflammatory Bowel Diseases, 2004;10(6):709–14. 5. Odze RD. Pathology of indeterminate colitis. Journal of Clinical Gastroenterology, 2004;38(5 Suppl):S36–S40. 6. Geboes K, De Hertogh G. Indeterminate colitis. Inflammatory Bowel Diseases, 2003; 9(5):324–31. 7. Moum B, Vatn MH, Ekbom A, et al. Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists. Digestion, 1995;56(5):377–81. 8. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. The Journal of Pediatrics, 2003;143(4):525–31. 9. Lindberg E, Lindquist B, Holmquist L, Hildebrand H. Inflammatory bowel disease in children and adolescents in Sweden, 1984–1995. Journal of Pediatric Gastroenterology and Nutrition, 2000;30(3):259–64. 10. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. The Journal of Pediatrics, 2005;146(1):35–40. 11. Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990–2001. Gut 2003;52(10):1432–4. 12. van der Zaag-Loonen HJ, Casparie M, Taminiau JA, Escher JC, Pereira RR, Derkx HH. The incidence of pediatric inflammatory bowel disease in the Netherlands: 1999–2001. Journal of Pediatric Gastroenterology and Nutrition, 2004;38(3):302–7. 13. Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflammatory Bowel Diseases, 2006;12(4):258–62. 14. Stewenius J, Adnerhill I, Ekelund GR, et al. Risk of relapse in new cases of ulcerative colitis and indeterminate colitis. Diseases of the Colon and Rectum, 1996;39(9):1019–25. 15. Moum B, Ekbom A, Vatn MH, et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut, 1997;40(3):328–32. 16. Meucci G, Bortoli A, Riccioli FA, et al. Frequency and clinical evolution of indeterminate colitis: a retrospective multi-centre study in northern Italy. GSMII (Gruppo di Studio per le Malattie Infiammatorie Intestinali). European Journal of Gastroenterology & Hepatology, 1999;11(8):909–13. 17. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology, 2002;122(5):1242–7. 18. Mamula P, Telega GW, Markowitz JE, et al. Inflammatory bowel disease in children 5 years of age and younger. The American Journal of Gastroenterology, 2002;97(8):2005–10. 19. Burakoff R. Indeterminate colitis: clinical spectrum of disease. Journal of Clinical Gastroenterology, 2004;38(5 Suppl):S41–3. 20. Black A, Bhayani H, Ryder C, Pugh M, Gardner-Medwin J, Southwood T. Infliximab in the Treatment of Medically Refractory Indeterminate Colitis. Alimentary Pharmacology & Therapeutics, 2003;18(7):741–8. 21. Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Diseases of the Colon and Rectum, 2000;43(11):1487–96. 22. McIntyre PB, Pemberton JH, Wolff BG, Dozois RR, Beart RW, Jr. Indeterminate colitis. Longterm outcome in patients after ileal pouch-anal anastomosis. Diseases of the Colon and Rectum, 1995;38(1):51–4. 23. Delaney CP, Remzi FH, Gramlich T, Dadvand B, Fazio VW. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Annals of Surgery, 2002;236(1):43–8.
9 Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease Shervin Rabizadeh and Maria Oliva-Hemker∗
Introduction Inflammatory bowel disease (IBD) is not just a disorder of one organ system, but rather a multisystemic disease. In addition to the more typical gastrointestinal involvement which can present with symptoms such as abdominal pain, chronic diarrhea, or bloody stools, other organs can be involved as well, including the eyes, skin, joints, kidneys and liver. In fact, these extraintestinal manifestations may become the predominant source of morbidity for a given patient. The pathogenesis of the extraintestinal manifestations, like the etiology of IBD, is unknown. It is postulated that the inflammatory response in IBD patients leads to the inability of the intestine to act as a selective barrier. Hence the uptake of bacterial products or dietary antigens can induce circulating immune complexes or a systemic inflammatory response [1]. Another theory involves the cross-reaction with a bacterial epitope leading to autoimmunity directed against an antigen shared among the intestine, skin, synovium, eye and biliary system [2]. An autoimmune reaction to an isoform of tropomyosin which is expressed in the eye (non-pigmented cilliary epithelium), skin (keratinocytes), joints (chondrocytes), biliary epithelium, and the gut is speculated as the focal point for this theory [3]. Similarly, extraintestinal manifestations may share a common pathway with the bowel disease in that recruitment of mucosal memory and/or effector T cells to various tissues via the expression of endothelial adhesion molecules that are usually restricted to the gut may lead to destruction from the influx of inflammatory cells [4]. There is a strong genetic influence on extraintestinal manifestations with reports of 83% concordance between siblings [5]. The Human leukocytes antigens (HLA) system is postulated as a link between IBD and certain extraintestinal manifestations, especially ocular and articular manifestations [5]. HLA-A2, -DR1, and -DQw5 are more commonly associated with extraintestinal co-morbidities in Crohn patients. On the other hand genotypes HLA-DRB1, -B27, and -B58 are linked with extraintestinal manifestations of ulcerative colitis. Primary sclerosing cholangitis as well as other autoimmune disorders (e.g. celiac disease, autoimmune hepatitis, myasthenia gravis) have been associated with IBD patients with haplotype HLA B8/DR3 while HLA B27 is reported in 50–80% of IBD patients with ankylosing spondylitis [3]. ∗
Division of Pediatric Gastroenterology and Nutrition, The Johns Hopkins University School of Medicine, 600 N Wolfe St., Brady 320, Baltimore, MD 21287-2631, Phone: 410-955-8765, Fax: 410-955-1464, E-mail:
[email protected]
91
92
Shervin Rabizadeh and Maria Oliva-Hemker
Table 9.1. Common extraintestinal manifestations of IBD in children and their relative prevalence. Extraintestinal Manifestation
Prevalence
Growth Failure Sacroiliitis Osteoporosis/Osteopenia Peripheral Joint Inflammation Aphthous Lesions Primary Sclerosing Cholangitis Granulomatous Skin Lesion Erythema Nodosum Pyoderma Gangrenosum Uveitis/Episcleritis Ankylosing Spondylitis
++++ ++++ +++ +++ +++ ++* ++ ++ + + +
*Adult Data
The incidence of developing any extraintestinal manifestation in IBD is estimated to be approximately 30% [6]. These manifestations have been classified in various ways such as their relationship with the degree of inflammation of the underlying bowel disease or by the location of the bowel disease, for example, colonic versus small intestinal [7]. Over 130 extraintestinal manifestations have been reported in the literature associated with IBD but fortunately most of these are rare [8]. Several excellent comprehensive reviews are available on the extraintestinal manifestations of IBD [9–13]. This chapter will focus on the more common extraintestinal manifestations found in the pediatric population and present them by the affected system and descending order of prevalence (Table 9.1).
Growth Failure Extraintestinal manifestations of pediatric IBD patients can not be discussed without first mentioning growth failure which is estimated to occur in 30% of children with Crohn disease and in 5–10% with ulcerative colitis [6]. Children can present with an obvious lack of growth such as a height below the 5th percentile for age, or growth changes can be more subtle with a gradual flattening of the child’s height velocity that is only evident upon plotting of multiple height measurements on a growth chart. Some children can have delays in bone maturation and pubertal development. It is important to not merely assume that growth failure is a consequence of gastrointestinal manifestations as decreases in weight and height velocities can precede any clinical evidence of bowel disease [14]. Thus, the concept of viewing growth failure as an independent manifestation of IBD will help health care providers develop a higher index of suspicion for the diagnosis of IBD in children presenting in this manner, even if they do not have gastrointestinal complaints. IBD-associated growth failure could be secondary to deficient nutrient intake, poor digestion and absorption as well as increased metabolic demands, however, the most likely etiology remains chronic caloric insufficiency [15]. Unfortunately, treatment for the IBD, especially with chronic corticosteroids, can have deleterious effects on overall growth and this needs to be weighed against the detrimental effects of the inflammatory process on growth. In addition to consideration of immunomodulator (e.g. 6-mercaptopurine) use earlier in the disease course of pediatric patients, administration of oral or enteral formula feedings should be considered to rehabilitate the growthstunted patient.
Chapter 9 Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease
93
Joint Manifestations Joint inflammation is a commonly seen extraintestinal manifestation of IBD in both adults and children [6]. Arthralgias are a frequent complaint and in fact arthritis occurs in up to a quarter of children with IBD [16]. Similar to most other extraintestinal manifestations, symptoms of joint inflammation may occur before or after the development of bowel disease. Joint manifestations can be divided into an axial form (involvement of the axial spine and sacroiliac joints) and a peripheral form (involvement of larger joints such as the knees, ankles, hips, wrists and elbows). The axial form of joint involvement includes ankylosing spondylitis and sacroiliitis. Ankylosing spondylitis, which is associated with the HLA-B27 antigen, is more commonly associated with ulcerative colitis and occurs in less than 2% of IBD patients. Symptoms include back stiffness, pain, and eventually stooped posture as well as peripheral joint complaints. Almost all of these patients will have involvement in their sacroiliac joints. On the other hand, asymptomatic sacroiliitis is more common with an estimated incidence of 10 to 52% [5]. Sacroiliitis is often not diagnosed especially in its early stages unless sought after with bone scans. Isolated sacroiliitis seems not to be associated with HLA-B27 [3]. Asymptomatic HLA-B27 negative patients with normal spinal mobility do not require specific treatment. Though ankylosing spondylitis has been shown to respond to sulfasalazine in multiple double-blind studies, none of the studies addressed ankylosing spondylitis in IBD patients [17]. In fact, therapy for IBD-related symptomatic axial disease primarily involves physical therapy and an exercise program to stop the progression of any disability and deformation. Peripheral joint inflammation is most frequently reported with Crohn disease and is most typically associated with colonic inflammation although can also be associated with small bowel disease [5]. The patient usually presents with erythema, swelling, and decreased range of motion in an asymmetric pauciarticular pattern. Fortunately, joint deformity is uncommon. The arthritis tends to worsen during times of increasing bowel disease and there is an association with other extraintestinal manifestations such as those of the skin, mouth, and ocular systems. Primary treatment of the bowel inflammation with aminosalicylate medications, corticosteroids or other immunomodulating agents is the first course of action for joint inflammation [6]. Often resolution is achieved with this approach in less than 8 weeks [16]. Treatment with non-steroidal inflammatory agents and cyclooxygenase-2-inhibitors have the potential for gastrointestinal mucosal injury and should be avoided if possible. In refractory cases, consideration is given to methotrexate and intraarticular corticosteroid injections. Recent studies have also shown that infliximab is efficacious in the treatment of spondyloarthropathies such as the articular and musculoskeletal findings in IBD [5].
Bone Disease There has been recent increasing interest in identifying osteopenia and osteoporosis in patients with IBD. In adult populations, the overall prevalence of osteoporosis in IBD is estimated between 4 to 40% with increasing prevalence in older patients [3]. A large population-based adult study reported an osteoporosis prevalence of 15% and relative risk of 1.4 for fractures in IBD patients compared to the general population [18]. Prevalence of osteopenia and osteoporosis in the pediatric population is estimated between 8 to 30% based on several smaller studies [19]. IBD commonly presents during adolescence and young adulthood when bone mass is being rapidly attained. IBD patients have inadequate intake or malabsorption of calcium and vitamin D. Also these patients are potentially prone to low bone mineral density secondary to corticosteroid use, low estrogen states in females, and effect of circulating proinflammatory cytokines [20]. Hence, IBD patients, especially those with Crohn disease, are at higher risk of eventually developing osteoporosis. This can make the patients prone to bone fracture, bone deformities, and chronic pain.
94
Shervin Rabizadeh and Maria Oliva-Hemker
Diagnosis of osteopenia/osteoporosis is made with dual-energy x-ray absorptiometry (DEXA) which measures bone mineral density in the spine, femoral neck or other bones rapidly and with low amounts of radiation. Treatment with calcium and vitamin D may prevent further deterioration of bone but not necessarily help in recovery of lost bone density. Prevention has not been well studied in IBD patients but it would be prudent to ensure intake of at least the recommended daily requirement for age of calcium and vitamin D, proper exercise, and minimization of corticosteroid usage to maximize the pediatric patient’s potential in achieving an appropriate peak bone mass. Other bone complications in IBD patients are osteonecrosis of the femoral head, hypertrophic osteoarthropathy, and chronic recurrent multifocal osteomyelitis (CRMO). Osteonecrosis of the femoral head is usually associated with patients who have received chronic steroids and have complaints of hip or knee pain. Clubbing or hypertrophic osteoarthropathy is another bone manifestation associated with IBD especially with small intestinal Crohn disease. The etiology, though unknown is postulated to involve increased blood flow to the fingers and hence increased connective tissue growth secondary to circulating cytokine production [6]. Chronic recurrent multifocal osteomyelitis (CRMO), rarely described in children with IBD, is an aseptic inflammatory bone disease that typically affects the long bones and clavicles [21].
Oral Lesions Recurrent aphthous lesions are the most common oral lesions associated with IBD. The reported incidence is approximately 20% of patients with Crohn disease and significantly less in those with ulcerative colitis [8]. Aphthous lesions tend to parallel intestinal disease though they often can predate intestinal symptoms. Other oral lesions can consist of lip swelling, fissures, and gingivitis which can demonstrate granulomas on histology [22]. Orofacial granulomatosis is a rare syndrome with chronic swelling of the lips and lower half of the face combined with oral ulcerations and hyperplastic gingivitis that has been reported in three dozen Crohn cases [23]. Another rare disorder seen in association with ulcerative colitis patients is pyostomatitis vegetans which can present with oral and cutaneous findings in the axillae, genital areas and scalp. The oral lesions consist of multiple neutrophil and eosinophil-filled pustules on erythematous bases which can erode and fuse to form shallow ulcers that have been described as being “snail track” configuration [24]. Treatment of oral lesions is usually reserved for those causing significant discomfort and may involve topical, intralesional or systemic corticosteroids, or aminosalicylate preparations directed at the bowel disease.
Skin Lesions Cutaneous manifestations of IBD can be classified into three principal groups: granulomatous, reactive, and secondary to nutritional deficiency. Granulomatous skin manifestations have the same histological features as the bowel disease and can include perianal and peristomal ulcers and fistulas, oral granulomatous ulcers, and metastatic Crohn disease. The latter is a rare complication that manifests as subcutaneous nodules or ulcers mainly in the lower extremities and on occasion can occur in the genital areas. It appears unrelated to bowel activity and can be treated successfully with corticosteroids, antibiotics, azathioprine, methotrexate, and infliximab [5]. Reactive skin manifestations of IBD include erythema nodosum (Figure 9.1), pyoderma gangrenosum (Figure 9.2), and Sweet’s syndrome. Of all the skin manifestations associated with IBD, erythema nodosum and pyoderma gangrenosum are the most common, however, in the
Chapter 9 Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease
95
pediatric patient, erythema nodosum, which is more commonly associated with Crohn disease than with ulcerative colitis, is encountered more frequently [6]. Erythema nodosum presents as tender, subcutaneous, erythematous nodules, usually on the extremities, especially the lower legs and the majority of patients with this skin manifestation will have associated joint pain or develop arthritis. Children may appear systemically ill with fever. Over days to weeks, the nodules will flatten, turn brown or gray and can be mistaken for bruises. Histologically, erythema nodosum is as a septal panniculitis consisting of a lymphohistiocytic infiltrate. The prevalence in all IBD patients, adult and pediatric, is estimated between 4% and 15% [25]. Exacerbations of erythema nodosum correlate most often with increased intestinal inflammation, hence treatment towards the bowels is considered a primary form of management. Recent reports in children have shown good response to infliximab [25]. Pyoderma gangrenosum is an ulcerating lesion often correlating with exacerbations of the bowel disease however it can persist for long periods while the intestinal inflammation is clinically quiescent. The lesions are often painful and located on the lower extremities. Histopathology reveals endothelial injury with fibrinoid necrosis of blood vessels and marked neutrophilic and lymphocytic infiltrates. Treatment is difficult and patients may require large doses of systemic corticosteroids or immunomodulators as well as topical ulcer care. Infliximab has shown to be effective in refractory cases [5, 25]. Some extreme cases might require skin grafting. Fortunately, pyoderma gangrenosum is a rare extraintestinal manifestation of IBD with a reported incidence of 2% in UC patients and a smaller number in Crohn patients [25]. Sweet’s syndrome is another very rare reactive cutaneous disorder associated with IBD. It is a neutrophilic dermatosis presenting with painful erythematous plaques or nodules often associated with fever and leukocytosis. Usually there is good response to corticosteroids. Nutritional issues, such as trace mineral and vitamin deficiencies, can be common in children with IBD, especially Crohn disease, however skin disorders secondary to these are unusual. There are rare reported cases of acrodermatitis enteropathica, pellagra and scurvy secondary to zinc, niacin, and vitamin C deficiency, respectively.
Figure 9.1. Erythema nodosum, Courtesy of Dr. Edwin King, www.dermatlas.org.
96
Shervin Rabizadeh and Maria Oliva-Hemker
Figure 9.2. Pyoderma gangrenosum, Courtesy of Dr. Rachel Nussbaum, Johns Hopkins Univeristy.
Eye Lesions The most common eye manifestations of IBD are episcleritis and uveitis [6]. These are often associated with other extraintestinal manifestations, especially arthritis and erythema nodosum. Episcleritis (Figure 9.3), inflammation of the blood-rich episclera, tends to parallel bowel activity. It is often confused with conjunctivitis as the patients present with eye redness and burning. Patients with episcleritis have no impairment of vision and usually respond clinically to topic corticosteroids. If visual impairment is present, the possibility of scleritis, which can occur with protracted intestinal disease, needs to be considered and an emergent evaluation by an ophthalmologist is required to evaluate for retinal detachment or optic nerve swelling. Uveitis, unlike episcleritis, is usually independent of the bowel activity and inflammation. Anterior uveitis involves inflammation of the iris and the ciliary body. Symptoms can include acute or subacute eye pain, headache, photophobia and blurred vision or occasionally decreased vision, however, many patients may be asymptomatic. Complications of uveitis can be serious and include
Figure 9.3. Episcleritis, Courtesy of Dr. Rachel Nussbaum, Johns Hopkins Univeristy.
Chapter 9 Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease
97
iris atrophy, synechiae, pigment deposits, glaucoma, cataracts and permanent visual deficits. Attention must be paid for early signs of uveitis which can include a cellular or proteinaceous exudate of inflammatory cells in the anterior chamber of the eye. An evaluation of 147 children with IBD who had no ophthalmologic complaints revealed a prevalence of uveitis of 6.1% in patients with Crohn disease [26]. Uveitis was not diagnosed in any child with ulcerative colitis. Like scleritis, acute anterior uveitis is an ophthalmologic emergency. Treatment involves covering the eye to reduce pain and photophobia, pupillary dilatation, and the use of topical or systemic corticosteroids.
Liver Disease Liver pathology, including hepatitis, fatty liver, cholelithiasis, amyloidosis and primary sclerosing cholangitis, is found in less than 5% of patients with IBD [6]. Screening with periodic checks of serum aminotransferases, alkaline phosphatase, gamma glutamyltransferase, and bilirubin is necessary as many of the children with liver disease are asymptomatic. Children with IBD are at risk for primary sclerosing cholangitis (PSC) and this is the most common extraintestinal liver manifestation of IBD. PSC is a chronic, fibrosing inflammation of unknown etiology affecting both intra- and extrahepatic bile ducts. Cirrhosis develops after obliteration of the bile duct lumen. PSC is more frequently associated with ulcerative colitis (reported incidence of 2–7% in adult studies) as compared to Crohn disease (reported incidence of 0.7–3.4% in adult studies) [5]. The presenting symptoms are often nonspecific but patients may present with fatigue, anorexia, jaundice, pruritus, and hepatomegaly. Laboratory analysis can reveal a persistent elevation in alanine aminotransferase, alkaline phosphatase and gamma glutamyltransferase. A study of 52 children with PSC, in which 81% also had IBD, suggested that lower platelet count, older age at presentation, and splenomegaly are risk factors associated with a poor outcome [27]. Interestingly, 20% of the children in this series were diagnosed with PSC prior to their diagnosis of IBD. Hence a diagnosis of PSC in a child should lead to an evaluation for IBD. This study’s reported prevalence of IBD in PSC patients is comparable to adult data in which 70% of patients with PSC have ulcerative colitis. Besides laboratory analysis, the work-up for PSC should include a cholangiogram by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), and/or intraoperative cholangiogram. Histology can demonstrate focal concentric (onion skin) edema and fibrosis around intralobular bile ducts and less commonly the pathognomonic fibrous-obliterative cholangitis. Overall the prognosis of PSC tends to be poor. Adults have a reported median survival time of 9-12 years from the time of PSC diagnosis, [5] however, pediatric patients can remain stable for many years without development of cirrhosis [6]. PSC is a risk factor for cholangiocarcinoma as it is reported in 6 to 11% of adult PSC patients [28]. Treatment of PSC with the choleretic agent, ursodeoxycholic acid, has improved symptoms and laboratory markers in small studies [17]. The treatment of choice for patients who develop end stage liver disease from PSC is liver transplantation. Thirty percent of patients in one pediatric series were transplanted or listed for liver transplantation due to rapid progression to cirrhosis or a high-grade extrahepatic biliary stricture [27]. PSC may lead to the development of biliary strictures which may be treated with balloon dilatation and stent placement, or in severe cases, with surgical biliary reconstruction [6]. Unfortunately, PSC does not improve with remission of intestinal inflammation and proctocolectomy does not have a beneficial effect. Other therapeutic agents such as corticosteroids, azathioprine, cyclosporine, and D-penicillamine, have shown no benefit in PSC. Management of end-stage liver disease complications that may arise from PSC is similar to the management of those complications in other forms of liver disease.
98
Shervin Rabizadeh and Maria Oliva-Hemker
Rare manifestations of liver disease described in both adult and pediatric IBD patients include gallstones, fatty liver, chronic active hepatitis, granulomatous hepatitis, amyloidosis, cholangiocarcinoma (most often related to PSC), and liver abscesses [29]. Patients with Crohn disease are at risk for cholelithiasis due to malabsorption of bile salts from the inflamed terminal ileum. In fact, it is reported to occur in up to 25% of adult Crohn patients [29]. Severely ill patients with poor nutrition and concomitant steroid therapy are at risk for fatty infiltration of the liver. Hepatic abscesses are very rare and have been reported in ∼60 cases [29]. Most of these patients were male and had Crohn disease.
Other Extraintestinal Manifestations Many other systems, listed below, have had reported involvement in IBD but they have been reported to occur in less than 1% of pediatric IBD patients [6]. Hematologic Abnormalities Anemia, thrombocytosis, and leukocytosis are common hematologic abnormalities in IBD patients and can be seen in up to half the patients with active disease [6]. Usually the anemia is secondary to iron, vitamin B12, and folic acid deficiency as well as anemia of chronic disease. The thrombocytosis is postulated to result from circulating inflammatory cytokines that stimulate platelet production. Similarly, leukocytosis can occur as a result of generalized inflammation. On the other hand, patients should be monitored for leucopenia on certain treatment regimens such as 6-mercatopurine. Vascular Patients with IBD have been reported to have a 3 fold increased risk of venous thrombosis compared to matched controls [30]. Interestingly, this increased risk is specific for IBD as it is not seen with other inflammatory conditions such as rheumatoid arthritis or other bowel disorders such as celiac disease. Deep venous thrombosis and pulmonary embolism are the most common complications resulting from an overall increased coagulation in IBD patients. Coagulation factors may be elevated as part of an acute phase response. Factor V Leiden, a genetic disorder characterized by an impaired anticoagulant response to protein C leading to a prothrombotic state, may be increased in Crohn patients [30]. Furthermore, IBD patients might have higher levels of homocysteine, which can be a potential cause of thrombosis [30]. Another vascular complication, arteritis of small or large vessels, has been reported in children with IBD [31]. Pancreatitis Most commonly, pancreatitis in patients with IBD appears to be associated with medications such as 5-aminosalicylate preparations or 6-mercaptopurine. As this is presumed to be an idiosyncratic reaction discontinuation of the medication is indicated. However, IBD patients appear to have a small increased risk for idiopathic pancreatitis. Although pancreatic autoantibodies have been found in up to 40% of Crohn patients their significance remains unclear. In one series, patients with Crohn who were pancreatic antibody positive had a higher rate of pancreatic exocrine insufficiency than those who were antibody negative [3]. Furthermore, chronic pancreatitis has also been reported in a series of six adult IBD patients, five of whom had changes on pancreatic pathology samples [32].
Chapter 9 Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease
99
Renal IBD patients, especially those with extensive ileal disease or ileal resection with significant fat malabsorption or fluid losses, are at risk for developing calcium oxalate and uric acid stones. Glomerulonephritis with immune complex deposition can also be seen which can progress to severe renal disease. Other renal diseases, described in children with IBD, include renal artery stenosis, amyloidosis leading to renal failure, ureteral compression and perinephritic abscesses secondary to abscesses or inflammation surrounding the terminal ileum [33]. Pulmonary Pulmonary manifestations associated with IBD, including reactive airway disease, bronchitis, bronchiectasis, tracheal obstruction, granulomatous lung disease, interstitial or hypersensitivity pneumonitis, and bronchiolitis obliterans are being reported at an increasing frequency [3, 6, 34–36]. However, the latter two have been associated with 5-aminosalicylate products and methotrexate used in the treatment of IBD [3, 36]. Similar to other extraintestinal manifestations, pulmonary disease can predate the bowel disease by months or years. Most pulmonary manifestations respond to corticosteroids via an inhaled, oral, or intravenous route. Neurologic Peripheral nerve disorders, myopathy, multiple sclerosis, optic neuritis, and epilepsy have been described in IBD patients [37]. A retrospective cross-sectional study of adult patients with IBD reported an odds ratio of 1.67 for developing multiple sclerosis, optic neuritis, or a demyelinating disorder [3]. Cardiac Rarely children with IBD can develop myopericarditis and pleuropericarditis with symptoms of chest pain and dyspnea. Cardiac manifestations are not necessarily associated with active bowel disease and respond to corticosteroids and nonsteroidal anti-inflammatory agents, which need to be used with caution in IBD patients.
Summary Crohn disease and ulcerative colitis are associated with numerous extraintestinal manifestations. It is clearly evident that IBD is a multi-systemic disease that stretches beyond the gastrointestinal tract. Knowledge about extraintestinal manifestations is critical as patients can present with these instead of the classical bowel symptoms. Furthermore, these extraintestinal manifestations of IBD are a cause of major morbidity in patients and need to be considered and addressed at all points of care. References 1. Levine JB, Lukawski-Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am 1995;24:633. 2. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994;107:103. 3. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel disease. World J Gastroenterol 2006;12:4819. 4. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006;6:244.
100
Shervin Rabizadeh and Maria Oliva-Hemker
5. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227. 6. Oliva-Hemker M. More than a gut reaction: Extraintestinal complications of IBD. Contemporary Pediatrics 1999;16:45. 7. Lichtman SN, Sartor RB: Extraintestinal manifestations of inflammatory bowel disease: clinical aspects and natural history. In Targan S and Shanahan F (eds): Inflammatory Bowel Disease: From Bench to Bedside, Baltimore, MD, Williams and Wilkins, 1994. 8. Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 1994;19:7. 9. Kethu SR. Extraintestinal manifestations of inflammatory bowel disease. J of Clinical Gastroenterology 2006;40: 467. 10. Urlep D, Mamula P, Baldassano R. Extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterologica e Dietologica 2005;51:147. 11. Loftus EV. Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Current Gastroenterology Reports 2004;6:506. 12. Hoffmann RM, Kruis W. Rare extraintestinal manifestations of inflammatory bowel disease. Inflammatory Bowel Diseases 2004;10:140. 13. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterology Clinics of North America 2002;31:307. 14. Kanof ME, Lake AM, Bayles TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn disease. Gastroenterology 1988;95:1523. 15. Oliva MM, Lake AM. Nutritional considerations and management of the child with inflammatory bowel disease. Nutrition 1996;12:151. 16. Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children— relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci 1986;31:492. 17. Juillerat P, Mottet C, Froehlich F, Felley C, Vader J, Burnand B, Gonvers J, Michetti P. Extraintestinal manifestations of Crohn disease. Digestion 2005;71:31–36. 18. Bernstein CN. Osteoporosis and other complications of inflammatory bowel disease. Current Opinion in Gastroenterology 2002;18:428. 19. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998;114:902 20. Hyams JS, Wyzga N, Kreutzer, et al. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 1997;24:289. 21. Bousvaros A, Marcon M, Treem W, Waters P, Issenman R, Couper R, Burnell R, Rosenberg A, Rabinovish E, Kirschner B. Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children. Digestive Diseases and Science 1999;44:2500–07. 22. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn disease. J Clin Gastroenterol 1991;13:29. 23. Grilich C, Bogenrieder T, Palitzsch KD, Scholmerich J, Lock G. Orofacial granulomatosis as initial manifestation of Crohn disease: a report of two cases. European Journal of Gastroenterology & Hepatology 2002;13:873–76. 24. Storwick GS, Prihoda MB, Fulton RJ, et al. Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J Am Acad Dermatol 1994;31:336. 25. Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. J of Pediatr Gastroenterol Nutr 2003;37:150–154. 26. Hofley P, Roarty J, McGinnity G, et al. Asymptomatic uveitis in children with chronic inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;17:397. 27. Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210 28. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000;31:7. 29. Margalit M, Elinav H, Ilan Y, Shalit M. Liver abscess in inflammatory bowel disease: report of two cases and review of the literature. J of Gastroenterology and Hepatology 2004;19:1338. 30. SriRajaskanthan R, Winter M, Muller AF. Venous thrombosis in inflammatory bowel disease. Eur J of Gastroenterology and Hepatology 2005;17:697.
Chapter 9 Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease
101
31. Mader R, Segol O, Adawi M, Trougoboff P, Nussinson E. Arthritis or vasculitis as presenting symptoms of Crohn disease. Rheumatol Int 2005;25:401–05. 32. Barthet M, Hastier P, Bernard JP, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol 1999;94:2141–8 33. Kuzmic AC, Kolacek S, Brkljacic B, Juzjak N. Renal artery stenosis associated with Crohn disease. Pediatr Nephrol 2001;16:371–73. 34. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine 1993;72:151. 35. Al-Binali AM, Scott B, Al-Garni A, Montgomery M, Robertson M. Granulomatous pulmonary disease in a child: an unusual presentation of Crohn disease. Pediatr Pulmonol 2003;36:76–80. 36. Haralambou G, Teirstein AS, Gil J, Present D. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. Mt Sinai J Med 2001;68:384–88. 37. Lossos A, River Y, Eliakim A, et al. Neurologic aspects of inflammatory bowel disease. Neurology 1995;45:416.
10 Growth Impairment in Pediatric Inflammatory Bowel Disease Thomas D. Walters and Anne M. Griffiths∗
Introduction The clinical course and severity of inflammatory bowel disease (IBD) vary widely in children and in adults [1, 2]. Unique to pediatric patient populations, however, is the potential for linear growth impairment as a complication of chronic intestinal inflammation. The challenge in treating each child or adolescent is to employ pharmacologic, nutritional, and where appropriate surgical interventions, to not only decrease mucosal inflammation and thereby alleviate symptoms, but also to optimize growth and normalize associated pubertal and social development. Indeed, normal growth is a marker of therapeutic success. This chapter reviews the prevalence of growth impairment in pediatric IBD, discusses its pathophysiology, and outlines strategies for its prevention and management.
Normal Growth and Pubertal Development “Normal” children grow at very different rates. Patterns of growth and pubertal progression in young patients with IBD can only be accurately recognized as pathologic, if the variations in normal development of healthy children and adolescents are first appreciated. A child’s growth is the result of both genes and environment; it appears principally mediated by hormones and nutrition [3]. Linear growth can be represented by stature (attained height) or by the rate of growth (height velocity). A child’s attained height represents the culmination of growth in all preceding years; height velocity reflects growth status at a particular point in time. Growth can be conceptualized as the product of three overlapping biological phases: infancy, childhood, and puberty. Final height represents the sum of each of the individual components. The growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis plays a pivotal role in normal postnatal growth. IGF-1 stimulates mitosis of epiphyseal chondrocytes resulting in linear bone growth [4]. Thyroxine, cortisol and sex steroids are also implicated in the maintenance of normal linear growth. Linear growth velocity decreases from birth onwards, punctuated by a short period of growth acceleration (the “adolescent growth spurt”) just prior to completion of growth. As the rapid
*Anne M. Griffiths MD, FRCP(C), Professor of Paediatrics, Division of Gastroenterology/Nutrition, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada, Phone: 416-8137734, Fax: 416-813-6531, E-mail:
[email protected]
103
104
Thomas D. Walters and Anne M. Griffiths
growth of infancy tails off, the steady growth of childhood predominates. Healthy children grow at a consistent rate in the range of 4 to 6 centimeters annually from six years of age until the onset of puberty [5]. At puberty there is a rapid alteration in body size, shape and composition; for a year or more height velocity approximately doubles. The age of onset of puberty, and hence of the pubertal growth spurt, vary among normal individuals and between ethnic populations. Puberty begins earlier in girls than in boys; moreover the pubertal growth spurt occurs in mid-puberty (prior to menarche) in girls but in late puberty (after Tanner stage 4) in boys [5]. There is hence quite consistently a two year differ